[
    {
        "id": "47c7331b-4dfa-45b9-b1db-de35ffe37188",
        "text": "E3 Structure and Content of Clinical Study Reports\n____________________________",
        "metadata": {
            "document_id": "E3 Structure - Document 2.pdf",
            "chunk_index": 0,
            "source": "markdown",
            "embedding_version": "v1"
        }
    },
    {
        "id": "42eb844d-898a-4315-91b2-ef70ab4dcb3b",
        "text": "Questions and Answers (R1)\nU.S. Department of Health and Human Services Food and Drug Administration Center for Drug Evaluation and Research (CDER) Center for Biologics Evaluation and Research (CBER)\nJanuary 2013 ICH",
        "metadata": {
            "document_id": "E3 Structure - Document 2.pdf",
            "chunk_index": 1,
            "source": "markdown",
            "embedding_version": "v1"
        }
    },
    {
        "id": "a6bac1ab-27b9-45a4-a566-d7bc53da3e6a",
        "text": "E3 Structure and Content of Clinical Study Reports\n____________________________",
        "metadata": {
            "document_id": "E3 Structure - Document 2.pdf",
            "chunk_index": 2,
            "source": "markdown",
            "embedding_version": "v1"
        }
    },
    {
        "id": "15a7e590-5d27-44bd-8fe2-92a87f3117c7",
        "text": "Questions and Answers (R1)\nAdditional copies are available from:\nOffice of Communications Division of Drug Information, WO51, Room 2201 Center for Drug Evaluation and Research Food and Drug Administration 10903 New Hampshire Ave., Silver Spring, MD 20993-0002 Phone: 301-796-3400; Fax: 301-847-8714 druginfo@fda.hhs.gov http://www.fda.gov/Drugs/GuidanceComplianceRegulatoryInformation/Guidances/default.htm and/or\nOffice of Communication, Outreach and Development, HFM-40 Center for Biologics Evaluation and Research Food and Drug Administration 1401 Rockville Pike, Rockville, MD 20852-1448 http://www.fda.gov/BiologicsBloodVaccines/GuidanceComplianceRegulatoryInformation/Guidances/default.htm\n(Tel) 800-835-4709 or 301-827-1800\nU.S. Department of Health and Human Services Food and Drug Administration Center for Drug Evaluation and Research (CDER) Center for Biologics Evaluation and Research (CBER)\nJanuary 2013 ICH",
        "metadata": {
            "document_id": "E3 Structure - Document 2.pdf",
            "chunk_index": 3,
            "source": "markdown",
            "embedding_version": "v1"
        }
    },
    {
        "id": "22b3e8ef-1849-4503-95c5-5955e087fe8f",
        "text": "TABLE OF CONTENTS\nI., 1 = INTRODUCTION............................................................................................................. 1. II., 1 = QUESTIONS AND ANSWERS....................................................................................... 1. A., 1 = Content and Structure (1)",
        "metadata": {
            "document_id": "E3 Structure - Document 2.pdf",
            "chunk_index": 4,
            "source": "markdown",
            "embedding_version": "v1"
        }
    },
    {
        "id": "e83494d0-d5c2-4937-864f-1732b96b9ce9",
        "text": "TABLE OF CONTENTS\n.............................................................................................................1. B., 1 = Appendices (2) ................................................................................................................................3.",
        "metadata": {
            "document_id": "E3 Structure - Document 2.pdf",
            "chunk_index": 5,
            "source": "markdown",
            "embedding_version": "v1"
        }
    },
    {
        "id": "5c0024bf-a10c-4132-a36d-3a14061e3967",
        "text": "TABLE OF CONTENTS\nC., 1 = Terminology (3)..............................................................................................................................5",
        "metadata": {
            "document_id": "E3 Structure - Document 2.pdf",
            "chunk_index": 6,
            "source": "markdown",
            "embedding_version": "v1"
        }
    },
    {
        "id": "b4221656-e83a-42d4-950b-6fdcd47a3e5b",
        "text": "E3 Structure and Content of Clinical Study Reports Questions and Answers (R1)\nThis guidance represents the Food and Drug Administration's (FDA's) current thinking on this topic.  It does not create or confer any rights for or on any person and does not operate to bind FDA or the public. You can use an alternative approach if the approach satisfies the requirements of the applicable statutes and regulations. If you want to discuss an alternative approach, contact the FDA staff responsible for implementing this guidance.  If you cannot identify the appropriate FDA staff, call the appropriate number listed on the title page of this guidance.",
        "metadata": {
            "document_id": "E3 Structure - Document 2.pdf",
            "chunk_index": 7,
            "source": "markdown",
            "embedding_version": "v1"
        }
    },
    {
        "id": "83064efb-fb43-4846-891e-f02b50569079",
        "text": "I. INTRODUCTION 2\nSince the ICH E3 guidance was made final, experiences implementing the guidance in the ICH regions have given rise to requests for clarification.  This question and answer (Q&A) document is intended to facilitate implementing the ICH E3 guidance by clarifying key issues.\nFDA's guidance documents, including this guidance, do not establish legally enforceable responsibilities.  Instead, guidances describe the Agency's current thinking on a topic and should be viewed only as recommendations, unless specific regulatory or statutory requirements are cited.  The use of the word should in Agency guidances means that something is suggested or recommended, but not required.",
        "metadata": {
            "document_id": "E3 Structure - Document 2.pdf",
            "chunk_index": 8,
            "source": "markdown",
            "embedding_version": "v1"
        }
    },
    {
        "id": "1c03ae0c-ed9d-406c-9264-0d96342bbcdb",
        "text": "A. Content and Structure (1)\n- Q1: Some in the pharmaceutical industry have expressed concern that the ICH E3 guidance, Structure and Content of Clinical Study Reports (ICH E3), is intended as a requirement (i.e., a template that must be followed).  The fact that the ICH M4 guidance for the Common Technical Document (CTD) refers to specific structural elements described in ICH E3 (e.g., Clinical Study Report (CSR) section headings) may have contributed to this interpretation.  Interpretation of ICH E3 as a rigid template\n1 This guidance was developed within the Efficacy Implementation Working Group of the International Conference on Harmonisation of Technical Requirements for Registration of Pharmaceuticals for Human Use (ICH) and has been subject to consultation by the regulatory parties, in accordance with the ICH process.  The Q&As in this document have been endorsed by the ICH Steering Committee at Step 4 of the ICH process, June 2012.  At Step 4 of the process, the final draft is recommended for adoption to the regulatory bodies of the European Union, Japan, and the United States.\n2 Arabic numbers reflect the organizational breakdown of the document endorsed by the ICH Steering Committee at Step 4 of the ICH process, June 2012.",
        "metadata": {
            "document_id": "E3 Structure - Document 2.pdf",
            "chunk_index": 9,
            "source": "markdown",
            "embedding_version": "v1"
        }
    },
    {
        "id": "ad479183-82e6-4562-961f-0e0b5c0df694",
        "text": "Contains Nonbinding Recommendations\ncan result in presentation of redundant and suboptimal information in CSRs.  This is a particular problem when ICH E3 is used for studies for which it was not designed (e.g., pharmacokinetic studies or studies with health economic or quality of life outcomes). Can ICH reaffirm that ICH E3 is a guidance and not a required template and that ICH E3 can be adapted to report studies that fall outside the original scope of ICH E3?\n- A1: Yes.  ICH E3 is a guidance, not a set of rigid requirements or a template, and flexibility is inherent in its use.  'The [guidance] is intended to assist sponsors in the development of a report that is complete, free from ambiguity, well organized, and easy to review.' Modifications and adaptations to the structure presented in the guidance that lead to better display and communication of information are encouraged.",
        "metadata": {
            "document_id": "E3 Structure - Document 2.pdf",
            "chunk_index": 10,
            "source": "markdown",
            "embedding_version": "v1"
        }
    },
    {
        "id": "6b7d374a-b430-40db-9ea1-3d8ec0a5d005",
        "text": "Contains Nonbinding Recommendations\nThe introduction to ICH E3 (page 3) clearly indicates that ICH E3 is to be interpreted as a guidance, not a set of requirements: 'Each report should consider all of the topics described (unless clearly not relevant) although the specific sequence and grouping of topics may be changed if alternatives are more logical for a particular study.  Some data in the appendices are specific requirements of individual regulatory authorities and should be submitted as appropriate.  The numbering should then be adapted accordingly.'\nTo illustrate this flexibility, consider demographic baseline information.  ICH E3 suggests presentation of this information in the efficacy evaluation, but many variations of this presentation are possible.  For example, if the efficacy and safety populations differ substantially, it would be appropriate to present demographic and baseline characteristics for the safety and efficacy populations in the safety and efficacy sections or in a new section preceding the efficacy and safety results sections.",
        "metadata": {
            "document_id": "E3 Structure - Document 2.pdf",
            "chunk_index": 11,
            "source": "markdown",
            "embedding_version": "v1"
        }
    },
    {
        "id": "038685ed-51cc-4737-9a11-3007329c1954",
        "text": "Contains Nonbinding Recommendations\nIf particular types of information or topics are not addressed in ICH E3 or if their location is not specified, this information or topic should be placed in the section that is most relevant.  For example, pharmacokinetic or quality of life results could be placed in appropriately identified subsections of the efficacy and safety results sections, or they could be placed in new, appropriately identified results sections.\nIf a report does not address all the aspects of ICH E3 that are relevant for a given study, this should be clearly indicated and the rationale for doing so should be provided - for example, if there is no presentation of efficacy for an efficacy study.  A rationale is not necessary if sections presented in ICH E3 are reordered, renamed, or deleted (if warranted by the study design) or if new sections are added.",
        "metadata": {
            "document_id": "E3 Structure - Document 2.pdf",
            "chunk_index": 12,
            "source": "markdown",
            "embedding_version": "v1"
        }
    },
    {
        "id": "d846779c-0fd1-4cd7-abd7-79c7cee20bb6",
        "text": "Contains Nonbinding Recommendations\nIt should be noted that ICH E3 was developed for submission of adequate and wellcontrolled clinical effectiveness studies.  Nevertheless, the basic principles described can be applied to other kinds of trials, such as clinical pharmacology studies and open-label safety studies, recognizing that not all sections or data presentations may be appropriate or important for these other types of trials.  Sponsors are encouraged to adapt the recommendations in the guidance as appropriate (e.g., by deleting sections that are not relevant or adding important sections that are not mentioned in the guidance).\n- Q2: The ICH E3 guidance provides limited guidance on the synopsis.  In the ICH M4E guidance, additional guidance on the synopsis of a CSR is given, including its use as a stand-alone document and its length.  Although ICH E3 asks for a usual maximum length of 3 pages, ICH M4E extends this page limit for more complex and important studies (e.g., to 10 pages).  How should both guidances be read together?",
        "metadata": {
            "document_id": "E3 Structure - Document 2.pdf",
            "chunk_index": 13,
            "source": "markdown",
            "embedding_version": "v1"
        }
    },
    {
        "id": "21e40529-689c-4b54-bdcd-a4a5bf50c206",
        "text": "Contains Nonbinding Recommendations\n- A2: The recommendations made in the ICH E3 guidance, which was developed before ICH M4E, should be combined with the suggestions made in the M4E guidance.  Because the synopsis will be used as a stand-alone document within a Common Technical Document, it should be written so that it can be understood and interpreted on its own (i.e., without the other sections of a CSR).  In addition to a brief description of the study design and critical methodological information, the synopsis should provide efficacy and safety results, as well as other critical information, including data on the study population, disposition of subjects, important protocol deviations, and treatment compliance.  Crossreferences to other sections of the CSR should be avoided.  As explained in ICH M4E, complex or large and important studies may call for a synopsis longer than three pages. The 10-page example given in M4E is not an absolute requirement or limit but should not need to be exceeded greatly.  The use of a tabular format for the synopsis is not mandatory.",
        "metadata": {
            "document_id": "E3 Structure - Document 2.pdf",
            "chunk_index": 14,
            "source": "markdown",
            "embedding_version": "v1"
        }
    },
    {
        "id": "18dc9b42-3b62-475e-8f58-6749aac78e05",
        "text": "B. Appendices (2)\n- Q3: The CSR appendices described in the ICH E3 guidance include material now available in the Trial Master File (TMF) in accordance with ICH E6.  Should documents available in the TMF be included in the CSR appendices?\n- A3: Documentation needed to review the CSR should be included in the CSR appendices.  It is not sufficient for such documents to be included only in the TMF, which is not submitted in the marketing application.",
        "metadata": {
            "document_id": "E3 Structure - Document 2.pdf",
            "chunk_index": 15,
            "source": "markdown",
            "embedding_version": "v1"
        }
    },
    {
        "id": "68190568-3706-4d0d-8386-a9ae17cc51fd",
        "text": "B. Appendices (2)\nDocuments that provide critical information on a study, such as the protocol (16.1.1), statistical methods (16.1.9), list of investigators and study sites, and sample case report forms, would always be needed by reviewers assessing a study and should be included in the trial report even if they are in a TMF.  Certain documents may be required for the CSR by individual countries or regions, in which case they should be included.  For example, according to the ICH guidance E6 Good Clinical Practice:  Consolidated Guidance , 3 an audit certificate (16.1.8) should be provided when required by applicable law or regulation.  If there is any uncertainty about whether documents should be included or not, the appropriate regulatory agency can be consulted.\n3 We update guidances periodically.  To make sure you have the most recent version of a guidance, check the FDA Drugs guidance Web page at\nhttp://www.fda.gov/Drugs/GuidanceComplianceRegulatoryInformation/Guidances/default.htm or the FDA Biologics guidance page at",
        "metadata": {
            "document_id": "E3 Structure - Document 2.pdf",
            "chunk_index": 16,
            "source": "markdown",
            "embedding_version": "v1"
        }
    },
    {
        "id": "42bc8100-56cd-4005-b31f-507347e0092a",
        "text": "B. Appendices (2)\nhttp://www.fda.gov/BiologicsBloodVaccines/GuidanceComplianceRegulatoryInformation/Guidances/default.htm.",
        "metadata": {
            "document_id": "E3 Structure - Document 2.pdf",
            "chunk_index": 17,
            "source": "markdown",
            "embedding_version": "v1"
        }
    },
    {
        "id": "fd3b0a45-3106-4f9d-8396-cf9292a72520",
        "text": "Contains Nonbinding Recommendations\nSupportive documents, such as investigator curricula vitae, ethics committee approvals, informed consent forms, and batch numbers per subject are in the TMF or clinical supply database and should generally not be included in the CSR appendices.\nAny documents not submitted and subsequently requested by the regulatory authority should be provided promptly.",
        "metadata": {
            "document_id": "E3 Structure - Document 2.pdf",
            "chunk_index": 18,
            "source": "markdown",
            "embedding_version": "v1"
        }
    },
    {
        "id": "1c139c71-0e8b-436c-8e46-07930cb8b8af",
        "text": "Contains Nonbinding Recommendations\n- Q4: How can I include data not mentioned in the ICH E3 text or appendices since the guidance predates the ICH M4 guidance associated with the CTD and Electronic Common Technical Document (eCTD)?  Specifically, what are the options for submission of data for topics such as pharmacokinetics, pharmacodynamics, pharmacogenomics (genomic markers), gene therapy, stem cells, biomarkers, devices, quality of life, assay validation, data monitoring/review committees, electrocardiogram, other safety reports, images, pictures/scans, diagnostic tests for individualized therapy, and patient-reported outcomes?\n- A4: It is appropriate to create new headings in the CSR and new appendices for these topics. The guidance provides for and focuses on efficacy and safety variables known at the time.  Other topics should be well referenced in the CSR body and clearly identified in the table of contents.\nCurrent submission options include:",
        "metadata": {
            "document_id": "E3 Structure - Document 2.pdf",
            "chunk_index": 19,
            "source": "markdown",
            "embedding_version": "v1"
        }
    },
    {
        "id": "3b5d1b22-ac5f-4a39-a470-c83c204ffdb8",
        "text": "Contains Nonbinding Recommendations\n1. Stand alone reports.  These can be placed in 'parallel' with the main clinical study report in the eCTD.  For example, a clinical pharmacology study might have the clinical study report, a pharmacokinetic report, and an assay validation report.  For an efficacy study with patient reported outcome (PRO) measures, there might be a PRO report.  Each of these reports can be referenced under the same heading in the eCTD and placed alongside one another in the eCTD folder for that study.  The nature of the information should be clearly described in the title of the document that is provided through the eCTD.\n2. Study tagging files.  In a region where study tagging files are used,  it is recommended that a file-tag option from the 'valid values list' be used - for example, safety report, antibacterial, special-pathogen (see Specifications for Study Tagging Files, http://www.ich.org/products/electronic-standards.html ).",
        "metadata": {
            "document_id": "E3 Structure - Document 2.pdf",
            "chunk_index": 20,
            "source": "markdown",
            "embedding_version": "v1"
        }
    },
    {
        "id": "b30970e0-9e4a-4a0d-9da8-1523769cc7c2",
        "text": "Contains Nonbinding Recommendations\nAlternatively, if a file-tag that adequately describes the material you are planning to submit is not available, you can request that a new file-tag be made available.  This request should be submitted to your regional authority.  In the event that this change cannot be accommodated within your time frame, you can place the document with the main body of the report (i.e., the document would be tagged with the 'study-report-body' file-tag).  The nature of the information should be contained in the title of the document that is provided through the eCTD.\nPlease refer to the most recent version of the 'valid values list,' as it is periodically updated as changes are requested.",
        "metadata": {
            "document_id": "E3 Structure - Document 2.pdf",
            "chunk_index": 21,
            "source": "markdown",
            "embedding_version": "v1"
        }
    },
    {
        "id": "c0779571-4c81-43d2-831a-5d1c0086e1eb",
        "text": "C. Terminology (3)\n- Q5: A subject's death could potentially be captured in two separate data listings:\n- a. The listing referenced in section 12.3.1.1, Deaths.  This section calls for sponsors to include a listing of 'all deaths during the study, including the post-treatment follow-up period, and deaths that resulted from a process that began during the study.'\n- b. The listing referenced in section 12.3.1.2, Other Serious Adverse Events.  This section defines other serious adverse events as events 'other than death but including the serious adverse events temporally associated with or preceding the deaths.'\nThere is concern that including events with fatal outcomes in section 12.3.1.2 may lead to double counting or miscounting of deaths.  Can this issue be clarified?",
        "metadata": {
            "document_id": "E3 Structure - Document 2.pdf",
            "chunk_index": 22,
            "source": "markdown",
            "embedding_version": "v1"
        }
    },
    {
        "id": "3e078c18-db7b-43aa-a4fa-614dd85842ad",
        "text": "C. Terminology (3)\n- A5: It is true that the structure and definitions provided in the ICH E3 guidance could result in deaths appearing in section 12.3.1.2 (as per E3 numbering), Other Serious Adverse Events, if an event terminated with, or was associated with, a subject's death. However, this should not result in double counting or miscounting of deaths. Although deaths may or may not be included in the listing for section 12.3.1.2, all deaths should be captured in the listing for section 12.3.1.1.  That is, any subject death reported under section 12.3.1.2 as an 'other serious adverse event' with a fatal outcome would also have been captured under deaths in section 12.3.1.1.",
        "metadata": {
            "document_id": "E3 Structure - Document 2.pdf",
            "chunk_index": 23,
            "source": "markdown",
            "embedding_version": "v1"
        }
    },
    {
        "id": "54288fb4-61e3-4c87-b321-c782d2a82ed1",
        "text": "C. Terminology (3)\n- Q6: Section 12.2.2 of the ICH E3 guidance states that all adverse events occurring after initiation of study treatments should be displayed in summary tables.  The example table in section 12.2.2 of ICH E3 (Adverse Events: Number Observed and Rate, with Subject Identification) is really a listing that will rarely be brief enough to place in the body of the study report.  Moreover, in addition to severity, relatedness, and subject identifiers (shown in the example table), each adverse event should include the original investigator's verbatim term.  How is it possible to include all of this information in a summary table?  Can this table be modified?\n- A6: The body of the clinical study report (ICH E3 section 12.2.2) should include a summary table of relatively common adverse events - those occurring in at least a particular percentage of subjects who received the investigational drug.  This summary tabulation compares treatment and control groups and does not include subject identifying numbers or verbatim adverse event terms.",
        "metadata": {
            "document_id": "E3 Structure - Document 2.pdf",
            "chunk_index": 24,
            "source": "markdown",
            "embedding_version": "v1"
        }
    },
    {
        "id": "5ab3b251-1805-4434-9e28-8e4a6eca1daf",
        "text": "C. Terminology (3)\nOf note, the example table provided in section 12.2.2 of the guidance is not meant to be presented in section 12.2.2 of the report, but in section 14.3.1, which is not part of the text of the clinical study report.",
        "metadata": {
            "document_id": "E3 Structure - Document 2.pdf",
            "chunk_index": 25,
            "source": "markdown",
            "embedding_version": "v1"
        }
    },
    {
        "id": "18cea880-dae4-4621-99a7-d3b8acb70859",
        "text": "Contains Nonbinding Recommendations\nThe ICH E3 guidance did not attempt to display all possible presentations of adverse event information, but rather outlined the summary table intended for section 12.2.2 and provided an illustration of the far more detailed display that would be placed in section 14.3.1.  The example provided for section 14.3.1, however, does not try to illustrate all possibilities, but shows individuals with adverse events by body system, severity, and perceived drug-relatedness for treatment group 'X.'  Listings should also display investigator's verbatim terms for each event and could be used to show demographic or disease-specific information, dosage, duration of treatment, or treatment cycle (for cancer chemotherapy).\nBecause it can be impractical to display all of this information in a single listing, such analyses can be presented in individual listings (e.g., by dose or other subgroup of interest).  When adverse event data are presented by subgroup, however, a display of overall adverse events should also be included.  For example, for a drug for subjects with chronic kidney disease, adverse events could be tabulated separately for subjects receiving or not receiving dialysis, but a table that includes adverse events in all subjects should also be included.",
        "metadata": {
            "document_id": "E3 Structure - Document 2.pdf",
            "chunk_index": 26,
            "source": "markdown",
            "embedding_version": "v1"
        }
    },
    {
        "id": "201f137d-b63e-46cb-aa8e-605c84468b37",
        "text": "Contains Nonbinding Recommendations\nThe listings that provide more comprehensive adverse event information, specifically subject identifiers and verbatim terms for each adverse event, should be provided in the study report, in sections 14.3.1 and 16.2.7.  If each adverse event is to be characterized extensively (i.e., many items in the listing), electronic approaches may be appropriate.\n- Q7: Section 10.2 of the ICH E3 guidance requests an accounting of important protocol deviations.  However, the flowchart in Annex IVa of ICH E3 (Disposition of Patients) recommends that data be provided on the number of subjects withdrawn from the study because of 'protocol violations.'  Neither the term 'protocol deviations' nor 'protocol violations' has been previously defined by ICH.  What is the distinction between a protocol deviation, important protocol deviation, and a protocol violation?  Can these terms be clarified?  In addition, does the guidance provide for sponsors' flexibility in defining what constitutes an important protocol deviation for a trial?\n- A7: A protocol deviation is any change, divergence, or departure from the study design or procedures defined in the protocol.",
        "metadata": {
            "document_id": "E3 Structure - Document 2.pdf",
            "chunk_index": 27,
            "source": "markdown",
            "embedding_version": "v1"
        }
    },
    {
        "id": "e84676c7-6abe-4278-8921-856d8685338e",
        "text": "Contains Nonbinding Recommendations\nImportant protocol deviations are a subset of protocol deviations that might significantly affect the completeness, accuracy, and/or reliability of the study data or that might significantly affect a subject's rights, safety, or well-being.  For example, important protocol deviations might include enrolling subjects in violation of key eligibility criteria designed to ensure a specific subject population or failing to collect data necessary to interpret primary endpoints, as this may compromise the scientific value of the trial.\nProtocol violation and important protocol deviation are sometimes used interchangeably to refer to a significant departure from protocol requirements.  The word violation can also have other meanings in a regulatory context.  However, in Annex IVa of the ICH E3\nguidance (Disposition of Patients), the term protocol violation was intended to mean only a change, divergence, or departure from the study requirements, whether by the subject or investigator, that resulted in a subject's withdrawal from study participation. (Whether such subjects should be included in the study analysis is a separate question.)",
        "metadata": {
            "document_id": "E3 Structure - Document 2.pdf",
            "chunk_index": 28,
            "source": "markdown",
            "embedding_version": "v1"
        }
    },
    {
        "id": "6f6a0b73-37e6-4419-b93b-bb4816761fe1",
        "text": "Contains Nonbinding Recommendations\nTo avoid confusion over terminology, sponsors are encouraged to replace the phrase 'protocol violation' in Annex IVa with 'protocol deviation,' as shown in the example flowchart below.  Sponsors can also choose to use another descriptor, provided that the information presented is generally consistent with the definition of protocol violation provided above.\nThe ICH E3 guidance provides examples of the types of deviations that are generally considered important protocol deviations and that should be described in section 10.2 and included in the listing in Appendix 16.2.2.  The definition of important protocol deviations for a particular trial is determined in part by study design, the critical procedures, study data, subject protections described in the protocol, and the planned analyses of study data.  In keeping with the flexibility of the guidance, sponsors can amend or add to the examples of important deviations provided in ICH E3 in consideration of a trial's requirements.  Substantial additions or changes should be clearly described for the reviewer.",
        "metadata": {
            "document_id": "E3 Structure - Document 2.pdf",
            "chunk_index": 29,
            "source": "markdown",
            "embedding_version": "v1"
        }
    },
    {
        "id": "c644ff39-eaca-46b9-97a7-84c38d76f85c",
        "text": "Contains Nonbinding Recommendations\nEXAMPLE FLOWCHART  \nDISPOSITION OF PATIENTS  \n\nN=1,724  \nPATIENTS RECEIVING DOUBLE-BLINDED MEDICATION  \n\n- N = 340  \n  REGIMEN A  \n  - N = 281  \n    COMPLETED STUDY  \n  - N = 59  \n    WITHDRAWN  \n    ADVERSE EVENT (20)  \n    UNSAT. RESPONSE  \n    EFFICACY (1)  \n    FAILURE TO RETURN (6)  \n    OTHER MED. EVENT (5)  \n    OTHER NONMED. EVENT (5)  \n    PROTOCOL DEVIATION (10)  \n    PATIENT REQUEST (12)  \n\n- N =  \n  REGIMEN B  \n  - N =  \n    COMPLETED STUDY  \n  - N =  \n    WITHDRAWN  \n    ADVERSE EVENT (19)  \n    UNSAT. RESPONSE  \n    EFFICACY (2)  \n    FAILURE TO RETURN (8)  \n    OTHER MED. EVENT (8)  \n    OTHER NONMED. EVENT (4)  \n    PROTOCOL DEVIATION (10)  \n    PATIENT REQUEST (10)  \n\n- N =  \n  REGIMEN C  \n  - N =  \n    COMPLETED STUDY  \n  - N =  \n    WITHDRAWN  \n    ADVERSE EVENT (26)  \n    UNSAT. RESPONSE  \n    EFFICACY (1)  \n    FAILURE TO RETURN (7)  \n    OTHER MED. EVENT (4)  \n    OTHER NONMED. EVENT (6)  \n    PROTOCOL DEVIATION (10)  \n    PATIENT REQUEST (25)  ",
        "metadata": {
            "document_id": "E3 Structure - Document 2.pdf",
            "chunk_index": 30,
            "source": "markdown",
            "embedding_version": "v1"
        }
    },
    {
        "id": "14ed1322-0646-4576-9a4d-823226a06fc7",
        "text": "Contains Nonbinding Recommendations\n- N =  \n  REGIMEN D  \n  - N =  \n    COMPLETED STUDY  \n  - N =  \n    WITHDRAWN  \n    ADVERSE EVENT (24)  \n    UNSAT. RESPONSE  \n    EFFICACY (1)  \n    FAILURE TO RETURN (6)  \n    OTHER MED. EVENT (8)  \n    OTHER NONMED. EVENT (7)  \n    PROTOCOL DEVIATION (6)  \n    PATIENT REQUEST (27)  \n\n- N =  \n  REGIMEN E  \n  - N =  \n    COMPLETED STUDY  \n  - N =  \n    WITHDRAWN  \n    ADVERSE EVENT (42)  \n    UNSAT. RESPONSE  \n    EFFICACY (0)  \n    FAILURE TO RETURN (6)  \n    OTHER MED. EVENT (14)  \n    OTHER NONMED. EVENT (1)  \n    PROTOCOL DEVIATION (14)  \n    PATIENT REQUEST (15)",
        "metadata": {
            "document_id": "E3 Structure - Document 2.pdf",
            "chunk_index": 31,
            "source": "markdown",
            "embedding_version": "v1"
        }
    },
    {
        "id": "ec4e4d14-1ac8-4236-a00a-3da7aee6a0ab",
        "text": "E 10 Choice of Control Group and Related Issues in Clinical Trials\nU.S. Department of Health and Human Services\nFood and Drug Administration Center for Drug Evaluation and Research (CDER) Center for Biologics Evaluation and Research (CBER)\nMay 2001 ICH\nAdditional copies are available from:\nOffice of Training and Communication Division of Drug Information, HFD-240 Center for Drug Evaluation and Research Food and Drug Administration 5600 Fishers Lane Rockville, MD  20857 (Tel) 301-827-4573 http://www.fda.gov/cder/guidance/index.htm or\nOffice of Communication, Training and Manufacturers Assistance, HFM-40 Center for Biologics Evaluation and Research Food and Drug Administration 1401 Rockville Pike, Rockville, MD 20852-1448 http://www.fda.gov/cber/guidelines.htm Fax: 1-888-CBERFAX or 301-827-3844\nPhone: the Voice Information System at 800-835-4709 or 301-827-1800",
        "metadata": {
            "document_id": "E10 - Document 3.pdf",
            "chunk_index": 0,
            "source": "markdown",
            "embedding_version": "v1"
        }
    },
    {
        "id": "c3fa5963-7b6a-48ca-b800-f27b4d591bb1",
        "text": "E 10 Choice of Control Group and Related Issues in Clinical Trials\nU.S. Department of Health and Human Services Food and Drug Administration Center for Drug Evaluation and Research (CDER) Center for Biologics Evaluation and Research (CBER)\nMay 2001 ICH",
        "metadata": {
            "document_id": "E10 - Document 3.pdf",
            "chunk_index": 1,
            "source": "markdown",
            "embedding_version": "v1"
        }
    },
    {
        "id": "05a74544-79a5-4a32-b7a2-8854137c5dde",
        "text": "TABLE OF CONTENTS\nA., 1 = GENERAL S CHEME AND P URPOSE OF GUIDANCE. A., 2 = .........................................................................................2. , 1 = (1.1). , 2 = . B., 1 = P URPOSE OF CONTROL GROUP (1.2)",
        "metadata": {
            "document_id": "E10 - Document 3.pdf",
            "chunk_index": 2,
            "source": "markdown",
            "embedding_version": "v1"
        }
    },
    {
        "id": "5ea6d700-d97c-41b6-a4a5-8dd2c8ff7646",
        "text": "TABLE OF CONTENTS\n......................................................................................................................3. B., 2 = . , 1 = Randomization",
        "metadata": {
            "document_id": "E10 - Document 3.pdf",
            "chunk_index": 3,
            "source": "markdown",
            "embedding_version": "v1"
        }
    },
    {
        "id": "e6c85680-f470-4399-858d-7d8cb0ba2a6a",
        "text": "TABLE OF CONTENTS\n(1.2.1).......................................................................................................................................3. , 2 = . 1. 2., 1 = Blinding",
        "metadata": {
            "document_id": "E10 - Document 3.pdf",
            "chunk_index": 4,
            "source": "markdown",
            "embedding_version": "v1"
        }
    },
    {
        "id": "29eb8532-1518-4107-a4cc-d1ebbe395659",
        "text": "TABLE OF CONTENTS\n(1.2.2)..................................................................................................................................................4. 1. 2., 2 = . C., 1 = T YPES OF CONTROLS (1.3)",
        "metadata": {
            "document_id": "E10 - Document 3.pdf",
            "chunk_index": 5,
            "source": "markdown",
            "embedding_version": "v1"
        }
    },
    {
        "id": "f5d68bd1-ee61-4e92-b38f-2fe84099f22c",
        "text": "TABLE OF CONTENTS\n.....................................................................................................................................4. C., 2 = . 1., 1 = Placebo Concurrent Control",
        "metadata": {
            "document_id": "E10 - Document 3.pdf",
            "chunk_index": 6,
            "source": "markdown",
            "embedding_version": "v1"
        }
    },
    {
        "id": "c13310f8-3652-4aa1-b30f-a783804030ff",
        "text": "TABLE OF CONTENTS\n(1.3.1)................................................................................................................5. 1., 2 = . 2., 1 = No-treatment Concurrent Control (1.3.2).......................................................................................................5. 2., 2",
        "metadata": {
            "document_id": "E10 - Document 3.pdf",
            "chunk_index": 7,
            "source": "markdown",
            "embedding_version": "v1"
        }
    },
    {
        "id": "6210c66d-5291-4ec1-9a4a-517240513de8",
        "text": "TABLE OF CONTENTS\n= . 3., 1 = Dose-response Concurrent Control (1.3.3).....................................................................................................5. 3., 2 = . 4., 1 = Active (Positive) Concurrent Control (1.3.4)..................................................................................................6. 4., 2 = .",
        "metadata": {
            "document_id": "E10 - Document 3.pdf",
            "chunk_index": 8,
            "source": "markdown",
            "embedding_version": "v1"
        }
    },
    {
        "id": "179104dc-be71-411f-ae7b-eec5328209c1",
        "text": "TABLE OF CONTENTS\n5., 1 = External Control (Including Historical Control) (1.3.5)................................................................................6. 5., 2 = . 6., 1 = Multiple Control Groups (1.3.6)......................................................................................................................6. 6., 2 = . D., 1 =",
        "metadata": {
            "document_id": "E10 - Document 3.pdf",
            "chunk_index": 9,
            "source": "markdown",
            "embedding_version": "v1"
        }
    },
    {
        "id": "2fef6958-b1b4-430b-8535-ad30cc2fbac7",
        "text": "TABLE OF CONTENTS\nP URPOSES OF CLINICAL T RIALS AND RELATED I SSUES (1.4) ...............................................................................6. D., 2 = . 1., 1 = Evidence of Efficacy (1.4.1)..............................................................................................................................7. 1., 2",
        "metadata": {
            "document_id": "E10 - Document 3.pdf",
            "chunk_index": 10,
            "source": "markdown",
            "embedding_version": "v1"
        }
    },
    {
        "id": "ea653183-efd7-47a3-b0fe-52f706fceaf6",
        "text": "TABLE OF CONTENTS\n= . 2., 1 = Comparative Efficacy and Safety (1.4.2).........................................................................................................7. 2., 2 = . 3., 1 = Fairness of Comparisons",
        "metadata": {
            "document_id": "E10 - Document 3.pdf",
            "chunk_index": 11,
            "source": "markdown",
            "embedding_version": "v1"
        }
    },
    {
        "id": "4464b633-fc5a-4013-99c4-78c26671ffa7",
        "text": "TABLE OF CONTENTS\n(1.4.3)......................................................................................................................7. 3., 2 = . , 1 = a. Dose (1.4.3.1)",
        "metadata": {
            "document_id": "E10 - Document 3.pdf",
            "chunk_index": 12,
            "source": "markdown",
            "embedding_version": "v1"
        }
    },
    {
        "id": "8440f0b7-6c39-476b-bec8-98eea4032325",
        "text": "TABLE OF CONTENTS\n.......................................................................................................................................................8. , 2 = . , 1 = b. Patient Population (1.4.3.2)",
        "metadata": {
            "document_id": "E10 - Document 3.pdf",
            "chunk_index": 13,
            "source": "markdown",
            "embedding_version": "v1"
        }
    },
    {
        "id": "d088f75c-15ab-4a23-994e-ac7ef190a1ec",
        "text": "TABLE OF CONTENTS\n...................................................................................................................................8. , 2 = . , 1 = c. Selection and Timing of Endpoints (1.4.3.3)",
        "metadata": {
            "document_id": "E10 - Document 3.pdf",
            "chunk_index": 14,
            "source": "markdown",
            "embedding_version": "v1"
        }
    },
    {
        "id": "61e22e3b-22a7-407c-9530-450391efdb78",
        "text": "TABLE OF CONTENTS\n..........................................................................................................8. , 2 = . E., 1 = ASSAY S ENSITIVITY",
        "metadata": {
            "document_id": "E10 - Document 3.pdf",
            "chunk_index": 15,
            "source": "markdown",
            "embedding_version": "v1"
        }
    },
    {
        "id": "ba7eb27f-6461-4629-87fd-6e99dbfbe0e1",
        "text": "TABLE OF CONTENTS\n(1.5).......................................................................................................................................9. E., 2 = . , 1 = Assay Sensitivity in Non-inferiority or Equivalence Trials (1.5.1)...............................................................9. , 2 = . 1., 1 = a. Historical Evidence of Sensitivity to Drugs Effects and",
        "metadata": {
            "document_id": "E10 - Document 3.pdf",
            "chunk_index": 16,
            "source": "markdown",
            "embedding_version": "v1"
        }
    },
    {
        "id": "1cec718e-e4c9-439a-a5cf-fdd52d25c784",
        "text": "TABLE OF CONTENTS\nChoosing the Non-inferiority Margin (1.5.1.1) .................. 1., 2 = 10. , 1 = b. Appropriate Trial Conduct (1.5.1.2)...................................................................................................................... , 2 = 12. 2., 1 = Assay Sensitivity in Trials Intended to Demonstrate Superiority",
        "metadata": {
            "document_id": "E10 - Document 3.pdf",
            "chunk_index": 17,
            "source": "markdown",
            "embedding_version": "v1"
        }
    },
    {
        "id": "43e5f6e3-329d-4abf-80fb-25f88a93776c",
        "text": "TABLE OF CONTENTS\n(1.5.2)...................................................13. 2., 2 = . II., 1 = DETAILED CONSIDERATION OF TYPES OF CONTROL(2.0).............................................................14. II., 2 = . 1., 1 = P LACEBO CONTROL (2.1). 1., 2 =",
        "metadata": {
            "document_id": "E10 - Document 3.pdf",
            "chunk_index": 18,
            "source": "markdown",
            "embedding_version": "v1"
        }
    },
    {
        "id": "63aab628-a678-438e-aa8f-15fda40ca85e",
        "text": "TABLE OF CONTENTS\n....................................................................................................................................14. A., 1 = Description (See Section 1.3.1)",
        "metadata": {
            "document_id": "E10 - Document 3.pdf",
            "chunk_index": 19,
            "source": "markdown",
            "embedding_version": "v1"
        }
    },
    {
        "id": "71e5bb19-9c0a-40f9-b059-8ec9f535fd3b",
        "text": "TABLE OF CONTENTS\n(2.1.1).........................................................................................................14 Ability to Minimize Bias (2.1.2)....................................................................................................................14. A., 2 = . 2. 3.,",
        "metadata": {
            "document_id": "E10 - Document 3.pdf",
            "chunk_index": 20,
            "source": "markdown",
            "embedding_version": "v1"
        }
    },
    {
        "id": "409bd288-df36-4177-aef2-9b54c4a3606c",
        "text": "TABLE OF CONTENTS\n1 = Ethical Issues (2.1.3)......................................................................................................................................14. 2. 3., 2 = . 4., 1 = Usefulness of Placebo-controlled Trials and Validity of Inference in Particular Situations. 4., 2 = (2.1.4).......15. 5., 1 = Modifications of Design and Combinations with Other Controls That Can Resolve Ethical, Practical,. 5., 2 = or. , 1 = Inferential Issues",
        "metadata": {
            "document_id": "E10 - Document 3.pdf",
            "chunk_index": 21,
            "source": "markdown",
            "embedding_version": "v1"
        }
    },
    {
        "id": "28d1af39-968e-49d8-9abc-7dd5a0fd16fb",
        "text": "TABLE OF CONTENTS\n(2.1.5)..........................................................................................................................................16. , 2 = 16 17. , 1 = a. Additional Control Groups (2.1.5.1)",
        "metadata": {
            "document_id": "E10 - Document 3.pdf",
            "chunk_index": 22,
            "source": "markdown",
            "embedding_version": "v1"
        }
    },
    {
        "id": "298a5c05-5dc3-4f59-a07a-0669dbfd83f7",
        "text": "TABLE OF CONTENTS\n.................................................................................................................... b. Other Modifications of Study Design (2.1.5.2) ...................................................................................................... , 2 = . 6., 1 = Advantages of Placebo-controlled Trials",
        "metadata": {
            "document_id": "E10 - Document 3.pdf",
            "chunk_index": 23,
            "source": "markdown",
            "embedding_version": "v1"
        }
    },
    {
        "id": "63d88912-bee1-4df2-a642-8673790f4c5a",
        "text": "TABLE OF CONTENTS\n(2.1.6).........................................................................................19 a. Ability to Demonstrate Efficacy (2.1.6.1) ............................................................................................................ 6., 2 = 19. , 1 = b. Measures Absolute Efficacy and Safety",
        "metadata": {
            "document_id": "E10 - Document 3.pdf",
            "chunk_index": 24,
            "source": "markdown",
            "embedding_version": "v1"
        }
    },
    {
        "id": "710fd593-f726-48e5-a968-c56cdd90eec3",
        "text": "TABLE OF CONTENTS\n(2.1.6.2)................................................................................................... , 2 = 19. , 1 = c. Efficiency (2.1.6.3)",
        "metadata": {
            "document_id": "E10 - Document 3.pdf",
            "chunk_index": 25,
            "source": "markdown",
            "embedding_version": "v1"
        }
    },
    {
        "id": "5f2abf64-6710-4454-b7b8-d1b8ea9df1d5",
        "text": "TABLE OF CONTENTS\n.............................................................................................................................................. , 2 = 19. , 1 = d. Minimizing the Effect of Subject and Investigator Expectations (2.1.6.4)............................................................... , 2 = 20. 7., 1 = Disadvantages of Placebo-controlled Trials",
        "metadata": {
            "document_id": "E10 - Document 3.pdf",
            "chunk_index": 26,
            "source": "markdown",
            "embedding_version": "v1"
        }
    },
    {
        "id": "a342cc6c-357e-4798-a380-4358a819cae5",
        "text": "TABLE OF CONTENTS\n(2.1.7)....................................................................................20. 7., 2 = . , 1 = a. Ethical Concerns (See Sections 2.1.3 and 2.1.4) (2.1.7.1) ...................................................................................... , 2 = 20. , 1 = b. Patient and Physician Practical Concerns (2.1.7.2)",
        "metadata": {
            "document_id": "E10 - Document 3.pdf",
            "chunk_index": 27,
            "source": "markdown",
            "embedding_version": "v1"
        }
    },
    {
        "id": "9f230043-59e1-4437-b14e-55b5b3d14454",
        "text": "TABLE OF CONTENTS\n................................................................................................ , 2 = 20. , 1 = c. Generalizability (2.1.7.3) ..................................................................................................................................... , 2",
        "metadata": {
            "document_id": "E10 - Document 3.pdf",
            "chunk_index": 28,
            "source": "markdown",
            "embedding_version": "v1"
        }
    },
    {
        "id": "66c1a9f7-b2c3-4d07-ac82-71b912a3eb4f",
        "text": "TABLE OF CONTENTS\n= 20. , 1 = d. No Comparative Information (2.1.7.4) .................................................................................................................. , 2 = 21. B., 1 = TREATMENT EE ECTION. B., 2 = . C., 1 = NO - CONCURRENT CONTROL (S S 1.3.2) (2.2)............................................................21. C., 2 = . , 1 = DOSE - RESPONSE CONCURRENT",
        "metadata": {
            "document_id": "E10 - Document 3.pdf",
            "chunk_index": 29,
            "source": "markdown",
            "embedding_version": "v1"
        }
    },
    {
        "id": "e187c6d5-b975-41c4-a316-b9918821e16d",
        "text": "TABLE OF CONTENTS\nCONTROL (S EE S ECTION 1.3.3) (2.3)............................................................21 (2.3.1).........................................................................................................................................21. , 2 = . 1., 1 = Description. 1., 2 = . 2. 3., 1 = Ability to Minimize Bias",
        "metadata": {
            "document_id": "E10 - Document 3.pdf",
            "chunk_index": 30,
            "source": "markdown",
            "embedding_version": "v1"
        }
    },
    {
        "id": "13908f01-907c-4828-b11a-18532005e245",
        "text": "TABLE OF CONTENTS\n(2.3.2)....................................................................................................................22 Ethical Issues",
        "metadata": {
            "document_id": "E10 - Document 3.pdf",
            "chunk_index": 31,
            "source": "markdown",
            "embedding_version": "v1"
        }
    },
    {
        "id": "78b323bb-87eb-4ad3-a778-260bddd753a1",
        "text": "TABLE OF CONTENTS\n(2.3.3)......................................................................................................................................22. 2. 3., 2 = . 4., 1 = Usefulness of Dose-response Studies and Validity of Inference in Particular Situations (2.3.4).............22. 4., 2 = . 5., 1 = Modifications of Design and Combinations with Other Controls That Can Resolve Ethical, Practical,. 5., 2 = or. , 1 =",
        "metadata": {
            "document_id": "E10 - Document 3.pdf",
            "chunk_index": 32,
            "source": "markdown",
            "embedding_version": "v1"
        }
    },
    {
        "id": "597ab4f5-b6d5-4297-8877-13ebe5e3995e",
        "text": "TABLE OF CONTENTS\n(2.3.5)....................................................................................................................................22. , 2 = . , 1 = Inferential Problems. , 2 = ",
        "metadata": {
            "document_id": "E10 - Document 3.pdf",
            "chunk_index": 33,
            "source": "markdown",
            "embedding_version": "v1"
        }
    },
    {
        "id": "e55bceb8-5d6c-4edc-b840-ae8eb954883c",
        "text": "TABLE OF CONTENTS\n6., 1 = Advantages of Dose-response Trials (2.3.6)................................................................................................22. 6., 2 = . , 1 = a. Efficiency (2.3.6.1)",
        "metadata": {
            "document_id": "E10 - Document 3.pdf",
            "chunk_index": 34,
            "source": "markdown",
            "embedding_version": "v1"
        }
    },
    {
        "id": "b4e35d82-3cc3-407f-bb38-e37e15a733e9",
        "text": "TABLE OF CONTENTS\n............................................................................................................................................. b. Possible Ethical Advantage (2.3.6.2)",
        "metadata": {
            "document_id": "E10 - Document 3.pdf",
            "chunk_index": 35,
            "source": "markdown",
            "embedding_version": "v1"
        }
    },
    {
        "id": "82923ba7-e36e-474e-b985-c432f78a865b",
        "text": "TABLE OF CONTENTS\n.................................................................................................................... , 2 = 22 23. 7., 1 = Disadvantages of Dose-response Study (2.3.7)............................................................................................23. 7., 2 = . D., 1 = ACTIVE CONTROL (S EE S",
        "metadata": {
            "document_id": "E10 - Document 3.pdf",
            "chunk_index": 36,
            "source": "markdown",
            "embedding_version": "v1"
        }
    },
    {
        "id": "0e134b10-219a-4da0-9803-369af9631007",
        "text": "TABLE OF CONTENTS\nECTION 1.3.4) (2.4) ....................................................................................................23. D., 2 = . 1., 1 = Description",
        "metadata": {
            "document_id": "E10 - Document 3.pdf",
            "chunk_index": 37,
            "source": "markdown",
            "embedding_version": "v1"
        }
    },
    {
        "id": "f999e9bb-977a-4b44-acac-eea7f936049c",
        "text": "TABLE OF CONTENTS\n(2.4.1).........................................................................................................................................23. 1., 2 = . 2., 1 = Ability to Minimize Bias",
        "metadata": {
            "document_id": "E10 - Document 3.pdf",
            "chunk_index": 38,
            "source": "markdown",
            "embedding_version": "v1"
        }
    },
    {
        "id": "9fd11126-0dc6-4d93-99b4-1a841626169f",
        "text": "TABLE OF CONTENTS\n(2.4.2)....................................................................................................................24. 2., 2 = . 3., 1 = Ethical Issues",
        "metadata": {
            "document_id": "E10 - Document 3.pdf",
            "chunk_index": 39,
            "source": "markdown",
            "embedding_version": "v1"
        }
    },
    {
        "id": "635b1d35-7a05-4b6f-80f1-9fd71575d457",
        "text": "TABLE OF CONTENTS\n(2.4.3)......................................................................................................................................24. 3., 2 = . 4., 1 = Usefulness of Active Control Trials; Validity of Inference in Particular Situations (2.4.4).....................24. 4., 2 = . 5., 1 = Modifications of Design and Combinations with Other Controls That Can Resolve Ethical, Practical,. 5., 2 = or. Inferential Issues",
        "metadata": {
            "document_id": "E10 - Document 3.pdf",
            "chunk_index": 40,
            "source": "markdown",
            "embedding_version": "v1"
        }
    },
    {
        "id": "d281c01e-e9e5-4ab7-9bf9-a370ff5c01d2",
        "text": "TABLE OF CONTENTS\n(2.4.5)..........................................................................................................................................25, 1 = Inferential Issues",
        "metadata": {
            "document_id": "E10 - Document 3.pdf",
            "chunk_index": 41,
            "source": "markdown",
            "embedding_version": "v1"
        }
    },
    {
        "id": "06d4d7a7-2a57-41f2-87f7-aed51d840d0d",
        "text": "TABLE OF CONTENTS\n(2.4.5)..........................................................................................................................................25. Inferential Issues",
        "metadata": {
            "document_id": "E10 - Document 3.pdf",
            "chunk_index": 42,
            "source": "markdown",
            "embedding_version": "v1"
        }
    },
    {
        "id": "c464b880-664b-4796-b2c9-2652b6251ca2",
        "text": "TABLE OF CONTENTS\n(2.4.5)..........................................................................................................................................25, 2 = . 6., 1 = Advantages of Active Control Trials",
        "metadata": {
            "document_id": "E10 - Document 3.pdf",
            "chunk_index": 43,
            "source": "markdown",
            "embedding_version": "v1"
        }
    },
    {
        "id": "171cfab5-626d-4243-a31a-d942b6556cbc",
        "text": "TABLE OF CONTENTS\n(2.4.6).................................................................................................25. 6., 2 = . a., 1 = Ethical and Practical Advantages (2.4.6.1) ............................................................................................................ a., 2 = 25. , 1 = b. Information Content",
        "metadata": {
            "document_id": "E10 - Document 3.pdf",
            "chunk_index": 44,
            "source": "markdown",
            "embedding_version": "v1"
        }
    },
    {
        "id": "559bb06a-71ca-4b3a-bd3f-51201f73b197",
        "text": "TABLE OF CONTENTS\n(2.4.6.2) ............................................................................................................................... , 2 = 25. 7., 1 = Disadvantages of Active Control Trials (2.4.7)...........................................................................................25.",
        "metadata": {
            "document_id": "E10 - Document 3.pdf",
            "chunk_index": 45,
            "source": "markdown",
            "embedding_version": "v1"
        }
    },
    {
        "id": "51c2a98d-d8a9-4ba3-a864-a1faebc000f6",
        "text": "TABLE OF CONTENTS\n7., 2 = . , 1 = a. Information Content (2.4.7.1) ............................................................................................................................... , 2 = 25. , 1 = b. Large Sample Size (2.4.7.2)",
        "metadata": {
            "document_id": "E10 - Document 3.pdf",
            "chunk_index": 46,
            "source": "markdown",
            "embedding_version": "v1"
        }
    },
    {
        "id": "31a36706-3978-4ba2-8c1a-29fbe7799f51",
        "text": "TABLE OF CONTENTS\n................................................................................................................................. , 2 = 25. E., 1 = E XTERNAL CONTROL (I NCLUDING HISTORICAL CONTROL , S EE S ECTION 1.3.5) (2.5)....................................26. E., 2 = . 1., 1 = Description",
        "metadata": {
            "document_id": "E10 - Document 3.pdf",
            "chunk_index": 47,
            "source": "markdown",
            "embedding_version": "v1"
        }
    },
    {
        "id": "cc2c8318-b2b6-4757-ba44-ab7eed1a37d5",
        "text": "TABLE OF CONTENTS\n(2.5.1).........................................................................................................................................26. 1., 2 = . 2., 1 = Ability to Minimize Bias",
        "metadata": {
            "document_id": "E10 - Document 3.pdf",
            "chunk_index": 48,
            "source": "markdown",
            "embedding_version": "v1"
        }
    },
    {
        "id": "848e42d7-22e8-43c6-8dea-7d73a5b5c2cf",
        "text": "TABLE OF CONTENTS\n(2.5.2)....................................................................................................................26. 2., 2 = . 3., 1 = Ethical Issues",
        "metadata": {
            "document_id": "E10 - Document 3.pdf",
            "chunk_index": 49,
            "source": "markdown",
            "embedding_version": "v1"
        }
    },
    {
        "id": "5b7a2e89-bdfd-441d-819a-7426c122fe74",
        "text": "TABLE OF CONTENTS\n(2.5.3)......................................................................................................................................27. 3., 2 = . 4., 1 = Usefulness of Externally Controlled Trials; Validity of Inference in Particular Situations (2.5.4).........28. 4., 2 = . 5., 1 = Modifications of Design and Combinations with Other Controls That Can Resolve Ethical, Practical or. 5., 2 = . Inferential Problems",
        "metadata": {
            "document_id": "E10 - Document 3.pdf",
            "chunk_index": 50,
            "source": "markdown",
            "embedding_version": "v1"
        }
    },
    {
        "id": "895c14b9-c7d4-4e62-9cbf-f9ddebe9e65c",
        "text": "TABLE OF CONTENTS\n(2.5.5)....................................................................................................................................28, 1 = Inferential Problems",
        "metadata": {
            "document_id": "E10 - Document 3.pdf",
            "chunk_index": 51,
            "source": "markdown",
            "embedding_version": "v1"
        }
    },
    {
        "id": "0a7e7eda-06d2-4317-b4fa-c8a7c178845d",
        "text": "TABLE OF CONTENTS\n(2.5.5)....................................................................................................................................28. Inferential Problems",
        "metadata": {
            "document_id": "E10 - Document 3.pdf",
            "chunk_index": 52,
            "source": "markdown",
            "embedding_version": "v1"
        }
    },
    {
        "id": "4eb83e68-12c0-417b-b466-d1956dba76db",
        "text": "TABLE OF CONTENTS\n(2.5.5)....................................................................................................................................28, 2 = . 6., 1 = Advantages of Externally Controlled Trials (2.5.6).....................................................................................29. 6., 2 =",
        "metadata": {
            "document_id": "E10 - Document 3.pdf",
            "chunk_index": 53,
            "source": "markdown",
            "embedding_version": "v1"
        }
    },
    {
        "id": "a5375eb2-4f21-4fba-b307-e760ae1bb983",
        "text": "TABLE OF CONTENTS\n. 7., 1 = Disadvantages of Externally Controlled Trials (2.5.7)...............................................................................29. 7., 2 = ",
        "metadata": {
            "document_id": "E10 - Document 3.pdf",
            "chunk_index": 54,
            "source": "markdown",
            "embedding_version": "v1"
        }
    },
    {
        "id": "bd8327ce-704c-4eeb-97e6-b581fb019cb4",
        "text": "Guidance for Industry 1 E10 Choice of Control Group and Related Issues in Clinical Trials\nThis guidance represents the Food and Drug Administration's (FDA's) current thinking on this topic.  It does not create or confer any rights for or on any person and does not operate to bind FDA or the public.  An alternative approach may be used if such approach satisfies the requirements of the applicable statutes and regulations.\nThis guidance is intended to assist applicants in choosing a control group for clinical trials intended to demonstrate the efficacy of a treatment.  The guidance also discusses related trial design and conduct issues and describes what trials using each design can demonstrate. This guidance does not address the regulatory requirements of any region.",
        "metadata": {
            "document_id": "E10 - Document 3.pdf",
            "chunk_index": 55,
            "source": "markdown",
            "embedding_version": "v1"
        }
    },
    {
        "id": "147e0826-3b8c-4ded-bf86-2bfccc003063",
        "text": "I. INTRODUCTION (1.0) 2\nThe choice of control group is always a critical decision in designing a clinical trial.  That choice affects the inferences that can be drawn from the trial, the ethical acceptability of the trial, the degree to which bias in conducting and analyzing the study can be minimized, the types of subjects that can be recruited and the pace of recruitment, the kind of endpoints that can be studied, the public and scientific credibility of the results, the acceptability of the results by regulatory authorities, and many other features of the study, its conduct, and its interpretation.\n1 This guidance was developed within the Expert Working Group (Efficacy) of the International Conference on Harmonisation of Technical Requirements for Registration of Pharmaceuticals for Human Use (ICH) and has been subject to consultation by the regulatory parties, in accordance with the ICH process.  This document has been endorsed by the ICH Steering Committee at Step 4 of the ICH process, July 2000.  At Step 4 of the process, the final draft is recommended for adoption to the regulatory bodies of the European Union, Japan, and the United States .\n2 Arabic numbers reflect the organizational breakdown in the document endorsed by the ICH Steering Committee at Step 4 of the ICH process, July 2000.",
        "metadata": {
            "document_id": "E10 - Document 3.pdf",
            "chunk_index": 56,
            "source": "markdown",
            "embedding_version": "v1"
        }
    },
    {
        "id": "f9c3b5d0-9cb2-42a9-b1c8-7ecdac67ab05",
        "text": "A. General Scheme and Purpose of Guidance (1.1)\nThe purpose of this guideance is to describe the general principles involved in choosing a control group for clinical trials intended to demonstrate the efficacy of a treatment and to discuss related trial design and conduct issues. This guidance does not address the regulatory requirements in any region, but describes what trials using each design can demonstrate.  The general principles described in this guidance are relevant to any controlled trial but the choice of control group is of particularly critical importance to clinical trials carried out during drug development to demonstrate efficacy.  The choice of the control group should be considered in the context of available standard therapies, the adequacy of the evidence to support the chosen design, and ethical considerations.",
        "metadata": {
            "document_id": "E10 - Document 3.pdf",
            "chunk_index": 57,
            "source": "markdown",
            "embedding_version": "v1"
        }
    },
    {
        "id": "8ed04d1b-000d-4b3d-9657-31967a4e686c",
        "text": "A. General Scheme and Purpose of Guidance (1.1)\nThis guidance first describes the purpose of the control group and the types of control groups commonly employed to demonstrate efficacy. It then discusses the critical design and interpretation issues associated with the use of an active control trial to demonstrate efficacy by showing non-inferiority or equivalence to the control (Section 1.5).  There are circumstances in which a finding of non-inferiority cannot be interpreted as evidence of efficacy.  Specifically, for a finding of non-inferiority to be interpreted as showing efficacy, the trial needs to have had the ability to distinguish effective from less effective or ineffective treatments.\nThe guidance then describes trials using each kind of control group in more detail (see sections 2.0-2.5.7) and considers, for each:\n- Its ability to minimize bias\n- Ethical and practical issues associated with its use\n- Its usefulness and the quality of inference in particular situations\n- Modifications of study design or combinations with other controls that can resolve ethical, practical, or inferential concerns\n- Its overall advantages and disadvantages\nSeveral other ICH guidances are particularly relevant to this guidance:",
        "metadata": {
            "document_id": "E10 - Document 3.pdf",
            "chunk_index": 58,
            "source": "markdown",
            "embedding_version": "v1"
        }
    },
    {
        "id": "d6a5cb04-af36-4406-a9be-c44c076f0e84",
        "text": "A. General Scheme and Purpose of Guidance (1.1)\n- E3:  Structure and Content of Clinical Study Reports\n- E5:  Ethnic Factors\n- E4:  Dose-Response Information to Support Drug Registration\n- E6:  Good Clinical Practice: Consolidated Guideline\n- E8:  General Considerations for Clinical Trials\n- E9:  Statistical Principles for Clinical Trials\nAlthough trials using any of the control groups described and discussed in this guidance may be useful and acceptable in clinical trials that serve as the basis for marketing approval in at least some circumstances, they are not equally appropriate or useful in every case.  The general approach to selecting the type of control is outlined in Section 3.0, Figure 1, and Table 1.\nAlthough this guidance is focused primarily on clinical trials intended to assess the efficacy of a treatment, many of the  considerations discussed also apply to the assessment of specific safety hypotheses and to safety or efficacy comparisons of two treatments.",
        "metadata": {
            "document_id": "E10 - Document 3.pdf",
            "chunk_index": 59,
            "source": "markdown",
            "embedding_version": "v1"
        }
    },
    {
        "id": "96941997-db9a-40c3-812a-bb7a0149c2f4",
        "text": "B. Purpose of Control Group (1.2)\nControl groups have one major purpose:  to allow discrimination of patient outcomes (for example, changes in symptoms, signs, or other morbidity) caused by the test treatment from outcomes caused by other factors, such as the natural progression of the disease, observer or patient expectations, or other treatment.  The control group experience tells us what would have happened to patients if they had not received the test treatment or if they had received a different treatment known to be effective.",
        "metadata": {
            "document_id": "E10 - Document 3.pdf",
            "chunk_index": 60,
            "source": "markdown",
            "embedding_version": "v1"
        }
    },
    {
        "id": "fea97fd9-500b-44cd-9868-1778d789649d",
        "text": "B. Purpose of Control Group (1.2)\nIf the course of a disease were uniform in a given patient population, or predictable from patient characteristics such that outcome could be predicted reliably for any given subject or group of subjects, results of treatment could simply be compared with the known outcome without treatment.  For example, one could assume that pain would have persisted for a defined time, blood pressure would not have changed, depression would have lasted for a defined time, tumors would have progressed, or the mortality after an acute infarction would have been the same as previously seen.  In unusual cases, the course of illness is in fact predictable in a defined population and it may be possible to use a similar group of patients previously studied as a historical control (see section 1.3.5).  In most situations, however, a concurrent control group is needed because it is not possible to predict outcome with adequate accuracy or certainty.",
        "metadata": {
            "document_id": "E10 - Document 3.pdf",
            "chunk_index": 61,
            "source": "markdown",
            "embedding_version": "v1"
        }
    },
    {
        "id": "41bcc652-78f6-4f1f-bf16-d44323feabd2",
        "text": "B. Purpose of Control Group (1.2)\nA concurrent control group is one chosen from the same population as the test group and treated in a defined way as part of the same trial that studies the test treatment, and over the same period of time.  The test and control groups should be similar with regard to all baseline and ontreatment variables that could influence outcome, except for the study treatment.  Failure to achieve this similarity can introduce a bias into the study.  Bias here (and as used in ICH E9) means the systematic tendency of any aspects of the design, conduct, analysis, and interpretation of the results of clinical trials to make the estimate of a treatment effect deviate from its true value.  Randomization and blinding are the two techniques usually used to minimize the chance of such bias and to ensure that the test treatment and control groups are similar at the start of the study and are treated similarly in the course of the study (see ICH E9).  Whether a trial design includes these features is a critical determinant of its quality and persuasiveness.",
        "metadata": {
            "document_id": "E10 - Document 3.pdf",
            "chunk_index": 62,
            "source": "markdown",
            "embedding_version": "v1"
        }
    },
    {
        "id": "4415eeaf-c776-4634-92bb-e09459a09d1f",
        "text": "1. Randomization (1.2.1)\nAssurance that subject populations are similar in test and control groups is best attained by randomly dividing a single sample population into groups that receive the test or control treatments.  Randomization avoids systematic differences between groups with respect to known or unknown baseline variables that could affect outcome.  Inability to eliminate systematic differences between treatment groups is a major problem of studies without a concurrent randomized control (see external control trials, section 1.3.5).  Randomization also provides a sound basis for statistical inference.",
        "metadata": {
            "document_id": "E10 - Document 3.pdf",
            "chunk_index": 63,
            "source": "markdown",
            "embedding_version": "v1"
        }
    },
    {
        "id": "a63c3716-93d3-4590-8b49-564bc3961d93",
        "text": "2. Blinding (1.2.2)\nThe groups should not only be similar at baseline, but should be treated and observed similarly during the trial, except for receiving the test and control drug.  Clinical trials are often double-blind (or double-masked ), meaning that both subjects and investigators, as well as sponsor or investigator staff involved in the treatment or clinical evaluation of subjects, are unaware of each subject's assigned treatment.  Blinding is intended to minimize the potential biases resulting from differences in management, treatment, or assessment of patients, or interpretation of results that could arise as a result of subject or investigator knowledge of the assigned treatment.  For example:",
        "metadata": {
            "document_id": "E10 - Document 3.pdf",
            "chunk_index": 64,
            "source": "markdown",
            "embedding_version": "v1"
        }
    },
    {
        "id": "31b9ed72-3642-41c8-bfea-9e20ec88d319",
        "text": "2. Blinding (1.2.2)\n- Subjects on active drug might report more favorable outcomes because they expect a benefit or might be more likely to stay in a study if they knew they were on active drug.\n- Observers might be less likely to identify and report treatment responses in a no-treatment group or might be more sensitive to a favorable outcome or adverse event in patients receiving active drug.\n- Knowledge of treatment assignment could affect vigor of attempts to obtain on-study or follow-up data.\n- Knowledge of treatment assignment could affect decisions about whether a subject should remain on treatment or receive concomitant medications or other ancillary therapy.\n- Knowledge of treatment assignment could affect decisions as to whether a given subject's results should be included in an analysis.\n- Knowledge of treatment assignment could affect choice of statistical analysis.\nBlinding is intended to ensure that subjective assessments and decisions are not affected by knowledge of treatment assignment.",
        "metadata": {
            "document_id": "E10 - Document 3.pdf",
            "chunk_index": 65,
            "source": "markdown",
            "embedding_version": "v1"
        }
    },
    {
        "id": "a22b762a-572e-4d4a-a6c1-4e75b7e26ab8",
        "text": "C. Types of Controls (1.3)\nControl groups in clinical trials can be classified on the basis of two critical attributes:  (1) the type of treatment used and (2) the method of determining who will be in the control group.  The type of control treatment may be any of the following four:  (1) placebo, (2) no treatment, (3) different dose or regimen of the study treatment, or (4) a different active treatment.  The principal methods of determining who will be in the control group are by randomization or by selection of a control population separate from the population treated in the trial (external or historical control).  This document categorizes control groups into five types.  The first four are concurrently controlled (the control group and test groups are chosen from the same population and treated concurrently), usually with random assignment to treatment; they are distinguished by the type of control treatment (listed above) used. External (historical) control groups, regardless of the comparator treatment, are considered together as the fifth type because of serious concerns about the ability of such trials to ensure comparability of test and control groups and their ability to minimize important biases, making this design usable only in unusual circumstances.",
        "metadata": {
            "document_id": "E10 - Document 3.pdf",
            "chunk_index": 66,
            "source": "markdown",
            "embedding_version": "v1"
        }
    },
    {
        "id": "4d442a49-bffb-40e3-a3fc-c101a56250a6",
        "text": "C. Types of Controls (1.3)\nIt is increasingly common to carry out studies that have more than one type of control group. Each type of control group is appropriate in some circumstances, but none is usable or adequate in every situation.  The five types of control group are:",
        "metadata": {
            "document_id": "E10 - Document 3.pdf",
            "chunk_index": 67,
            "source": "markdown",
            "embedding_version": "v1"
        }
    },
    {
        "id": "a972c7be-2754-456b-bcde-8209214fae49",
        "text": "1. Placebo Concurrent Control (1.3.1)\nIn a placebo-controlled trial, subjects are randomly assigned to a test treatment or to an identical-appearing treatment that does not contain the test drug.  The treatments may be titrated to effect or tolerance, or may be given at one or more fixed doses.  Such trials are almost always double-blind. The name of the control suggests that its purpose is to control for placebo effect (improvement in a subject resulting from thinking that he or she is taking a drug), but that is not its only or major benefit. Rather, the placebo control design, by allowing blinding and randomization and including a group that receives an inert treatment, controls for all potential influences on the actual or apparent course of the disease other than those arising from the pharmacologic action of the test drug.",
        "metadata": {
            "document_id": "E10 - Document 3.pdf",
            "chunk_index": 68,
            "source": "markdown",
            "embedding_version": "v1"
        }
    },
    {
        "id": "2647ed26-5310-493f-b9a4-1d488851601c",
        "text": "1. Placebo Concurrent Control (1.3.1)\nThese influences include spontaneous change (natural history of the disease and regression to the mean), subject or investigator expectations, the effect of being in a trial, use of other therapy, and subjective elements of diagnosis or assessment. Placebo-controlled trials seek to show a difference between treatments when they are studying effectiveness, but may also seek to show lack of difference (of specified size) in evaluating a safety measurement.  In that case, the question of whether the trial could have shown such a difference if there had been one is critical (see section 1.5).\nThe use of a placebo control group does not imply that the control group is untreated.  In many placebo-controlled trials, the new treatment and placebo are each added to a common standard therapy (so-called add-on studies , see section 2.1.5.2.1).",
        "metadata": {
            "document_id": "E10 - Document 3.pdf",
            "chunk_index": 69,
            "source": "markdown",
            "embedding_version": "v1"
        }
    },
    {
        "id": "de163e9d-9ef0-4319-bd0d-1f1129657cf1",
        "text": "2. No-treatment Concurrent Control (1.3.2)\nIn a no treatment-controlled trial, subjects are randomly assigned to test treatment or to no (i.e., absence of) study treatment.  The principal difference between this design and a placebo-controlled trial is that subjects and investigators are not blind to treatment assignment. Because of the advantages of double-blind designs, this design is likely to be needed and suitable only when it is difficult or impossible to double-blind (e.g., treatments with easily recognized toxicity) and only when there is reasonable confidence that study endpoints are objective and that the results of the trial are unlikely to be influenced by the factors listed in section 1.2.2.  Note that it is often possible to have a blinded evaluator carry out endpoint assessment, even if the overall trial is not double-blind. This is a valuable approach and should always be considered in trials that cannot be blinded, but it does not solve the other problems associated with knowing the treatment assignment (see section 1.2.2).",
        "metadata": {
            "document_id": "E10 - Document 3.pdf",
            "chunk_index": 70,
            "source": "markdown",
            "embedding_version": "v1"
        }
    },
    {
        "id": "fd8cfd74-8232-4148-bfab-333125febdcd",
        "text": "3. Dose-response Concurrent Control (1.3.3)\nIn a randomized, fixed-dose, dose-response trial, subjects are randomized to one of several fixeddose groups. Subjects may either be placed on their fixed dose initially or be raised to that dose gradually, but the intended comparison is between the groups on their final dose. Dose-response\ntrials are usually double-blind.  They may include a placebo (zero dose) and/or active control.  In a concentration-controlled trial, treatment groups are titrated to several fixed-concentration windows; this type of trial is conceptually similar to a fixed-dose, dose-response trial.  In a regimen-controlled trial subjects are randomized to two or more regimens of the study drug (e.g., once vs. twice daily, 3 days vs. 7 days).",
        "metadata": {
            "document_id": "E10 - Document 3.pdf",
            "chunk_index": 71,
            "source": "markdown",
            "embedding_version": "v1"
        }
    },
    {
        "id": "8136f5c9-34b8-48ac-ac93-ef1ac643fc10",
        "text": "4. Active (Positive) Concurrent Control (1.3.4)\nIn an active control (or positive control) trial, subjects are randomly assigned to the test treatment or to an active control treatment.  Such trials are usually double-blind, but this is not always possible; many oncology trials, for example, are considered difficult or impossible to blind (see section 1.3.2) because of different regimens, different routes of administration, and different toxicities.  Active control trials can have two distinct objectives with respect to showing efficacy: (1) to show efficacy of the test treatment by showing it is as good as a known effective treatment or (2) to show efficacy by showing superiority of the test treatment to the active control.  They may also be used with the primary objective of comparing the efficacy and/or safety of the two treatments (see section 1.4).  Whether the purpose of the trial is to show efficacy of the new treatment or to compare two treatments, the question of whether the trial would be capable of distinguishing effective from less effective or ineffective treatments is critical (see section 1.5).",
        "metadata": {
            "document_id": "E10 - Document 3.pdf",
            "chunk_index": 72,
            "source": "markdown",
            "embedding_version": "v1"
        }
    },
    {
        "id": "2b1480d5-6b81-441d-903a-2c520025776a",
        "text": "5. External Control (Including Historical Control) (1.3.5)\nAn externally controlled trial compares a group of subjects receiving the test treatment with a group of patients external to the study, rather than to an internal control group consisting of patients from the same population assigned to a different treatment.  The external control can be a group of patients treated at an earlier time (historical control) or a group treated during the same time period but in another setting.  The external control may be defined (a specific group of patients) or non-defined (a comparator group based on general medical knowledge of outcome). Use of this latter comparator is particularly treacherous (such trials are usually considered uncontrolled) because general impressions are so often inaccurate.  So-called baseline-controlled studies, in which subjects' status on therapy is compared with status before therapy (e.g., blood pressure, tumor size), have no internal control and are thus uncontrolled or externally controlled (see section 2.5).",
        "metadata": {
            "document_id": "E10 - Document 3.pdf",
            "chunk_index": 73,
            "source": "markdown",
            "embedding_version": "v1"
        }
    },
    {
        "id": "24498693-4f64-4cf5-90d6-6506a3cc5ed3",
        "text": "6. Multiple Control Groups (1.3.6)\nAs will be described further below (see section 1.5.1), it is often possible and advantageous to use more than one kind of control in a single study, e.g., use of both an active control and placebo.  Similarly, trials can use several doses of test drug and several doses of an active control, with or without placebo. This design may be useful for active drug comparisons where the relative potency of the two drugs is not well established, or where the purpose of the trial is to establish relative potency.",
        "metadata": {
            "document_id": "E10 - Document 3.pdf",
            "chunk_index": 74,
            "source": "markdown",
            "embedding_version": "v1"
        }
    },
    {
        "id": "6c95ce41-ad08-4a4f-ad07-e9097c1bf1cb",
        "text": "D. Purposes of Clinical Trials and Related Issues (1.4)\nTwo purposes of clinical trials should be distinguished:  (1) assessment of the efficacy and/or safety of a treatment and (2) assessment of the relative (comparative) efficacy, safety, risk/benefit relationship or utility of two treatments.",
        "metadata": {
            "document_id": "E10 - Document 3.pdf",
            "chunk_index": 75,
            "source": "markdown",
            "embedding_version": "v1"
        }
    },
    {
        "id": "38e57fbd-6785-4eda-826b-cdfcaccd4efe",
        "text": "1. Evidence of Efficacy (1.4.1)\nA trial using any of the control types may demonstrate efficacy of the test treatment by showing that it is superior to the control (placebo, no treatment, and low dose of test drug, active drug). An active control trial may, in addition, demonstrate efficacy in some cases by showing the new treatment to be similar in efficacy to a known effective treatment. This similarity establishes the efficacy of the test treatment, however, only if it can be assumed that the active control was effective under the conditions of the trial, as two treatments would also look similar if neither were effective in the trial (see section 1.5).\nClinical trials designed to demonstrate efficacy of a new drug by showing that it is similar in efficacy to a standard agent have been called equivalence trials. Most of these are actually noninferiority trials, attempting to show that the new drug is not less effective than the control by more than a defined amount, generally called the margin.",
        "metadata": {
            "document_id": "E10 - Document 3.pdf",
            "chunk_index": 76,
            "source": "markdown",
            "embedding_version": "v1"
        }
    },
    {
        "id": "65c2439c-80c0-405d-9461-5afc3fb545d3",
        "text": "2. Comparative Efficacy and Safety (1.4.2)\nIn some cases, the focus of the trial is on the comparison of one treatment with another treatment, not the efficacy of the test drug per se. Depending on the therapeutic area, these trials may be seen as providing information that is important for relative risk/benefit assessment.  The active comparator(s) should be acceptable to the region for which the data are intended.  It is not necessary to demonstrate superiority to the active comparator, and, depending on the situation, it may not be necessary to show non-inferiority.  For example, a less effective treatment could have safety advantages and thus be considered useful.\nEven though the primary focus of such a trial is the comparison of treatments, rather than demonstration of efficacy, the cautions described for conducting and interpreting non-inferiority trials need to be taken into account (see section 1.5).  Specifically, the ability of the comparative trial to detect a difference between treatments when one exists needs to be established because a trial incapable of distinguishing between treatments that are in fact different cannot provide useful comparative information.",
        "metadata": {
            "document_id": "E10 - Document 3.pdf",
            "chunk_index": 77,
            "source": "markdown",
            "embedding_version": "v1"
        }
    },
    {
        "id": "bf4a9b1c-0217-4a1e-8ba7-aba563e5041e",
        "text": "3. Fairness of Comparisons (1.4.3)\nFor the comparative trial to be informative concerning relative safety and/or efficacy, the trial needs to be fair; i.e., the conditions of the trial should not inappropriately favor one treatment over the other.  In practice, an active control equivalence or non-inferiority trial offered as evidence of efficacy also almost always needs to provide a fair effectiveness comparison with the control, because any doubt as to whether the control in the study had its usual effect would undermine assurance that the trial had assay sensitivity (see section 1.5). Among aspects of trial\ndesign that could unfairly favor one treatment are choice of dose or patient population and selection and timing of endpoints.",
        "metadata": {
            "document_id": "E10 - Document 3.pdf",
            "chunk_index": 78,
            "source": "markdown",
            "embedding_version": "v1"
        }
    },
    {
        "id": "43e8101f-e07d-440e-b46e-34dffd0bcfa2",
        "text": "a. Dose (1.4.3.1)\nIn comparing the test drug with an active control, it is important to choose an appropriate dose and dose regimen of the control and test drugs.  In examining the results of a comparison of two treatments, it is important to consider whether an apparently less effective treatment has been used at too low a dose or whether the apparently less well-tolerated treatment has been used at too high a dose.  In some cases, to show superior efficacy or safety convincingly it will be necessary to study several doses of the control and perhaps several doses of the test treatment.",
        "metadata": {
            "document_id": "E10 - Document 3.pdf",
            "chunk_index": 79,
            "source": "markdown",
            "embedding_version": "v1"
        }
    },
    {
        "id": "d5968532-9c5c-41bd-93c0-23129e7901e3",
        "text": "b. Patient Population (1.4.3.2)\nSelection of subjects for an active control trial can affect outcome; the population studied should be carefully considered in evaluating what the trial has shown.  For example, if many subjects in a trial have previously failed to respond to the control treatment, there would be a bias in favor of the new treatment. The results of such a trial could not be generalized to the entire population of previously untreated patients.  A finding of superiority of the new treatment, however, still would be evidence of the efficacy of the new treatment in the population studied.   In fact, a trial of a new treatment in apparent nonresponders to another treatment, in which the nonresponders are randomized to either the new or failed treatment (so long as this does not place the patients at risk), can provide a demonstration of the value of the new treatment in such nonresponders, a clinically valuable observation.",
        "metadata": {
            "document_id": "E10 - Document 3.pdf",
            "chunk_index": 80,
            "source": "markdown",
            "embedding_version": "v1"
        }
    },
    {
        "id": "01e8eea1-7dda-4811-b6c7-9666af80764c",
        "text": "b. Patient Population (1.4.3.2)\nSimilarly, it is sometimes possible to identify patient subsets more or less likely to have a favorable response or to have an adverse response to a particular drug.  For example, blacks usually respond poorly to the blood pressure effects of beta blockers and angiotensin- converting enzyme inhibitors, so that a comparison of a new antihypertensive with these drugs in these patients would tend to show superiority of the new drug. It would not be appropriate to conclude that the new drug is generally superior.  Again, however, a planned trial in a subgroup, with recognition of its limitations and of what conclusion can properly be drawn, could be informative.",
        "metadata": {
            "document_id": "E10 - Document 3.pdf",
            "chunk_index": 81,
            "source": "markdown",
            "embedding_version": "v1"
        }
    },
    {
        "id": "971e44db-d355-4686-b8b3-f4ab7644f5f1",
        "text": "c. Selection and Timing of Endpoints (1.4.3.3)\nWhen two treatments are used for the same disease or condition, they may differentially affect various outcomes of interest in that disease, particularly if they represent different classes or modalities of treatment.  Therefore, when comparing them in a clinical trial, the choice and timing of endpoints may favor one treatment or the other.  For example, thrombolytics in patients with acute myocardial infarction can reduce mortality but increase hemorrhagic stroke risk.  If a new, more pharmacologically active, thrombolytic were compared with an older thrombolytic, the more active treatment might look better if the endpoint were mortality, but worse if the endpoint were a composite of mortality and disabling stroke. Similarly, in comparing two analgesics in the management of dental pain, assigning a particularly heavy weight to pain at\nearly time points would favor the drug with more rapid onset of effect, while assigning more weight to later time points would favor a drug with a longer duration of effect.",
        "metadata": {
            "document_id": "E10 - Document 3.pdf",
            "chunk_index": 82,
            "source": "markdown",
            "embedding_version": "v1"
        }
    },
    {
        "id": "83d37fa3-0678-4816-ac50-18a32052d14e",
        "text": "E. Assay Sensitivity (1.5)\nAssay sensitivity is a property of a clinical trial defined as the ability to distinguish an effective treatment from a less effective or ineffective treatment.  Assay sensitivity is important in any trial but has different implications for trials intended to show differences between treatments (superiority trials) and trials intended to show non-inferiority.  If a trial intended to demonstrate efficacy by showing superiority of a test treatment to control lacks assay sensitivity, it will fail to show that the test treatment is superior and will fail to lead to a conclusion of efficacy.  In contrast, if a trial is intended to demonstrate efficacy by showing a test treatment to be noninferior to an active control, but lacks assay sensitivity, the trial may find an ineffective treatment to be non-inferior and could lead to an erroneous conclusion of efficacy.\nWhen two treatments within a trial are shown to have different efficacy (i.e., when one treatment is superior), that finding itself demonstrates that the trial had assay sensitivity.  In contrast, a successful non-inferiority trial (i.e., one that has shown non-inferiority), or an unsuccessful superiority trial, generally does not contain such direct evidence of assay sensitivity.",
        "metadata": {
            "document_id": "E10 - Document 3.pdf",
            "chunk_index": 83,
            "source": "markdown",
            "embedding_version": "v1"
        }
    },
    {
        "id": "305ad805-4945-48cb-b45d-d020bde1dd66",
        "text": "1. Assay Sensitivity in Non-inferiority or Equivalence Trials  (1.5.1)\nThe presence of assay sensitivity in a non-inferiority or equivalence trial may be deduced from two determinations:\nHistorical evidence of sensitivity to drug effects , i.e., that similarly designed trials in the past regularly distinguished effective treatments from less effective or ineffective treatments and\nAppropriate trial conduct , i.e., that the conduct of the trial did not undermine its ability to distinguish effective treatments from less effective or ineffective treatments.\nHistorical evidence of sensitivity to drug effects can, and should, be evaluated before beginning a non-inferiority trial.  Specifically, it should be determined that, in the specific therapeutic area under study, appropriately designed and conducted trials that used a specific active treatment, or other treatments with similar effects, reliably showed an effect. Optimally, this is demonstrated by finding that the active treatment intended for use as the active control was reliably found superior to placebo.  If this is the case, there is historical evidence of sensitivity to drug effects for similarly designed active control trials (see section 1.5.1.1).",
        "metadata": {
            "document_id": "E10 - Document 3.pdf",
            "chunk_index": 84,
            "source": "markdown",
            "embedding_version": "v1"
        }
    },
    {
        "id": "9809c290-54b4-4640-b68b-ea48293e7c00",
        "text": "1. Assay Sensitivity in Non-inferiority or Equivalence Trials  (1.5.1)\nAppropriateness of trial conduct can only be fully evaluated after the active control noninferiority trial is completed.  Not only should the design of the non-inferiority trial be similar to that of previous trials used to determine historical evidence of sensitivity to drug effects (e.g., entry criteria, allowable concomitant therapy); but, in addition, the actual study population entered, the concomitant therapies actually used, etc., should be assessed to ensure that conduct of the study was, in fact, similar to the previous trials.  The trial should also be conducted with\nhigh quality (e.g. good compliance, few losses to follow-up). Together with historical evidence of sensitivity to drug effects, appropriate trial conduct (section 1.5.1.2) provides assurance of assay sensitivity in the new active control trial.\nThe design and conduct of a non-inferiority trial thus involve four critical steps:\nDetermining that historical evidence of sensitivity to drug effects exists. Without this determination, demonstration of efficacy from a showing of non-inferiority is not possible and should not be attempted.",
        "metadata": {
            "document_id": "E10 - Document 3.pdf",
            "chunk_index": 85,
            "source": "markdown",
            "embedding_version": "v1"
        }
    },
    {
        "id": "6523df41-d312-4e06-b976-88476ad971bd",
        "text": "1. Assay Sensitivity in Non-inferiority or Equivalence Trials  (1.5.1)\nDesigning a trial. Important details of the trial design, e.g., study population, concomitant therapy, endpoints, run-in periods, should adhere closely to the design of the trials used to determine that  historical evidence of sensitivity to drug effects exists\nSetting a margin. An acceptable non-inferiority margin should be defined, taking into account the historical data and relevant clinical and statistical considerations.\nConducting the trial. The trial conduct should also adhere closely to that of the historical trials and should be of high quality.",
        "metadata": {
            "document_id": "E10 - Document 3.pdf",
            "chunk_index": 86,
            "source": "markdown",
            "embedding_version": "v1"
        }
    },
    {
        "id": "9ccaff10-93f2-4ac5-aae1-4aca8b46d9da",
        "text": "a. Historical Evidence of Sensitivity to Drug Effects and Choosing the Non-inferiority Margin (1.5.1.1)\nAs noted earlier, most active control equivalence trials are really non-inferiority trials intended to establish the efficacy of a new treatment.  Analysis of the results of non-inferiority trials is discussed in ICH guidances E9 and E3.  Briefly, in such a trial, test and known effective treatments are compared.  Prior to the trial, an equivalence or non-inferiority margin, sometimes called delta , is selected.  This margin is the degree of inferiority of the test treatments to the control that the trial will attempt to exclude statistically.  If the confidence interval for the difference between the test and control treatments excludes a degree of inferiority of the test treatment as large as, or larger than, the margin, the test treatment can be declared non-inferior; if the confidence interval includes a difference as large as the margin, the test treatment cannot be declared non-inferior.",
        "metadata": {
            "document_id": "E10 - Document 3.pdf",
            "chunk_index": 87,
            "source": "markdown",
            "embedding_version": "v1"
        }
    },
    {
        "id": "f981a65e-7b73-42e0-af27-f6387767f1e6",
        "text": "a. Historical Evidence of Sensitivity to Drug Effects and Choosing the Non-inferiority Margin (1.5.1.1)\nThe margin chosen for a non-inferiority trial cannot be greater than the smallest effect size that the active drug would be reliably expected to have compared with placebo in the setting of the planned trial.  If a difference between active control and the new drug favors the control by as much as or more than this margin, the new drug might have no effect at all.  Identification of the smallest effect size that the active drug would be reliably expected to have is only possible when there is historical evidence of sensitivity to drug effects and, indeed, identification of the margin is based upon that evidence.  The margin generally is identified based on past experience in placebo-controlled trials of adequate design under conditions similar to those planned for the new trial, but could also be supported by dose response or active control superiority studies. Regardless of the control groups used in those earlier studies, the value of interest in determining the margin is the measure of superiority of the active treatment to its control, not uncontrolled",
        "metadata": {
            "document_id": "E10 - Document 3.pdf",
            "chunk_index": 88,
            "source": "markdown",
            "embedding_version": "v1"
        }
    },
    {
        "id": "0d1203b7-f66a-4fbe-8bd5-d9fe3bd2399e",
        "text": "a. Historical Evidence of Sensitivity to Drug Effects and Choosing the Non-inferiority Margin (1.5.1.1)\nmeasures such as change from baseline.  Note that exactly how to calculate the margin is not described in this document, and there is little published experience on how to do this.\nThe determination of the margin in a non-inferiority trial is based on both statistical reasoning and clinical judgment, should reflect uncertainties in the evidence on which the choice is based, and should be suitably conservative.  If this is done properly, a finding that the confidence interval for the difference between new drug and the active control excludes a suitably chosen margin provides assurance that the test drug has an effect greater than zero.  In practice, the noninferiority margin chosen usually will be smaller than that suggested by the smallest expected effect size of the active control because of interest in ensuring that some clinically acceptable effect size (or fraction of the control drug effect) was maintained.  For example, it would not generally be considered sufficient in a mortality non-inferiority study to ensure that the test treatment had an effect greater than zero; retention of some substantial fraction of the mortality effect of the control would usually be sought.",
        "metadata": {
            "document_id": "E10 - Document 3.pdf",
            "chunk_index": 89,
            "source": "markdown",
            "embedding_version": "v1"
        }
    },
    {
        "id": "1717efd3-f672-45f3-820c-9170bb5428f8",
        "text": "a. Historical Evidence of Sensitivity to Drug Effects and Choosing the Non-inferiority Margin (1.5.1.1)\nThis would also be true in a trial whose primary focus is the relative effectiveness of a test drug and active control (see section 1.4.2), where it would be usual to seek assurance that the test and control drug were quite similar, not simply that the new drug had any effect at all.",
        "metadata": {
            "document_id": "E10 - Document 3.pdf",
            "chunk_index": 90,
            "source": "markdown",
            "embedding_version": "v1"
        }
    },
    {
        "id": "1260008d-3cff-4b21-bdf6-bccbc9b1b63d",
        "text": "a. Historical Evidence of Sensitivity to Drug Effects and Choosing the Non-inferiority Margin (1.5.1.1)\nThe fact that the choice of the margin to be excluded is based on historical evidence gives the non-inferiority trial an element in common with a historically controlled (externally controlled) trial. The non-inferiority trial design is appropriate and reliable only when the historical estimate of drug effect size can be well supported by reference to the results of previous studies of the control drug.  These studies should lead to the conclusion that the active control can consistently be distinguished from placebo in appropriately sized trials of design similar to the proposed trial and should identify an effect size that represents the smallest effect that the control can reliably be expected to have.  If placebo-controlled trials of a design similar to the one proposed more than occasionally show no difference between the proposed active control and placebo, and this cannot be explained by some characteristic of the study, only superiority of the test drug would be interpretable.",
        "metadata": {
            "document_id": "E10 - Document 3.pdf",
            "chunk_index": 91,
            "source": "markdown",
            "embedding_version": "v1"
        }
    },
    {
        "id": "f58a29f8-8b3f-46f5-9a48-1bd966ef6f72",
        "text": "a. Historical Evidence of Sensitivity to Drug Effects and Choosing the Non-inferiority Margin (1.5.1.1)\nWhether there is historical evidence of sensitivity to drug effects in any given case is to some degree a matter of judgment.  In some cases sensitivity to drug effects is clear from the consistency of results of prior placebo-controlled trials or is obvious because the outcome of treated and untreated disease is very different.  For example, in many infectious diseases cure rates on effective treatment far exceed the spontaneous cure rates over the course of a short-term study.  There are many conditions, however, in which drugs considered effective cannot regularly be shown superior to placebo in well-controlled trials; and one therefore cannot reliably determine a minimum effect the drug will have in the setting of a specific trial.  Such conditions tend to include those in which there is substantial improvement and variability in placebo groups, and/or in which the effects of therapy are small or variable, such as depression, anxiety, dementia, angina, symptomatic congestive heart failure, seasonal allergies, and symptomatic gastroesophageal reflux disease.",
        "metadata": {
            "document_id": "E10 - Document 3.pdf",
            "chunk_index": 92,
            "source": "markdown",
            "embedding_version": "v1"
        }
    },
    {
        "id": "996f725f-b784-414f-b8d0-479a1500daea",
        "text": "a. Historical Evidence of Sensitivity to Drug Effects and Choosing the Non-inferiority Margin (1.5.1.1)\nIn all these cases, there is no doubt that the standard treatments are effective because there are many well-controlled trials of each of these drugs that have shown an effect. Based on available\nexperience, however, it would be difficult to describe trial conditions in which the drug would reliably have at least a minimum effect (i.e., conditions in which there is historical evidence of sensitivity to drug effects) and that, therefore, could be used to identify an appropriate margin.  In some cases, the experience on which the historical evidence of sensitivity to drug effects is based may be of questionable relevance, e.g., if standards of treatment and diagnosis have changed substantially over time (for an example, see section 2.1.7.1).  If someone proposing to use an active-control or non-inferiority design cannot provide sufficient support for historical evidence of the sensitivity to drug effects of the study with the chosen non-inferiority margin, a finding of non-inferiority cannot be considered informative with respect to efficacy.",
        "metadata": {
            "document_id": "E10 - Document 3.pdf",
            "chunk_index": 93,
            "source": "markdown",
            "embedding_version": "v1"
        }
    },
    {
        "id": "926636a0-55c0-415e-ad61-a16913f4913e",
        "text": "a. Historical Evidence of Sensitivity to Drug Effects and Choosing the Non-inferiority Margin (1.5.1.1)\nAs noted, a determination regarding historical evidence of sensitivity to drug effects applies only to trials of a specific design.  For a planned non-inferiority trial to be similarly sensitive to drug effects, it is essential that the trial have critical design characteristics similar to those of the historical trials.  These design characteristics include, for example, the entry criteria (severity of medical condition, concomitant illness, method of diagnosis), dose and regimen of control drug, concomitant treatments used, the endpoint measured and timing of assessments, and the use of a washout period to exclude selected patients.  When differences in study design characteristics are unavoidable or desirable (e.g. because of technological or therapeutic advances), the implications of any differences for the determination of the presence of historical evidence of sensitivity to drug effects and for choice of margin should be carefully considered.",
        "metadata": {
            "document_id": "E10 - Document 3.pdf",
            "chunk_index": 94,
            "source": "markdown",
            "embedding_version": "v1"
        }
    },
    {
        "id": "c0fc9825-fdb5-4bff-8f27-036a2e449d53",
        "text": "b. Appropriate Trial Conduct (1.5.1.2)\nEven where there is historical evidence of sensitivity to drug effects and the new study is similar in design to the past studies, assay sensitivity can be undermined by the actual conduct of the trial.  To ensure assay sensitivity of a trial, its conduct should be of high quality and the patients actually enrolled, the treatments (other than the test treatment) actually given, and the assessments actually made should be similar to those of the trials on which the determination of historical sensitivity to drug effects was based.\nThere are many factors in the conduct of a trial that can reduce the observed difference between an effective treatment and a less effective or ineffective treatment and therefore may reduce a trial's assay sensitivity, such as:",
        "metadata": {
            "document_id": "E10 - Document 3.pdf",
            "chunk_index": 95,
            "source": "markdown",
            "embedding_version": "v1"
        }
    },
    {
        "id": "84165437-8045-4302-a59b-3bab1a06a037",
        "text": "b. Appropriate Trial Conduct (1.5.1.2)\n1. Poor compliance with therapy\n2. Poor responsiveness of the enrolled study population to drug effects\n3. Use of concomitant non-protocol medication or other treatment that interferes with the test drug or that reduces the extent of the potential response\n4. An enrolled population that tends to improve spontaneously, leaving no room for further drug-induced improvement\n5. Poorly applied diagnostic criteria (patients lacking the disease to be studied)\n6. Biased assessment of endpoint because of knowledge that all patients are receiving a potentially active drug, e.g., a tendency to read blood pressure responses as normalized, potentially reducing the difference between test drug and control",
        "metadata": {
            "document_id": "E10 - Document 3.pdf",
            "chunk_index": 96,
            "source": "markdown",
            "embedding_version": "v1"
        }
    },
    {
        "id": "03c5ffee-90a1-4720-9a0b-50afa6becb1f",
        "text": "b. Appropriate Trial Conduct (1.5.1.2)\nClinical researchers and trial sponsors intend to perform high-quality trials, and the availability of the Good Clinical Practices guidance (ICH E6) will continue to enhance trial quality. Nonetheless, it should be appreciated that in trials intended to show a difference between treatments there is a strong imperative to use a good trial design and minimize trial errors because many trial imperfections increase the likelihood of failing to show a difference between treatments when one exists.  In placebo-controlled trials many efforts are made to improve compliance and increase the likelihood that the patient population will be responsive to drug effects to ensure that an effective treatment will be distinguished from placebo.  Nonetheless, in many clinical settings, despite the strong stimulus and extensive efforts to ensure trial excellence and assay sensitivity, clinical trials are often unable to reliably distinguish effective drugs from placebo.",
        "metadata": {
            "document_id": "E10 - Document 3.pdf",
            "chunk_index": 97,
            "source": "markdown",
            "embedding_version": "v1"
        }
    },
    {
        "id": "836dd4c8-0ab8-430f-a0ad-7dfb4c658a7b",
        "text": "b. Appropriate Trial Conduct (1.5.1.2)\nIn contrast, in trials intended to show that there is not a difference of a particular size (noninferiority) between two treatments, there may be a much weaker stimulus to engage in many of these efforts to ensure study quality that will help ensure that differences will be detected, i.e., that ensure assay sensitivity.  The kinds of trial error that diminish observed differences between treatments (e.g., poor compliance, high placebo response, certain concomitant treatment, misclassification of outcomes) are of particular concern with respect to preservation of assay sensitivity.  However, when it is believed that the new drug is actually superior to the control, there will be a strong stimulus to conduct a high quality trial so that the non-inferiority margin is more likely to be excluded.  It should also be noted that some kinds of trial errors can increase variance, which would decrease the likelihood of showing non-inferiority by widening the confidence interval, so that a difference between treatment and control greater than the margin could not be excluded.  There would therefore be a strong stimulus in non-inferiority trials to reduce such sources of variance as poor measurement technique.",
        "metadata": {
            "document_id": "E10 - Document 3.pdf",
            "chunk_index": 98,
            "source": "markdown",
            "embedding_version": "v1"
        }
    },
    {
        "id": "a24f1de7-414d-4c7c-83fc-4c7c407462ab",
        "text": "b. Appropriate Trial Conduct (1.5.1.2)\nAs noted, to determine that a non-inferiority trial had appropriate trial conduct, its conduct should be reviewed not only for the presence of factors that might obscure differences between treatments but also for factors that might make the trial different from the trials that provided the basis for determining the non-inferiority margin.  In particular, it should be determined whether any observed differences in the populations enrolled, the use of concomitant therapies, compliance with therapy, and the extent of, and reasons for, dropping out could adversely affect assay sensitivity.  Even when the design and conduct of a trial appear to have been quite similar to those of the trials providing the basis for determining the non-inferiority margin, outcomes with the active control treatment that are visibly atypical (e.g., cure rate in an antibiotic trial that is unusually high or low) can indicate that important differences existed.",
        "metadata": {
            "document_id": "E10 - Document 3.pdf",
            "chunk_index": 99,
            "source": "markdown",
            "embedding_version": "v1"
        }
    },
    {
        "id": "ae4b50ef-1a08-48ac-868a-5ac3faec021f",
        "text": "2. Assay Sensitivity in Trials Intended to Demonstrate Superiority (1.5.2)\nThe question of assay sensitivity, although particularly critical in non-inferiority trials, actually arises in any trial that fails to detect a difference between treatments, including a placebo-controlled trial and a dose-response trial. If a treatment fails to show superiority to placebo, for example, it means either that the treatment was ineffective or that the study as designed and conducted was not capable of distinguishing an effective treatment from placebo.\nA useful approach to the assessment of assay sensitivity in active control trials and in placebocontrolled trials is the three-arm trial , including both placebo and a known active treatment, a trial design with several advantages.  Such a trial measures effect size (test drug versus placebo) and allows comparison of test drug and active control in a setting where assay sensitivity is established by the active control versus placebo comparison. (See Section 2.1.5.1.1).",
        "metadata": {
            "document_id": "E10 - Document 3.pdf",
            "chunk_index": 100,
            "source": "markdown",
            "embedding_version": "v1"
        }
    },
    {
        "id": "59094ec3-6022-4255-a6f4-4c3f03b566d2",
        "text": "1. Description (See Section 1.3.1) (2.1.1)\nIn a placebo-controlled trial, subjects are assigned, almost always by randomization, to either a test treatment or to a placebo. A placebo is a dummy treatment that appears as identical as possible to the test treatment with respect to physical characteristics such as color, weight, taste and smell, but that does not contain the test drug.  Some trials may study more than one dose of the test treatment or include both an active control and placebo.  In these cases, it may be easier for the investigator to use more than one placebo ( double-dummy ) than to try to make all treatments look the same. The use of placebo facilitates, and is almost always accompanied by, double-blinding (or double-masking). The difference in outcome between the active treatment and placebo groups is the measure of treatment effect under the conditions of the trial.  Within this general description there are a wide variety of designs that can be used successfully: Parallel or crossover designs (see ICH E9), single fixed dose or titration in the active drug group, several fixed doses.  Several designs meriting special attention will be described below.",
        "metadata": {
            "document_id": "E10 - Document 3.pdf",
            "chunk_index": 101,
            "source": "markdown",
            "embedding_version": "v1"
        }
    },
    {
        "id": "dc6bea93-c680-44b1-943e-30f1be56fb73",
        "text": "1. Description (See Section 1.3.1) (2.1.1)\nNote that not every study that includes a placebo is a placebo-controlled study.  For example, an active control study could use a placebo for each drug (double-dummy) to facilitate blinding; this is still an active control trial, not a placebo-controlled trial.  A placebo-controlled trial is one in which treatment with a placebo is compared with treatment with a test drug.\nIt should also be noted that not all placebos are completely inactive.  For example, some vehicle controls used in studies of topical skin preparations may have beneficial activity.  This does not impair the ability of the design to measure the specific effect of the test agent.  Special problems arise when the chosen vehicle control may have harmful effects.   In this case a no treatment arm would allow the measurement of the total effect of the test agent plus its vehicle.",
        "metadata": {
            "document_id": "E10 - Document 3.pdf",
            "chunk_index": 102,
            "source": "markdown",
            "embedding_version": "v1"
        }
    },
    {
        "id": "0e6fd3fd-b3f6-4f7e-ad2a-0b53d314e91d",
        "text": "2. Ability to Minimize Bias (2.1.2)\nThe placebo-controlled trial, using randomization and blinding, generally minimizes subject and investigator bias.  Such trials, however, are not impervious to blind-breaking through recognition of pharmacologic effects of one treatment; blinded outcome assessment can enhance bias reduction in such cases.  This concern may be particularly relevant in crossover studies.",
        "metadata": {
            "document_id": "E10 - Document 3.pdf",
            "chunk_index": 103,
            "source": "markdown",
            "embedding_version": "v1"
        }
    },
    {
        "id": "e75a9ca5-40d2-4d6e-bc68-9f4dcc1f8886",
        "text": "3. Ethical Issues (2.1.3)\nWhen a new treatment is tested for a condition for which no effective treatment is known, there is usually no ethical problem with a study comparing the new treatment to placebo. Use of a placebo control may raise problems of ethics, acceptability, and feasibility, however, when an effective treatment is available for the condition under study in a proposed trial.  In cases where an available treatment is known to prevent serious harm, such as death or irreversible morbidity in the study population, it is generally inappropriate to use a placebo control.  There are occasional exceptions, however, such as cases in which standard therapy has toxicity so severe that many patients have refused to receive it.",
        "metadata": {
            "document_id": "E10 - Document 3.pdf",
            "chunk_index": 104,
            "source": "markdown",
            "embedding_version": "v1"
        }
    },
    {
        "id": "96d15b74-f22d-4458-b9e0-0aec7eeb1957",
        "text": "3. Ethical Issues (2.1.3)\nIn other situations, when there is no serious harm, it is generally considered ethical to ask patients to participate in a placebo-controlled trial, even if they may experience discomfort as a result, provided the setting is noncoercive and patients are fully informed about available therapies and the consequences of delaying treatment.  Such trials, however, even if ethical, may pose important practical problems.  For example, deferred treatment of pain or other symptoms may be unacceptable to patients or physicians and they may not want to participate in a trial that requires this.  Whether a particular placebo controlled trial of a new agent will be acceptable to subjects and investigators when there is known effective therapy is a matter of investigator, patient, and institutional review board (IRB)/ independent ethics committee (IEC) judgment, and acceptability may differ among ICH regions.  Acceptability could depend on the specific design of the trial and the patient population chosen, as will be discussed below (see section 2.1.5).",
        "metadata": {
            "document_id": "E10 - Document 3.pdf",
            "chunk_index": 105,
            "source": "markdown",
            "embedding_version": "v1"
        }
    },
    {
        "id": "5cdb6677-c46d-47c1-a21d-6bf649c33c21",
        "text": "3. Ethical Issues (2.1.3)\nWhether a particular placebo-controlled trial is ethical may in some cases depend on what is believed to have been clinically demonstrated under the particular circumstances of the trial.  For example, a short term placebo-controlled trial of a new antihypertensive agent in patients with mild essential hypertension and no end-organ disease might be considered generally acceptable, while a longer trial, or one that included sicker patients, probably would not be.\nIt should be emphasized that use of a placebo or no-treatment control does not imply that the patient does not get any treatment at all.  For example, in an oncology trial, when no active drug is approved, patients in both the placebo or no-treatment group and the test drug group will receive needed palliative treatment, such as analgesics, and best supportive care.  Many placebocontrolled trials are conducted as add-on trials , where all patients receive a specified standard therapy or therapy left to the choice of the treating physician or institution (see section 2.1.5.2.1).",
        "metadata": {
            "document_id": "E10 - Document 3.pdf",
            "chunk_index": 106,
            "source": "markdown",
            "embedding_version": "v1"
        }
    },
    {
        "id": "f37cf9ed-a738-4033-aaae-54a1088da5cd",
        "text": "4. Usefulness of Placebo-controlled Trials and Validity of Inference in Particular Situations (2.1.4)\nWhen used to show effectiveness of a treatment, the placebo-controlled trial is as free of assumptions and reliance on external (extra-study) information as it is possible to be.  Most problems in the design or conduct of a trial increase the likelihood of failure to demonstrate a treatment difference (and thereby establish efficacy), so that the trial contains built-in incentives for trial excellence.  Even when the primary purpose of a trial is comparison of two active agents or assessment of dose-response, the addition of a placebo provides an internal standard that enhances the inferences that can be drawn from the other comparisons.",
        "metadata": {
            "document_id": "E10 - Document 3.pdf",
            "chunk_index": 107,
            "source": "markdown",
            "embedding_version": "v1"
        }
    },
    {
        "id": "0a0ebff2-9844-4434-9c3a-59164c1941d5",
        "text": "4. Usefulness of Placebo-controlled Trials and Validity of Inference in Particular Situations (2.1.4)\nPlacebo-controlled trials also provide the maximum ability to distinguish adverse effects caused by a drug from those resulting from underlying disease or intercurrent illness.  Note, however, that when used to show similarity of two treatments, for example, to show that a drug does not have a particular adverse effect by showing similar rates of the event in drug-treated and placebotreated patients, placebo-controlled trials have the same assay sensitivity problem as any equivalence or non-inferiority trial (see section 1.5.1).  To interpret the result, one must know that if the study drug had caused an adverse event, the event would have been observed.  Ordinarily, such a study should include an active control treatment that does cause the adverse event in question, but in some cases it may be possible to conclude that a study has assay sensitivity to such an effect by documenting historical sensitivity to adverse drug effects for a particular study design.",
        "metadata": {
            "document_id": "E10 - Document 3.pdf",
            "chunk_index": 108,
            "source": "markdown",
            "embedding_version": "v1"
        }
    },
    {
        "id": "da1e4f44-3bce-4a3a-b4de-29571a484a94",
        "text": "5. Modifications of Design and Combinations with Other Controls That Can Resolve Ethical, Practical, or Inferential Issues (2.1.5)\nIt is often possible to address the ethical or practical limitations of placebo-controlled trials by using modified study designs that still retain the inferential advantages of these trials.  In addition, placebo-controlled trials can be made more informative by including additional treatment groups, such as multiple doses of the test agent or a known active control treatment.",
        "metadata": {
            "document_id": "E10 - Document 3.pdf",
            "chunk_index": 109,
            "source": "markdown",
            "embedding_version": "v1"
        }
    },
    {
        "id": "ac366a3a-803c-4da4-95c2-3b798bb9dd86",
        "text": "i. Three-arm Trial; Placebo and Active Control  (2.1.5.1.1)\nAs noted in section 1.5.1, three-arm trials including an active control as well as a placebo-control group can readily assess whether a failure to distinguish test treatment from placebo implies ineffectiveness of the test treatment or is simply the result of a trial that lacked the ability to identify an active drug.  The comparison of placebo to standard drug in such a trial provides internal evidence of assay sensitivity.  It is possible to make the active groups larger than the placebo group to improve the precision of the active drug comparison, if this is considered important.  This may also make the trial more acceptable to patients and investigators, as there is less chance of being randomized to placebo.",
        "metadata": {
            "document_id": "E10 - Document 3.pdf",
            "chunk_index": 110,
            "source": "markdown",
            "embedding_version": "v1"
        }
    },
    {
        "id": "73219e40-afa9-4886-84a3-f72684e75ab3",
        "text": "ii. Additional Doses  (2.1.5.1.2)\nRandomization to several fixed doses of the test drug in addition to placebo allows assessment of dose-response and may be particularly useful in a comparative trial to ensure a fair comparison of treatments (see ICH E4: Dose-Response Information to Support Drug Registration).",
        "metadata": {
            "document_id": "E10 - Document 3.pdf",
            "chunk_index": 111,
            "source": "markdown",
            "embedding_version": "v1"
        }
    },
    {
        "id": "9535f2f5-b7d0-4573-9f83-8e42a23827ec",
        "text": "iii. Factorial Designs (2.1.5.1.3)\nFactorial designs may be used to explore several doses of the investigational drug as monotherapy and in combination with several doses of another agent proposed for use in combination with it.  A single study of this type can define the properties of a wide array of combinations.  Such studies are common in the evaluation of new antihypertensive therapies, but\ncan be considered in a variety of settings where more than one treatment is used simultaneously. For example, the independent additive effects of aspirin and streptokinase in preventing mortality after a heart attack were shown in such a trial.",
        "metadata": {
            "document_id": "E10 - Document 3.pdf",
            "chunk_index": 112,
            "source": "markdown",
            "embedding_version": "v1"
        }
    },
    {
        "id": "b6b6f58a-a4bf-4d60-9c56-b55a7f90b90b",
        "text": "i. Add on Study, Placebo-Controlled; Replacement Study. (2.1.5.2.1)\nAn add-on study is a placebo-controlled trial of a new agent conducted in people also receiving standard treatment.  Such studies are particularly important when available treatment is known to decrease mortality or irreversible morbidity, and when a non-inferiority trial with standard treatment as the active control cannot be carried out or would be difficult to interpret (see section 1.5).  It is common to study anticancer, antiepileptic, and heart failure drugs this way. This design is useful only when standard treatment is not fully effective (which, however, is almost always the case), and it has the advantage of providing evidence of improved clinical outcomes (rather than mere non-inferiority). Efficacy is, of course, established by such studies only for the combination treatment, and the dose in a monotherapy situation might be different from the dose found to be effective in combination.  In general, this approach is likely to succeed only when the new and standard treatments possess different pharmacologic mechanisms, although there are exceptions.",
        "metadata": {
            "document_id": "E10 - Document 3.pdf",
            "chunk_index": 113,
            "source": "markdown",
            "embedding_version": "v1"
        }
    },
    {
        "id": "4caba4ff-552d-47fe-9aa0-14cc68de3b77",
        "text": "i. Add on Study, Placebo-Controlled; Replacement Study. (2.1.5.2.1)\nFor example, combination treatments for people with AIDS may show a beneficial effect of pharmacologically related drugs because of delays in development of resistance.\nA variation of this design that can sometimes give information on monotherapy, and that is particularly applicable in the setting of chronic disease, is the replacement study, in which the new drug or placebo is added by random assignment to conventional treatment given at an effective dose and the conventional treatment is then withdrawn, usually by tapering. The ability to maintain the subjects' baseline status is then observed in the drug and placebo groups using predefined success criteria.  This approach has been used to study steroid-sparing substitutions in steroid-dependent patients, avoiding initial steroid withdrawal and the recrudescence of symptoms in a washout period.  The approach has also been used to study antiepileptic drug monotherapy.",
        "metadata": {
            "document_id": "E10 - Document 3.pdf",
            "chunk_index": 114,
            "source": "markdown",
            "embedding_version": "v1"
        }
    },
    {
        "id": "5dfb6386-cecc-48f3-9147-df1d62ff8751",
        "text": "ii. Early Escape ; Rescue Treatment (2.1.5.2.2)\nIt is possible to design a study to plan for early escape from ineffective therapy.  Early escape refers to prompt removal of subjects whose clinical status worsens or fails to improve to a defined level (blood pressure not controlled by a prespecified time, seizure rate greater than some prescribed value, blood pressure rising to a certain level, angina frequency above a defined level, liver enzymes failing to normalize by a preset time in patients with hepatitis), who have a single event that treatment was intended to prevent (first recurrence of unstable angina, grand mal seizure, paroxysmal supraventricular arrhythmia), or who otherwise require rescue treatment.  In such cases, the need to change treatment becomes a study endpoint. The criteria for deciding whether these endpoints have occurred should be well specified, and the timing of measurements should ensure that patients would not remain untreated with an active drug while their disease is poorly controlled. The primary difficulty with this trial design is that it may give information",
        "metadata": {
            "document_id": "E10 - Document 3.pdf",
            "chunk_index": 115,
            "source": "markdown",
            "embedding_version": "v1"
        }
    },
    {
        "id": "b9b4360c-49c6-46a0-9451-53e137f8f95c",
        "text": "ii. Early Escape ; Rescue Treatment (2.1.5.2.2)\nonly on short-term effectiveness. The randomized withdrawal trial (see section 2.1.5.2.4), however, which can also incorporate early-escape features, can give information on long-term effectiveness.",
        "metadata": {
            "document_id": "E10 - Document 3.pdf",
            "chunk_index": 116,
            "source": "markdown",
            "embedding_version": "v1"
        }
    },
    {
        "id": "d5e21e28-3a35-405b-ab16-2d9fc618e082",
        "text": "iii. Limited Placebo Period (2.1.5.2.3)\nIn a situation where long-term placebo treatment would not be acceptable, the use of a placebo group for a short period at the beginning of an active control trial could establish assay sensitivity (at least for short-term effects). The trial would then continue without the placebo group.",
        "metadata": {
            "document_id": "E10 - Document 3.pdf",
            "chunk_index": 117,
            "source": "markdown",
            "embedding_version": "v1"
        }
    },
    {
        "id": "d0771012-0b82-4ba7-b971-e1c128e8a502",
        "text": "iv. Randomized Withdrawal (2.1.5.2.4)\nIn a randomized withdrawal trial, subjects receiving a test treatment for a specified time are randomly assigned to continued treatment with the test treatment or to placebo (i.e., withdrawal of active therapy).  Subjects for such a trial could be derived from an organized open single-arm study, from an existing clinical cohort (but usually with a protocol-specified wash-in phase to establish the initial on-therapy baseline), from the active arm of a controlled trial, or from one or both arms of an active control trial.  Any difference that emerges between the group receiving continued treatment and the group randomized to placebo would demonstrate the effect of the active treatment.  The pre-randomization observation period on treatment can be of any length; this approach can therefore be used to study long-term persistence of effectiveness when longterm placebo treatment would not be acceptable.  The post-withdrawal observation period could be of fixed duration or could use early escape or time to event (e.g., relapse of depression) approaches.",
        "metadata": {
            "document_id": "E10 - Document 3.pdf",
            "chunk_index": 118,
            "source": "markdown",
            "embedding_version": "v1"
        }
    },
    {
        "id": "cd7af9ab-a698-4990-8e73-5ac4305e2334",
        "text": "iv. Randomized Withdrawal (2.1.5.2.4)\nAs with the early-escape design, careful attention should be paid to procedures for monitoring patients and assessing study endpoints to ensure that patients failing on an assigned treatment are identified rapidly.\nThe randomized withdrawal approach is useful in several situations.  First, it may be suitable for drugs that appear to resolve an episode of recurring illness (e.g., antidepressants), in which case the withdrawal study is, in effect, a relapse-prevention study.  Second, it may be used for drugs that suppress a symptom or sign (chronic pain, hypertension, and angina), but where a long-term placebo-controlled trial would be difficult; in this case, the study can establish long-term efficacy. Third, the design is particularly useful in determining how long a therapy should be continued (e.g., post-infarction treatments with a beta-blocker).\nThe general advantage of randomized withdrawal designs, when used with an early-escape endpoint, such as return of symptoms, is that the period of placebo exposure with poor response that a patient would have to undergo is short.",
        "metadata": {
            "document_id": "E10 - Document 3.pdf",
            "chunk_index": 119,
            "source": "markdown",
            "embedding_version": "v1"
        }
    },
    {
        "id": "4fcbec46-9524-418e-a893-9acc4f991cdf",
        "text": "iv. Randomized Withdrawal (2.1.5.2.4)\nThis type of design can address dosing issues.  After all patients have received an initial fixed dose, they could be randomly assigned in the withdrawal phase to several different doses (as well as placebo), a particularly useful approach when there is reason to think the initial and maintenance doses might be different, either on pharmacodynamic grounds or because there is substantial accumulation of active drug resulting from a long half life of parent drug or active metabolite. Note that the randomized withdrawal design could be used to assess dose-response\nafter an initial placebo-controlled titration study (See ICH E4). The titration study is an efficient design for establishing effectiveness, but does not give good dose-response information in many cases.  The randomized withdrawal phase, with responders randomly assigned to several fixed doses and placebo, will permit dose-response to be studied rigorously while allowing the efficiency of the titration design to be used in the initial phase of the trial.",
        "metadata": {
            "document_id": "E10 - Document 3.pdf",
            "chunk_index": 120,
            "source": "markdown",
            "embedding_version": "v1"
        }
    },
    {
        "id": "0d4da446-df5f-4952-ae0e-6abe5b600a94",
        "text": "iv. Randomized Withdrawal (2.1.5.2.4)\nIn using randomized withdrawal designs, it is important to appreciate the possibility of withdrawal phenomena, suggesting the wisdom of relatively slow tapering.  A patient may develop tolerance to a drug such that no benefit is being accrued, but the drug's withdrawal may lead to disease exacerbation, resulting in an erroneous conclusion of persisting efficacy.  It is also important to realize that treatment effects observed in these trials may be larger than those seen in an unselected population because randomized withdrawal studies are enriched with responders and exclude people who cannot tolerate the drug.  This phenomenon results when the trial explicitly includes only subjects who appear to have responded to the drug or includes only people who have completed a previous phase of study (which is often an indicator of a good response and always indicates ability to tolerate the drug).  In the case of studies intended to determine how long a therapy should be continued, such entry criteria provide the study population and comparison of interest.",
        "metadata": {
            "document_id": "E10 - Document 3.pdf",
            "chunk_index": 121,
            "source": "markdown",
            "embedding_version": "v1"
        }
    },
    {
        "id": "077008b7-3bac-4c3d-82ae-fa2110b2e46b",
        "text": "v. Other Design Considerations  (2.1.5.2.5)\nIn any placebo-controlled study, unbalanced randomization (e.g., 2:1, study drug to placebo) may enhance the safety database and may also make the study more attractive to patients and/or investigators.",
        "metadata": {
            "document_id": "E10 - Document 3.pdf",
            "chunk_index": 122,
            "source": "markdown",
            "embedding_version": "v1"
        }
    },
    {
        "id": "455a2ca7-3089-4ac2-b9ff-2a45fa71369b",
        "text": "6. Advantages of Placebo-controlled Trials (2.1.6)\n- a. Ability to Demonstrate Efficacy  (2.1.6.1)\nLike other superiority trials, a placebo-controlled trial contains internal evidence of assay sensitivity.  When a difference is demonstrated it is interpretable without reference to external findings.",
        "metadata": {
            "document_id": "E10 - Document 3.pdf",
            "chunk_index": 123,
            "source": "markdown",
            "embedding_version": "v1"
        }
    },
    {
        "id": "7b98b6c3-bb0b-4fb7-8a7b-2283da845654",
        "text": "b. Measures Absolute Efficacy and Safety (2.1.6.2)\nThe placebo-controlled trial measures the total pharmacologically mediated effect of treatment. In contrast, an active control trial or a dose-comparison trial measures the effect relative to another treatment.  The placebo-controlled trial also allows a distinction between adverse events due to the drug and those due to the underlying disease or background noise . The absolute effect size information is valuable in a three-group trial (test, placebo, active), even if the primary purpose of the trial is the test versus active control comparison.\n- c. Efficiency (2.1.6.3)\nPlacebo-controlled trials are efficient in that they can detect treatment effects with a smaller sample size than any other type of concurrently controlled study.",
        "metadata": {
            "document_id": "E10 - Document 3.pdf",
            "chunk_index": 124,
            "source": "markdown",
            "embedding_version": "v1"
        }
    },
    {
        "id": "5d8f3277-adbb-453b-8c5d-e4355cb5ddb2",
        "text": "d. Minimizing the Effect of Subject and Investigator Expectations (2.1.6.4)\nUse of a blinded placebo control may decrease the amount of improvement resulting from subject or investigator expectations because both are aware that some subjects will receive no active drug.  This may increase the ability of the study to detect true drug effects.",
        "metadata": {
            "document_id": "E10 - Document 3.pdf",
            "chunk_index": 125,
            "source": "markdown",
            "embedding_version": "v1"
        }
    },
    {
        "id": "1e32964c-4f46-4c7e-98c3-6b50ecfcf943",
        "text": "a. Ethical Concerns (See Sections 2.1.3 and 2.1.4) (2.1.7.1)\nWhen effective therapy that is known to prevent death or irreversible morbidity exists for a particular population, that population cannot usually be ethically studied in placebo-controlled trials; the particular conditions and populations for which this is true may be controversial. Ethical concerns may also direct studies toward less ill subjects or toward examination of short-term endpoints when long-term outcomes are of greater interest.  Where a placebocontrolled trial is unethical and an active control trial would not be credible, it may be very difficult to study new drugs at all.  For example, it would not be considered ethical to carry out a placebo-controlled trial of a thrombolytic agent in patients with acute myocardial infarction.  Yet it would be difficult in the current environment to establish a valid non-inferiority margin based on historical data because of the emergence of acute revascularization procedures that might alter the size of the benefits of the thrombolytics.  The designs described in section 2.1.5 may be useful in some of these cases.",
        "metadata": {
            "document_id": "E10 - Document 3.pdf",
            "chunk_index": 126,
            "source": "markdown",
            "embedding_version": "v1"
        }
    },
    {
        "id": "0194a899-c8fd-4378-88c9-5c20c3117e5c",
        "text": "b. Patient and Physician Practical Concerns (2.1.7.2)\nPhysicians and/or patients may be reluctant to accept the possibility that the patient will be assigned to the placebo treatment, even if there is general agreement that withholding or delaying treatment will not result in harm.  Subjects who sense they are not improving may withdraw from treatment because they attribute lack of effect to having been treated with placebo, complicating the analysis of the study.  With care, however, withdrawal for lack of effectiveness can sometimes be used as a study endpoint.  Although this may provide some information on drug effectiveness, such information is less precise than actual information on clinical status in subjects receiving their assigned treatment.",
        "metadata": {
            "document_id": "E10 - Document 3.pdf",
            "chunk_index": 127,
            "source": "markdown",
            "embedding_version": "v1"
        }
    },
    {
        "id": "e3d429c8-042a-4a9a-b03b-900a2e99828c",
        "text": "c. Generalizability (2.1.7.3)\nIt is sometimes argued that any controlled trial, but especially a placebo-controlled trial, represents an artificial environment that gives results different from true real world effectiveness. If study populations are unrepresentative in placebo-controlled trials because of ethical or practical concerns, questions about the generalizability of study results can arise.  For example, protocol, investigator, or patient choice from placebo-controlled trials may exclude patients with more serious disease.  In some cases, only a limited number of patients or centers may be willing\nto participate in studies.  Whether these concerns actually (as opposed to theoretically) limit generalizability has not been established.",
        "metadata": {
            "document_id": "E10 - Document 3.pdf",
            "chunk_index": 128,
            "source": "markdown",
            "embedding_version": "v1"
        }
    },
    {
        "id": "ce561b9c-ac9b-462b-815d-55d66f411a1b",
        "text": "d. No Comparative Information (2.1.7.4)\nPlacebo-controlled trials lacking an active control give little useful information about comparative effectiveness, information that is of interest and importance in many circumstances. Such information cannot reliably be obtained from cross-study comparisons, as the conditions of the studies may have been quite different.",
        "metadata": {
            "document_id": "E10 - Document 3.pdf",
            "chunk_index": 129,
            "source": "markdown",
            "embedding_version": "v1"
        }
    },
    {
        "id": "b135b91f-067e-4497-b555-ca85dd7d33d5",
        "text": "B. No-treatment Concurrent Control (See Section 1.3.2) (2.2)\nThe randomized no-treatment control is similar in its general properties and its advantages and disadvantages to the placebo-controlled trial.  Unlike the placebo-controlled trial, however, it cannot be fully blinded, and this can affect all aspects of the trial, including subject retention, patient management, and all aspects of observation (see section 1.2.2).  This design is appropriate in circumstances where a placebo-controlled trial would be performed, except that blinding is not feasible or practical.  When this design is used, it is desirable to have critical decisions, such as eligibility and endpoint determination or changes in management, made by an observer blinded to treatment assignment.  Decisions related to data analysis, such as inclusion of patients in analysis sets, should also be made by individuals without access to treatment assignment.  See ICH E9 for further discussion.",
        "metadata": {
            "document_id": "E10 - Document 3.pdf",
            "chunk_index": 130,
            "source": "markdown",
            "embedding_version": "v1"
        }
    },
    {
        "id": "935df04b-2cc7-4a89-bdff-d64c1583816b",
        "text": "1. Description (2.3.1)\nA dose-response study is one in which subjects are randomly assigned to two or more dosage groups, with or without a placebo group. Dose-response studies are carried out to establish the relation between dose and efficacy and adverse effects and/or to demonstrate efficacy.  The first use is considered in ICH E4; the use to demonstrate efficacy is the subject of this guidance. Evidence of efficacy could be based on significant differences in pair-wise comparisons between dosage groups or between dosage groups and placebo, or on evidence of a significant positive trend with increasing dose, even if no two groups are significantly different.  In the latter case, however, further study may be needed to assess the effectiveness of the low doses.  As noted in ICH E9, the particular approach for the primary efficacy analysis should be prespecified.\nStudies in which the treatment groups vary in regimen raise many of the same considerations as dose-response trials.  Since the use of regimen-controlled trials to establish efficacy is uncommon, the current discussion is focussed on dose-response trials.",
        "metadata": {
            "document_id": "E10 - Document 3.pdf",
            "chunk_index": 131,
            "source": "markdown",
            "embedding_version": "v1"
        }
    },
    {
        "id": "39fa052a-df42-4194-9022-27a662752300",
        "text": "1. Description (2.3.1)\nThere are several advantages to inclusion of a placebo (zero-dose) group in a dose-response study.  First, it avoids studies that are uninterpretable because all doses produce similar effects so that one cannot assess whether all doses are equally effective or equally ineffective.  Second, the placebo group permits an estimate of the total pharmacologically mediated effect of treatment,\nalthough the estimate may not be very precise if the dosing groups are relatively small.  Third, as the drug-placebo difference is generally larger than inter-dose differences, use of placebo may permit smaller sample sizes.  The size of various dose groups need not be identical; e.g., larger samples could be used to give more precise information about the effect of smaller doses or be used to increase the power of the study to show a clear effect of what is expected to be the optimal dose.  Dose-response studies can include one or more doses of an active control treatment. Randomized withdrawal designs can also assign subjects to multiple dosage levels.",
        "metadata": {
            "document_id": "E10 - Document 3.pdf",
            "chunk_index": 132,
            "source": "markdown",
            "embedding_version": "v1"
        }
    },
    {
        "id": "dbe57073-e596-4c9d-a802-a615a49d8ac6",
        "text": "2. Ability to Minimize Bias (2.3.2)\nIf the dose-response study is blinded, it shares with other randomized and blinded designs an ability to minimize subject and investigator bias.  When a drug has pharmacologic effects that could break the blind for some patients or investigators, it may be easier to preserve blinding in a dose-response study than in a placebo-controlled trial.  Masking treatments may necessitate multiple dummies or preparation of several different doses that look alike.",
        "metadata": {
            "document_id": "E10 - Document 3.pdf",
            "chunk_index": 133,
            "source": "markdown",
            "embedding_version": "v1"
        }
    },
    {
        "id": "79c33701-2057-4edd-bf66-b805bf677661",
        "text": "3. Ethical Issues (2.3.3)\nThe ethical and practical concerns related to a dose-response study are similar to those affecting placebo-controlled trials.  Where there is therapy known to be effective in preventing death or irreversible morbidity, it is no more ethically acceptable to randomize deliberately to subeffective control therapy than it is to randomize to placebo.  Where therapy is directed at less serious conditions or where the toxicity of the therapy is substantial relative to its benefits, dose-response studies that use lower, potentially less effective and less toxic doses or placebo may be acceptable to patients and investigators.",
        "metadata": {
            "document_id": "E10 - Document 3.pdf",
            "chunk_index": 134,
            "source": "markdown",
            "embedding_version": "v1"
        }
    },
    {
        "id": "9e015cee-e0bc-4f6a-84ec-111acff29e3d",
        "text": "4. Usefulness of Dose-response Studies and Validity of Inference in Particular Situations (2.3.4)\nIn general, a blinded dose-response study is useful for the determination of efficacy and safety in situations where a placebo-controlled trial would be useful and has similar credibility (see section 2.1.4).",
        "metadata": {
            "document_id": "E10 - Document 3.pdf",
            "chunk_index": 135,
            "source": "markdown",
            "embedding_version": "v1"
        }
    },
    {
        "id": "fea08d4b-2f75-494f-b66b-87eb9f618bab",
        "text": "5. Modifications of Design and Combinations with Other Controls That Can Resolve Ethical, Practical, or Inferential Problems (2.3.5)\nIn general, the sorts of modification made to placebo-controlled studies to mitigate ethical, practical, or inferential problems are also applicable to dose-response studies (see section 2.1.5).",
        "metadata": {
            "document_id": "E10 - Document 3.pdf",
            "chunk_index": 136,
            "source": "markdown",
            "embedding_version": "v1"
        }
    },
    {
        "id": "b29ea677-70cd-4398-9daf-5bce7e4c7a87",
        "text": "a. Efficiency (2.3.6.1)\nAlthough a comparison of a large, fully effective dose to placebo may be maximally efficient for showing efficacy, this design may produce unacceptable toxicity and gives no dose-response\ninformation.  When the dose-response is monotonic, the dose-response trial is reasonably efficient in showing efficacy and also yields dose-response information.  If the optimally effective dose is not known, it may be more prudent to study a range of doses than to choose a single dose that may prove to be suboptimal or to have unacceptable adverse effects.",
        "metadata": {
            "document_id": "E10 - Document 3.pdf",
            "chunk_index": 137,
            "source": "markdown",
            "embedding_version": "v1"
        }
    },
    {
        "id": "f7257a15-4e2f-4547-a1e7-d37178deab8b",
        "text": "b. Possible Ethical Advantage (2.3.6.2)\nIn some cases, notably those in which there is likely to be dose-related efficacy and dose-related important toxicity, the dose-response study may represent a difference-showing trial that can be ethically or practically conducted, even where a placebo-controlled trial could not be, because there is reason for patients and investigators to accept lesser effectiveness in return for greater safety.",
        "metadata": {
            "document_id": "E10 - Document 3.pdf",
            "chunk_index": 138,
            "source": "markdown",
            "embedding_version": "v1"
        }
    },
    {
        "id": "09de282b-435d-4d23-8d3b-78cc371796b7",
        "text": "7. Disadvantages of Dose-response Study (2.3.7)\nA potential problem that should be recognized is that a positive dose-response trend (i.e., a significant correlation between the dose and the efficacy outcome), without significant pair-wise differences, can establish efficacy (see 2.3.1), but may leave uncertainty as to which doses (other than the largest) are actually effective.  Of course, a single-dose study poses a similar problem with respect to doses below the one studied, giving no information at all about such doses.\nIt should also be appreciated that it is not uncommon to show no difference between doses in a dose-response study; if there is no placebo group this is usually an uninformative outcome.\nIf the therapeutic range is not known at all, the design may be inefficient, as many patients may be assigned to sub-therapeutic or supratherapeutic doses.\nDose-response designs may be less efficient than placebo-controlled titration designs for showing the presence of a drug effect; they do, however, in most cases provide better dose-response information (see ICH E4).",
        "metadata": {
            "document_id": "E10 - Document 3.pdf",
            "chunk_index": 139,
            "source": "markdown",
            "embedding_version": "v1"
        }
    },
    {
        "id": "c21e1fd7-a89b-434e-9571-abf07090e4d0",
        "text": "1. Description (2.4.1)\nAn active control (positive control) trial is one in which an investigational drug is compared with a known active drug. Such trials are randomized and usually double blind. The most crucial design question is whether the trial is intended to show a difference between the two treatments or to show non-inferiority or equivalence.  A sponsor intending to demonstrate effectiveness by means of a trial showing non-inferiority of the test drug to a standard agent needs to address the issue of the assay sensitivity of the trial, as discussed in section 1.5.  In a non-inferiority or equivalence trial, the active control treatment needs to be of established efficacy at the dose used and under the conditions of the study (see ICH E9:  Statistical Principles for Clinical Trials).  In general, this means it should be a drug acceptable in the region to which the studies will be submitted for the same indication at the dose being studied.  A superiority study favoring the test",
        "metadata": {
            "document_id": "E10 - Document 3.pdf",
            "chunk_index": 140,
            "source": "markdown",
            "embedding_version": "v1"
        }
    },
    {
        "id": "c2319a5e-3b45-43e1-b6b6-8c5de03f1554",
        "text": "1. Description (2.4.1)\ndrug, on the other hand, is readily interpretable as evidence of efficacy, even if the dose of active control is too low or the active control is of uncertain benefit (but not if it could be harmful). Such a result, however--superiority in the trial of the test agent to the control--is interpretable as true superiority of the test treatment to the control treatment only when the active control is used in appropriate patients at an appropriate dose and schedule (see section 1.4.3).  Lack of appropriate use of the control treatment would also make the study unusable as a non-inferiority study, if superiority of the test drug is not shown, because assay sensitivity of the study would not be ensured (see section 1.5.2).",
        "metadata": {
            "document_id": "E10 - Document 3.pdf",
            "chunk_index": 141,
            "source": "markdown",
            "embedding_version": "v1"
        }
    },
    {
        "id": "0af9e40a-2baf-4e1a-90d4-789112c2ef8b",
        "text": "2. Ability to Minimize Bias (2.4.2)\nA randomized and blinded active control trial generally minimizes subject and investigator bias, but a note of caution is warranted.  In a non-inferiority trial, investigators and subjects know that all subjects are getting active drug, although they do not know which one.  This could lead to a tendency toward categorizing borderline cases as successes in partially subjective evaluations, e.g., in an antidepressant study, which could decrease observed treatment differences and increase the likelihood that a finding of non-inferiority would not represent evidence of effectiveness.",
        "metadata": {
            "document_id": "E10 - Document 3.pdf",
            "chunk_index": 142,
            "source": "markdown",
            "embedding_version": "v1"
        }
    },
    {
        "id": "56973faa-2332-43dc-8903-90577b51dddf",
        "text": "3. Ethical Issues (2.4.3)\nActive control trials are generally considered to pose fewer ethical and practical problems than placebo-controlled trials because all subjects receive active treatment.  It should be appreciated, however, that subjects receiving a new treatment are not receiving standard therapy (just as a placebo control group is not) and may be receiving an ineffective or harmful drug.  This is an important matter if the active control therapy is known to improve survival or decrease the occurrence of irreversible morbidity, i.e. conditions in which a placebo or no treatment control would be unacceptable.  There should therefore be a sound rationale for the test treatment.  If there is no strong reason to expect the new drug to be at least as good as the standard, an add-on study (see section 2.1.5.2.1) may be more appropriate, if the conditions allow such a design.",
        "metadata": {
            "document_id": "E10 - Document 3.pdf",
            "chunk_index": 143,
            "source": "markdown",
            "embedding_version": "v1"
        }
    },
    {
        "id": "14989c3c-df62-417d-8dd3-1d4c1c81d814",
        "text": "4. Usefulness of Active Control Trials; Validity of Inference in Particular Situations (2.4.4)\nWhen a new treatment shows an advantage over an active control, the study is readily interpreted as showing efficacy, just as any other superiority trial is, assuming that the active control is not actually harmful.  When an active control trial is used to show efficacy by demonstrating noninferiority, there is the special consideration of assay sensitivity, which is considered above in section 1.5. The active control trial can also be used to assess comparative efficacy if assay sensitivity is established.",
        "metadata": {
            "document_id": "E10 - Document 3.pdf",
            "chunk_index": 144,
            "source": "markdown",
            "embedding_version": "v1"
        }
    },
    {
        "id": "dcfb40ab-c871-4b7e-bc77-561ed7f1d98b",
        "text": "5. Modifications of Design and Combinations with Other Controls That Can Resolve Ethical, Practical, or Inferential Issues (2.4.5)\nAs discussed earlier (section 2.1.5), active control trials can include a placebo group, multipledose groups of the test drug, and/or other dose groups of the active control.  Comparative doseresponse studies, in which there are several doses of both test and active control, are typical in analgesic trials.  The doses in active control trials can be fixed or titrated, and both cross-over and parallel designs can be used.  The assay sensitivity of a non-inferiority trial can sometimes be supported by a randomized placebo-controlled withdrawal phase at the end (see section 2.1.5.2.4) or by an initial short period of comparison to placebo (see section 2.1.5.2.3). Active control superiority studies in selected populations (nonresponders to other therapy or to the active control) can be very useful and are generally easy to interpret, although the results may not be generalizable.",
        "metadata": {
            "document_id": "E10 - Document 3.pdf",
            "chunk_index": 145,
            "source": "markdown",
            "embedding_version": "v1"
        }
    },
    {
        "id": "8ca075f3-9500-4fa6-a5d6-ae01ce8c0b46",
        "text": "a. Ethical and Practical Advantages (2.4.6.1)\nThe active control design, whether intended to show non-inferiority or equivalence or superiority, reduces ethical concerns that arise from failure to use drugs with documented important health benefits.  It also addresses patient and physician concerns about failure to use documented effective therapy.  Recruitment and IRB/IEC approval may be facilitated, and it may be possible to study larger samples.  There may be fewer withdrawals due to lack of effectiveness.",
        "metadata": {
            "document_id": "E10 - Document 3.pdf",
            "chunk_index": 146,
            "source": "markdown",
            "embedding_version": "v1"
        }
    },
    {
        "id": "d61e6d20-405c-423d-9e81-083fe4bb6a33",
        "text": "b. Information Content (2.4.6.2)\nWhere superiority to an active treatment is shown, active control studies are readily interpretable regarding evidence of efficacy.  The larger sample sizes needed are sometimes more achievable and acceptable in active control trials and can provide more safety information. Active control trials also can, if properly designed, provide information about relative efficacy.",
        "metadata": {
            "document_id": "E10 - Document 3.pdf",
            "chunk_index": 147,
            "source": "markdown",
            "embedding_version": "v1"
        }
    },
    {
        "id": "42a2d0f4-f20a-43fa-8200-6aeadac4dedf",
        "text": "a. Information Content (2.4.7.1)\nSee section 1.5 for discussion of the problem of assay sensitivity and the ability of the trial to support an efficacy conclusion in non-inferiority or equivalence trials.  Even when assay sensitivity is supported and the study is suitable for detecting efficacy, there is no direct assessment of effect size, and there is also greater difficulty in quantitating safety outcomes.",
        "metadata": {
            "document_id": "E10 - Document 3.pdf",
            "chunk_index": 148,
            "source": "markdown",
            "embedding_version": "v1"
        }
    },
    {
        "id": "0bac0de9-8708-4422-ac11-57af99c319e8",
        "text": "b. Large Sample Size (2.4.7.2)\nGenerally, the non-inferiority margin to be excluded is chosen conservatively in order to be reasonably sure that the margin is not greater than the smallest effect size that the active control would reliably be expected to have.  In addition, because there will usually be an intent to rule\nout loss of more than some reasonable fraction (see section 1.5.1) of the control drug effect, a still smaller non-inferiority margin is often used.  Because the choice of the margin will therefore be conservative, sample sizes may be very large.  In an active control superiority trial, the expected difference between two drugs is always smaller than the expected difference between test drug and placebo, again leading to large sample sizes.",
        "metadata": {
            "document_id": "E10 - Document 3.pdf",
            "chunk_index": 149,
            "source": "markdown",
            "embedding_version": "v1"
        }
    },
    {
        "id": "793e0437-aed8-4be3-ad27-df9c11554d16",
        "text": "1. Description (2.5.1)\nAn externally controlled trial is one in which the control group consists of patients who are not part of the same randomized study as the group receiving the investigational agent; i.e., there is no concurrently randomized control group. The control group is thus not derived from exactly the same population as the treated population.  Usually, the control group is a well-documented population of patients observed at an earlier time (historical control), but it could be a group at another institution observed contemporaneously, or even a group at the same institution but outside the study.  An external control study could be a superiority study (e.g. comparison with an untreated group) or a non-inferiority study.  Sometimes certain patients from a larger external experience are selected as a control group on the basis of particular characteristics that make them similar to the treatment group; there may even be an attempt to match particular control and treated patients.",
        "metadata": {
            "document_id": "E10 - Document 3.pdf",
            "chunk_index": 150,
            "source": "markdown",
            "embedding_version": "v1"
        }
    },
    {
        "id": "961869bf-7435-4086-8dcd-8078cc868925",
        "text": "1. Description (2.5.1)\nIn so-called baseline-controlled studies, the patient's state over time is compared with their baseline state. Although these studies are sometimes thought to use the patient as his own control , they do not in fact have an internal control.  Rather, changes from baseline are compared with an estimate of what would have happened to the patients in the absence of treatment with the test drug. Both baseline-controlled trials and trials that use a more complicated sequential on-offon (drug, placebo, drug) design, but that do not include a concurrently randomized control group, are of this type.  As noted, in these trials the observed changes from baseline or between study periods are always compared, at least implicitly, to some estimate of what would have happened without the intervention.  Such estimates are generally made on the basis of general knowledge, without reference to a specific control population.  Although in some cases this is plainly reasonable, e.g., when the effect is dramatic, occurs rapidly following treatment, and is unlikely to have occurred spontaneously (e.g., general anesthesia, cardioversion, measurable tumor shrinkage), in most cases it is not so obvious and a specific historical experience should be sought.",
        "metadata": {
            "document_id": "E10 - Document 3.pdf",
            "chunk_index": 151,
            "source": "markdown",
            "embedding_version": "v1"
        }
    },
    {
        "id": "9d89410f-adc5-4cee-b044-3cd432f23ed8",
        "text": "1. Description (2.5.1)\nDesigners and analysts of such trials need to be aware of the limitations of this type of study and should be prepared to justify its use.",
        "metadata": {
            "document_id": "E10 - Document 3.pdf",
            "chunk_index": 152,
            "source": "markdown",
            "embedding_version": "v1"
        }
    },
    {
        "id": "eeed7b2d-bba1-48ed-ba25-deca5253a600",
        "text": "2. Ability to Minimize Bias (2.5.2)\nInability to control bias is the major and well-recognized limitation of externally controlled trials and is sufficient in many cases to make the design unsuitable.  It is always difficult, and in many cases impossible, to establish comparability of the treatment and control groups and thus to fulfill the major purpose of a control group (see section 1.2).  The groups can be dissimilar with respect to a wide range of factors, other than use of the study treatment, that could affect outcome,",
        "metadata": {
            "document_id": "E10 - Document 3.pdf",
            "chunk_index": 153,
            "source": "markdown",
            "embedding_version": "v1"
        }
    },
    {
        "id": "678579a9-64aa-4cf4-a93e-06e81e04210e",
        "text": "2. Ability to Minimize Bias (2.5.2)\nincluding demographic characteristics, diagnostic criteria, stage or severity of disease, concomitant treatments, and observational conditions (such as methods of assessing outcome, investigator expectations).  Such dissimilarities can include important but unrecognized prognostic factors that have not been measured.  Blinding and randomization are not available to minimize bias when external controls are used.  It is well documented that untreated historicalcontrol groups tend to have worse outcomes than an apparently similarly chosen control group in a randomized study, possibly reflecting a selection bias.  Control groups in a randomized study need to meet certain criteria to be entered into the study, criteria that are generally more stringent and identify a less sick population than is typical of external control groups.  An external control group is often identified retrospectively, leading to potential bias in its selection.  A consequence of the recognized inability to control bias is that the potential persuasiveness of findings from externally controlled trials depends on obtaining much more extreme levels of statistical significance and much larger estimated differences between treatments than would be considered necessary in concurrently controlled trials.",
        "metadata": {
            "document_id": "E10 - Document 3.pdf",
            "chunk_index": 154,
            "source": "markdown",
            "embedding_version": "v1"
        }
    },
    {
        "id": "89ba0155-6b8e-4777-8034-dd0f903356fd",
        "text": "2. Ability to Minimize Bias (2.5.2)\nThe inability to control bias restricts use of the external control design to situations in which the effect of treatment is dramatic and the usual course of the disease highly predictable.  In addition, use of external controls should be limited to cases in which the endpoints are objective and the impact of baseline and treatment variables on the endpoint is well characterized.",
        "metadata": {
            "document_id": "E10 - Document 3.pdf",
            "chunk_index": 155,
            "source": "markdown",
            "embedding_version": "v1"
        }
    },
    {
        "id": "b7efa900-4dc4-4974-83b2-746cd6412c14",
        "text": "2. Ability to Minimize Bias (2.5.2)\nAs noted, the lack of randomization and blinding, and the resultant problems with lack of assurance of comparability of test group and control group, make the possibility of substantial bias inherent in this design and impossible to quantitate. Nonetheless, some approaches to design and conduct of externally controlled trials could lead them to be more persuasive and potentially less biased.  A control group should be chosen for which there is detailed information, including, where pertinent, individual patient data regarding demographics, baseline status, concomitant therapy, and course on study. The control patients should be as similar as possible to the population expected to receive the test drug in the study and should have been treated in a similar setting and in a similar manner, except with respect to the study therapy. Study observations should use timing and methodology similar to those used in the control patients. To reduce selection bias, selection of the control group should be made before performing comparative analyses; this may not always be feasible, as outcomes from these control groups may have been published.",
        "metadata": {
            "document_id": "E10 - Document 3.pdf",
            "chunk_index": 156,
            "source": "markdown",
            "embedding_version": "v1"
        }
    },
    {
        "id": "1d0ec292-c3bc-46ba-992e-99249816661c",
        "text": "2. Ability to Minimize Bias (2.5.2)\nAny matching on selection criteria or adjustments made to account for population differences should be specified prior to selection of the control and performance of the study. Where no obvious single optimal external control exists, it may be advisable to study multiple external controls, providing that the analytic plan specifies conservatively how each will be used in drawing inferences (e.g., study group should be substantially superior to the most favorable control to conclude efficacy).  In some cases, it may be useful to have an independent set of reviewers reassess endpoints in the control group and in the test group in a blinded manner according to common criteria.",
        "metadata": {
            "document_id": "E10 - Document 3.pdf",
            "chunk_index": 157,
            "source": "markdown",
            "embedding_version": "v1"
        }
    },
    {
        "id": "638f5d12-9a4d-4881-bf99-8fff1d8d874e",
        "text": "3. Ethical Issues (2.5.3)\nWhen a drug is intended to treat a serious illness for which there is no satisfactory treatment, especially if the new drug is seen as promising on the basis of theoretical considerations, animal\ndata, or early human experience, there may be understandable reluctance to perform a comparative study with a concurrent control group of patients who would not receive the new treatment.  At the same time, it is not responsible or ethical to carry out studies that have no realistic chance of credibly showing the efficacy of the treatment. It should be appreciated that many promising therapies have had less dramatic effects than expected or have shown no efficacy at all when tested in controlled trials.  Investigators may, in these situations, be faced with very difficult judgments.  It may be tempting in exceptional cases to initiate an externally controlled trial, hoping for a convincingly dramatic effect, with a prompt switch to randomized trials if this does not materialize.",
        "metadata": {
            "document_id": "E10 - Document 3.pdf",
            "chunk_index": 158,
            "source": "markdown",
            "embedding_version": "v1"
        }
    },
    {
        "id": "6bf88e52-d652-4096-9e3c-0915c958daa1",
        "text": "3. Ethical Issues (2.5.3)\nAlternatively, and generally preferably, in dealing with serious illnesses for which there is no satisfactory treatment, but where the course of the disease cannot be reliably predicted, even the earliest studies should be randomized.  This is usually possible when studies are carried out before there is an impression that the therapy is effective.  Studies can be monitored by independent data monitoring committees so that dramatic benefit can be detected early.  The concurrently controlled trial can detect extreme effects very rapidly and, in addition, can detect modest, but still valuable, effects that would not be credibly demonstrated by an externally controlled trial.",
        "metadata": {
            "document_id": "E10 - Document 3.pdf",
            "chunk_index": 159,
            "source": "markdown",
            "embedding_version": "v1"
        }
    },
    {
        "id": "567617ae-6818-4083-91ba-d8ce07cc0b05",
        "text": "4. Usefulness of Externally Controlled Trials; Validity of Inference in Particular Situations (2.5.4)\nAn externally controlled trial should generally be considered only when prior belief in the superiority of the test therapy to all available alternatives is so strong that alternative designs appear unacceptable and the disease or condition to be treated has a well-documented, highly predictable course.  It is often possible, even in these cases, to use alternative, randomized, concurrently controlled designs (see section 2.1.5).\nExternally controlled trials are most likely to be persuasive when the study endpoint is objective, when the outcome on treatment is markedly different from that of the external control and a high level of statistical significance for the treatment-control comparison is attained, when the covariates influencing outcome of the disease are well characterized, and when the control closely resembles the study group in all known relevant baseline, treatment (other than study drug), and observational variables.  Even in such cases, however, there are documented examples of erroneous conclusions arising from such trials.\nWhen an external control trial is considered, appropriate attention to design and conduct may help reduce bias (see section 2.5.2).",
        "metadata": {
            "document_id": "E10 - Document 3.pdf",
            "chunk_index": 160,
            "source": "markdown",
            "embedding_version": "v1"
        }
    },
    {
        "id": "811fa780-6ebc-4af0-84c5-62d56ced8734",
        "text": "5. Modifications of Design and Combinations with Other Controls That Can Resolve Ethical, Practical or Inferential Problems (2.5.5)\nThe external control design can incorporate elements of randomization and blinding through use of a randomized, placebo controlled withdrawal phase, often with early escape provisions, as described earlier (see section 2.1.5.2.4). The results of the initial period of treatment, in which\nsubjects who appear to respond are identified and maintained on therapy, are thus validated by a rigorous, largely assumption- and bias-free study.",
        "metadata": {
            "document_id": "E10 - Document 3.pdf",
            "chunk_index": 161,
            "source": "markdown",
            "embedding_version": "v1"
        }
    },
    {
        "id": "43995616-3764-4120-b1b4-2861fe2a2050",
        "text": "6. Advantages of Externally Controlled Trials (2.5.6)\nThe main advantage of an externally controlled trial is that all patients can receive a promising drug, making the study more attractive to patients and physicians.\nThe design has some potential efficiencies because all patients are exposed to test drug, of particular importance in rare diseases.  However, despite the use of a single treatment group in an externally controlled trial, the estimate of the external control group outcome always should be made conservatively, possibly leading to a larger sample size than would be needed in a placebocontrolled trial.  Great caution (e.g., applying a more stringent significance level) is called for because there are likely to be both identified and unidentified or unmeasurable differences between the treatment and control groups, often favoring treatment.",
        "metadata": {
            "document_id": "E10 - Document 3.pdf",
            "chunk_index": 162,
            "source": "markdown",
            "embedding_version": "v1"
        }
    },
    {
        "id": "4c83904d-c433-4f6b-9244-23977bdd2a45",
        "text": "7. Disadvantages of Externally Controlled Trials (2.5.7)\nThe externally controlled study cannot be blinded and is subject to patient, observer, and analyst bias; these are major disadvantages.  It is possible to mitigate these problems to a degree, but even the steps suggested in section 2.5.2 cannot resolve such problems fully, as treatment assignment is not randomized and comparability of control and treatment groups at the start of treatment, and comparability of treatment of patients during the trial, cannot be ensured or well assessed.  It is well documented that externally controlled trials tend to overestimate efficacy of test therapies.  It should be recognized that tests of statistical significance carried out in such studies are less reliable than in randomized trials.",
        "metadata": {
            "document_id": "E10 - Document 3.pdf",
            "chunk_index": 163,
            "source": "markdown",
            "embedding_version": "v1"
        }
    },
    {
        "id": "b618dd7e-ac96-4ce0-b58c-0ea6f0e71a1f",
        "text": "III. CHOOSING THE CONCURRENT CONTROL GROUP (3.0)\nTable 1 describes the usefulness of specific types of control groups, and Figure 1 provides a decision tree for choosing among different types of control groups.  Although the table and figure focus on the choice of control to demonstrate efficacy, some designs also allow comparisons of test and control agents. The choice of control can be affected by the availability of therapies and by medical practices in specific regions.\nThe potential usefulness of the principal types of control (placebo, active, and dose-response) in specific situations and for specific purposes is shown in Table 1.  The table should be used with the text describing the details of specific circumstances in which potential usefulness can be realized.  In all cases, it is presumed that studies are appropriately designed. External controls are a case so distinct that they are not included in the table.\nIn most cases, evidence of efficacy is most convincingly demonstrated by showing superiority to a concurrent control treatment.  If a superiority trial is not feasible or is inappropriate for ethical or practical reasons, and if a defined treatment effect of the active control is regularly seen (e.g.,",
        "metadata": {
            "document_id": "E10 - Document 3.pdf",
            "chunk_index": 164,
            "source": "markdown",
            "embedding_version": "v1"
        }
    },
    {
        "id": "150f58d2-7fa8-49f9-9ceb-7ce00ea4dfff",
        "text": "III. CHOOSING THE CONCURRENT CONTROL GROUP (3.0)\nas it is for antibiotics in most situations), a non-inferiority or equivalence trial can be used and can be persuasive.\n\nTable 1. Usefulness of Specific Concurrent Control Types in Various Situations",
        "metadata": {
            "document_id": "E10 - Document 3.pdf",
            "chunk_index": 165,
            "source": "markdown",
            "embedding_version": "v1"
        }
    },
    {
        "id": "c3980d11-3f0c-45a6-b60a-cd9db55670c5",
        "text": "III. CHOOSING THE CONCURRENT CONTROL GROUP (3.0)\nMeasure Absolute effect size, Type of Control.Placebo = Y. Measure Absolute effect size, Type of Control.Active non- inferiority = N. Measure Absolute effect size, Type of Control.Active Superiority = N. Measure Absolute effect size, Type of Control.Dose Response (D/R) = N. Measure Absolute effect size, Type of Control.Placebo + Active = Y. Measure Absolute effect size, Type of Control.Placebo + D/R = Y. Measure Absolute effect size, Type of Control.Active + D/R = N. Measure Absolute effect size, Type of Control.Placebo + Active + D/R = Y. Show existence of effect, Type of Control.Placebo = Y. Show existence of effect, Type of Control.Active non- inferiority = P. Show existence of effect, Type of Control.Active Superiority = Y. Show existence of effect, Type of Control.Dose Response (D/R) = Y. Show existence of effect, Type of Control.Placebo + Active = Y. Show existence of effect, Type of Control.Placebo + D/R = Y. Show existence of effect, Type of Control.Active +",
        "metadata": {
            "document_id": "E10 - Document 3.pdf",
            "chunk_index": 166,
            "source": "markdown",
            "embedding_version": "v1"
        }
    },
    {
        "id": "90d438d5-951e-404d-9447-aaf23016b333",
        "text": "III. CHOOSING THE CONCURRENT CONTROL GROUP (3.0)\nD/R = Y. Show existence of effect, Type of Control.Placebo + Active + D/R = Y. Show Dose- Response relationship, Type of Control.Placebo = N. Show Dose- Response relationship, Type of Control.Active non- inferiority = N. Show Dose- Response relationship, Type of Control.Active Superiority = N. Show Dose- Response relationship, Type of Control.Dose Response (D/R) = Y. Show Dose- Response relationship, Type of Control.Placebo + Active = N. Show Dose- Response relationship, Type of Control.Placebo + D/R = Y. Show Dose- Response relationship, Type of Control.Active + D/R = Y. Show Dose- Response relationship, Type of Control.Placebo + Active + D/R = Y. Compare therapies, Type of Control.Placebo = N. Compare therapies, Type of Control.Active non- inferiority = P. Compare therapies, Type of Control.Active Superiority = Y. Compare therapies, Type of Control.Dose Response (D/R) = N. Compare therapies, Type of Control.Placebo",
        "metadata": {
            "document_id": "E10 - Document 3.pdf",
            "chunk_index": 167,
            "source": "markdown",
            "embedding_version": "v1"
        }
    },
    {
        "id": "bbb2d865-eda8-4ac5-86f4-104018004a63",
        "text": "III. CHOOSING THE CONCURRENT CONTROL GROUP (3.0)\n+ Active = Y. Compare therapies, Type of Control.Placebo + D/R = N. Compare therapies, Type of Control.Active + D/R = P. Compare therapies, Type of Control.Placebo + Active + D/R = Y\nY=Yes, N=No, P=Possible, depending on whether there is historical evidence of sensitivity to drug effects\nFigure 1: Choosing the Concurrent Control for Demonstrating Efficacy\nThis figure shows the basic logic for choosing the control group; the decision may depend on the available drugs or medical practices in the specific region.",
        "metadata": {
            "document_id": "E10 - Document 3.pdf",
            "chunk_index": 168,
            "source": "markdown",
            "embedding_version": "v1"
        }
    },
    {
        "id": "dd2d4d13-8cb5-41bc-8293-d9f0ba8afd5d",
        "text": " YES\n-----------------------------\n",
        "metadata": {
            "document_id": "E10 - Document 3.pdf",
            "chunk_index": 169,
            "source": "markdown",
            "embedding_version": "v1"
        }
    },
    {
        "id": "27c1beac-2051-4b67-bd75-0f976a7813b2",
        "text": "Options\n- Placebo control (see 2.1), with design modifications, if appropriate\n- Dose-response control\n- Active control showing superiority to control\n- Active control non-inferiority (see 1.5)\n- Active and placebo controls (3-arm study; see 2.1.5.1.1)\n1 Add-on, replacement, early escape, brief placebo period, and randomized withdrawal (see section 2.1.5.2).",
        "metadata": {
            "document_id": "E10 - Document 3.pdf",
            "chunk_index": 170,
            "source": "markdown",
            "embedding_version": "v1"
        }
    },
    {
        "id": "e4955048-8622-4213-9e00-48512b17be1f",
        "text": "Informed Consent Guidance for IRBs, Clinical Investigators, and Sponsors\nU.S. Department of Health and Human Services\nFood and Drug Administration Office of Clinical Policy Center for Drug Evaluation and Research Center for Biologics Evaluation and Research Center for Devices and Radiological Health\nAugust 2023 Good Clinical Practice\nAdditional copies are available from:\nOffice of Clinical Policy Food and Drug Administration 10903 New Hampshire Avenue WO32, Rm. 5103 Silver Spring, MD 20993 (Tel) (301) 796-8340\nEmail: gcpquestions@fda.hhs.gov\nhttps://www.fda.gov/regulatory-information/search-fda-guidance-documents/clinical-trials-guidancedocuments\nU.S. Department of Health and Human Services Food and Drug Administration\nAugust 2023 Good Clinical Practice",
        "metadata": {
            "document_id": "ICD - Document 1.pdf",
            "chunk_index": 0,
            "source": "markdown",
            "embedding_version": "v1"
        }
    },
    {
        "id": "6b01c676-dfde-433e-b994-fe2f5f355437",
        "text": "TABLE OF CONTENTS\nI., 1 = INTRODUCTION ......................................................................................................................... 1. II., 1 = SUMMARYOFTHECONSENT PROCESS.............................................................................3. III., 1 = FDA INFORMED CONSENT REQUIREMENTS AND",
        "metadata": {
            "document_id": "ICD - Document 1.pdf",
            "chunk_index": 1,
            "source": "markdown",
            "embedding_version": "v1"
        }
    },
    {
        "id": "9f39066f-5b3e-4e7e-9e0c-c16fe6a56553",
        "text": "TABLE OF CONTENTS\nDISCUSSION.................................5. A. General Requirements for Informed Consent................................................................................5, 1 = A. General Requirements for Informed Consent................................................................................5. , 1 = 1. Exceptions to Informed Consent",
        "metadata": {
            "document_id": "ICD - Document 1.pdf",
            "chunk_index": 2,
            "source": "markdown",
            "embedding_version": "v1"
        }
    },
    {
        "id": "10cee2fa-eb53-4575-a3b0-c765c07aa956",
        "text": "TABLE OF CONTENTS\n..................................................................................................6. , 1 = 2. Coercion and Undue Influence .....................................................................................................6. , 1 = 3. Language Understandable to the Subject or the Legally Authorized Representative ............8. , 1 = 4.",
        "metadata": {
            "document_id": "ICD - Document 1.pdf",
            "chunk_index": 3,
            "source": "markdown",
            "embedding_version": "v1"
        }
    },
    {
        "id": "4fc7e526-0143-41fc-9753-21c7c2d891a1",
        "text": "TABLE OF CONTENTS\nExculpatory Language...................................................................................................................9. B. Basic Elements of Informed Consent ............................................................................................10, 1 = B. Basic Elements of Informed Consent",
        "metadata": {
            "document_id": "ICD - Document 1.pdf",
            "chunk_index": 4,
            "source": "markdown",
            "embedding_version": "v1"
        }
    },
    {
        "id": "a0ad3f45-1de6-46b2-9f8f-1ee8b324d19d",
        "text": "TABLE OF CONTENTS\n............................................................................................10. , 1 = 1. Description of Clinical Investigation..........................................................................................10. , 1 = 2. Risks and",
        "metadata": {
            "document_id": "ICD - Document 1.pdf",
            "chunk_index": 5,
            "source": "markdown",
            "embedding_version": "v1"
        }
    },
    {
        "id": "2414d731-d05d-4492-978a-646d4fbb1f70",
        "text": "TABLE OF CONTENTS\nDiscomforts................................................................................................................. 12. , 1 = 3.",
        "metadata": {
            "document_id": "ICD - Document 1.pdf",
            "chunk_index": 6,
            "source": "markdown",
            "embedding_version": "v1"
        }
    },
    {
        "id": "87c12c05-d20f-4bdd-a9ec-72249fef2f77",
        "text": "TABLE OF CONTENTS\nBenefits.......................................................................................................................................... 13. , 1 = 4. Alternative Procedures or Treatments ......................................................................................14. , 1 = 5.",
        "metadata": {
            "document_id": "ICD - Document 1.pdf",
            "chunk_index": 7,
            "source": "markdown",
            "embedding_version": "v1"
        }
    },
    {
        "id": "59b2bffd-7ba1-44ef-be55-26487eda44a1",
        "text": "TABLE OF CONTENTS\nConfidentiality.............................................................................................................................. 16. , 1 = 6. Compensation and Medical Treatment in Event of Injury......................................................17. , 1 = 7. Contacts",
        "metadata": {
            "document_id": "ICD - Document 1.pdf",
            "chunk_index": 8,
            "source": "markdown",
            "embedding_version": "v1"
        }
    },
    {
        "id": "472d0a12-3e28-4280-a579-b787fb9e2727",
        "text": "TABLE OF CONTENTS\n........................................................................................................................................ 18. , 1 = 8. Voluntary",
        "metadata": {
            "document_id": "ICD - Document 1.pdf",
            "chunk_index": 9,
            "source": "markdown",
            "embedding_version": "v1"
        }
    },
    {
        "id": "ca53db93-b9e5-425d-868e-94e655cc7f32",
        "text": "TABLE OF CONTENTS\nParticipation............................................................................................................... 18. C. Additional Elements of Informed Consent ...................................................................................19, 1 = C. Additional Elements of Informed Consent",
        "metadata": {
            "document_id": "ICD - Document 1.pdf",
            "chunk_index": 10,
            "source": "markdown",
            "embedding_version": "v1"
        }
    },
    {
        "id": "b0b15684-7fc4-43dd-8b34-63da1425d78f",
        "text": "TABLE OF CONTENTS\n...................................................................................19. , 1 = 1. Unforeseeable Risks..................................................................................................................... 19. , 1 = 2. Involuntary Termination of Subject's Participation",
        "metadata": {
            "document_id": "ICD - Document 1.pdf",
            "chunk_index": 11,
            "source": "markdown",
            "embedding_version": "v1"
        }
    },
    {
        "id": "37745dbd-a713-438d-9960-6ae7eac2ba67",
        "text": "TABLE OF CONTENTS\n................................................................20. , 1 = 3. Additional Costs to Subject.........................................................................................................20. , 1 = 4. Consequences of Subject's Decision to Withdraw",
        "metadata": {
            "document_id": "ICD - Document 1.pdf",
            "chunk_index": 12,
            "source": "markdown",
            "embedding_version": "v1"
        }
    },
    {
        "id": "09a6bf55-6f6c-493d-af88-d2e0febcbad6",
        "text": "TABLE OF CONTENTS\n....................................................................22. , 1 = 5. Providing Significant New Findings to Subjects .......................................................................23. , 1 = 6. Number of",
        "metadata": {
            "document_id": "ICD - Document 1.pdf",
            "chunk_index": 13,
            "source": "markdown",
            "embedding_version": "v1"
        }
    },
    {
        "id": "36aa1227-642f-4ec1-ab30-d18b345961a2",
        "text": "TABLE OF CONTENTS\nSubjects...................................................................................................................... 23. D. Element of Informed Consent for 'Applicable Clinical Trials' .................................................23, 1 = D. Element of Informed Consent for 'Applicable Clinical Trials' .................................................23. E. Documentation of",
        "metadata": {
            "document_id": "ICD - Document 1.pdf",
            "chunk_index": 14,
            "source": "markdown",
            "embedding_version": "v1"
        }
    },
    {
        "id": "c4053681-a16e-483e-b137-f2a47f128fd7",
        "text": "TABLE OF CONTENTS\nInformed Consent............................................................................................24, 1 = E. Documentation of Informed Consent............................................................................................24. 1. Requirement for Written Documentation of Informed",
        "metadata": {
            "document_id": "ICD - Document 1.pdf",
            "chunk_index": 15,
            "source": "markdown",
            "embedding_version": "v1"
        }
    },
    {
        "id": "33e76199-35ae-4bdd-b204-44e2f74fbc7f",
        "text": "TABLE OF CONTENTS\nConsent.............................................24, 1 = 1. Requirement for Written Documentation of Informed Consent.............................................24",
        "metadata": {
            "document_id": "ICD - Document 1.pdf",
            "chunk_index": 16,
            "source": "markdown",
            "embedding_version": "v1"
        }
    },
    {
        "id": "46056c65-e48b-44e7-b7d3-5634a517f09b",
        "text": "Contains Nonbinding Recommendations\n2. Alternative Methods of Obtaining Informed Consent..............................................................25, 1 = 2. Alternative Methods of Obtaining Informed Consent..............................................................25. 2. Alternative Methods of Obtaining Informed Consent..............................................................25, 2 = 2. Alternative Methods of Obtaining Informed",
        "metadata": {
            "document_id": "ICD - Document 1.pdf",
            "chunk_index": 17,
            "source": "markdown",
            "embedding_version": "v1"
        }
    },
    {
        "id": "afa58eec-fb64-47a6-bd68-b26ef3a1bbe3",
        "text": "Contains Nonbinding Recommendations\nConsent..............................................................25. , 1 = 3. Requirement for Dating Consent Form.....................................................................................27. , 2 = 3. Requirement for Dating Consent",
        "metadata": {
            "document_id": "ICD - Document 1.pdf",
            "chunk_index": 18,
            "source": "markdown",
            "embedding_version": "v1"
        }
    },
    {
        "id": "19f4affb-e980-4acf-af56-9f39818f1299",
        "text": "Contains Nonbinding Recommendations\nForm.....................................................................................27. , 1 = 4. Forms for Documentation of Informed Consent.......................................................................27. , 2 = 4. Forms for Documentation of Informed",
        "metadata": {
            "document_id": "ICD - Document 1.pdf",
            "chunk_index": 19,
            "source": "markdown",
            "embedding_version": "v1"
        }
    },
    {
        "id": "5c076290-0275-48a1-b90b-560c05bb6ab1",
        "text": "Contains Nonbinding Recommendations\nConsent.......................................................................27. , 1 = a. Long Form.............................................................................................................................. , 2 = 28. , 1 = b. Short Form. , 2 =",
        "metadata": {
            "document_id": "ICD - Document 1.pdf",
            "chunk_index": 20,
            "source": "markdown",
            "embedding_version": "v1"
        }
    },
    {
        "id": "5a7f6c03-15ef-44a0-b9e0-2b6bbfe65c14",
        "text": "Contains Nonbinding Recommendations\n............................................................................................................................ 28. IV., 1 = RESPONSIBILITIES FOR INFORMED CONSENT.............................................................29. IV., 2 = RESPONSIBILITIES FOR INFORMED",
        "metadata": {
            "document_id": "ICD - Document 1.pdf",
            "chunk_index": 21,
            "source": "markdown",
            "embedding_version": "v1"
        }
    },
    {
        "id": "e69f56ff-7b10-4675-b51e-e5653bccd9a9",
        "text": "Contains Nonbinding Recommendations\nCONSENT.............................................................29. , 1 = A. The IRB............................................................................................................................................ 30. , 2 = A. The",
        "metadata": {
            "document_id": "ICD - Document 1.pdf",
            "chunk_index": 22,
            "source": "markdown",
            "embedding_version": "v1"
        }
    },
    {
        "id": "75ca8974-3352-4e75-a75f-2c2d10985dd3",
        "text": "Contains Nonbinding Recommendations\nIRB............................................................................................................................................ 30. , 1 = 1. Review of All Informed Consent Materials ...............................................................................30. , 2 = 1. Review of All Informed Consent Materials",
        "metadata": {
            "document_id": "ICD - Document 1.pdf",
            "chunk_index": 23,
            "source": "markdown",
            "embedding_version": "v1"
        }
    },
    {
        "id": "083d7ea8-b82d-46b2-9055-5240994d3751",
        "text": "Contains Nonbinding Recommendations\n...............................................................................30. , 1 = a. Adequacy and Appropriateness of Wording......................................................................32. , 2 = . , 1 = b. Use of Standardized Language",
        "metadata": {
            "document_id": "ICD - Document 1.pdf",
            "chunk_index": 24,
            "source": "markdown",
            "embedding_version": "v1"
        }
    },
    {
        "id": "5e096d7b-2509-4dfa-ac27-87ef60b6893c",
        "text": "Contains Nonbinding Recommendations\n............................................................................................32. , 2 = . , 1 = 2. Review of the Consent Process....................................................................................................33. , 2 = 2. Review of the Consent",
        "metadata": {
            "document_id": "ICD - Document 1.pdf",
            "chunk_index": 25,
            "source": "markdown",
            "embedding_version": "v1"
        }
    },
    {
        "id": "6db03e90-5c30-4f7a-b3cd-c02ab475a400",
        "text": "Contains Nonbinding Recommendations\nProcess....................................................................................................33. , 1 = 3. IRB Review of Updated Informed Consent Documents...........................................................34. , 2 = 3. IRB Review of Updated Informed Consent Documents...........................................................34.",
        "metadata": {
            "document_id": "ICD - Document 1.pdf",
            "chunk_index": 26,
            "source": "markdown",
            "embedding_version": "v1"
        }
    },
    {
        "id": "a244a79a-7971-497b-b612-e2f392eda1ab",
        "text": "Contains Nonbinding Recommendations\n, 1 = 4. Identification of Revised Consent Forms...................................................................................35. , 2 = 4. Identification of Revised Consent Forms...................................................................................35. B. The Clinical Investigator",
        "metadata": {
            "document_id": "ICD - Document 1.pdf",
            "chunk_index": 27,
            "source": "markdown",
            "embedding_version": "v1"
        }
    },
    {
        "id": "d42325dc-9d85-4380-b630-72bef7b2c5b2",
        "text": "Contains Nonbinding Recommendations\n................................................................................................................ 35, 1 = B. The Clinical Investigator ................................................................................................................ 35. B. The Clinical Investigator",
        "metadata": {
            "document_id": "ICD - Document 1.pdf",
            "chunk_index": 28,
            "source": "markdown",
            "embedding_version": "v1"
        }
    },
    {
        "id": "1751073f-2509-4d09-8a98-91d65bf28d6c",
        "text": "Contains Nonbinding Recommendations\n................................................................................................................ 35, 2 = B. The Clinical Investigator ................................................................................................................ 35. , 1 = 1. Delegation of Consent",
        "metadata": {
            "document_id": "ICD - Document 1.pdf",
            "chunk_index": 29,
            "source": "markdown",
            "embedding_version": "v1"
        }
    },
    {
        "id": "c4209df8-8d70-40fd-a309-e32612fd5b3f",
        "text": "Contains Nonbinding Recommendations\nDiscussion...............................................................................................36. , 2 = 1. Delegation of Consent Discussion...............................................................................................36. , 1 = 2. Financial Relationships and Interests",
        "metadata": {
            "document_id": "ICD - Document 1.pdf",
            "chunk_index": 30,
            "source": "markdown",
            "embedding_version": "v1"
        }
    },
    {
        "id": "f91e1e85-c03b-41c4-9278-906993777732",
        "text": "Contains Nonbinding Recommendations\n........................................................................................37. , 2 = 2. Financial Relationships and Interests ........................................................................................37. C. The",
        "metadata": {
            "document_id": "ICD - Document 1.pdf",
            "chunk_index": 31,
            "source": "markdown",
            "embedding_version": "v1"
        }
    },
    {
        "id": "f6e40f42-8fe6-4068-a252-d8e644c0b68a",
        "text": "Contains Nonbinding Recommendations\nSponsor..................................................................................................................................... 38, 1 = C. The",
        "metadata": {
            "document_id": "ICD - Document 1.pdf",
            "chunk_index": 32,
            "source": "markdown",
            "embedding_version": "v1"
        }
    },
    {
        "id": "16ed1015-fe6c-4d50-a896-55056ed85752",
        "text": "Contains Nonbinding Recommendations\nSponsor..................................................................................................................................... 38. C. The",
        "metadata": {
            "document_id": "ICD - Document 1.pdf",
            "chunk_index": 33,
            "source": "markdown",
            "embedding_version": "v1"
        }
    },
    {
        "id": "39e7bf42-8ab1-4258-80c7-91b77ccc271c",
        "text": "Contains Nonbinding Recommendations\nSponsor..................................................................................................................................... 38, 2 = C. The",
        "metadata": {
            "document_id": "ICD - Document 1.pdf",
            "chunk_index": 34,
            "source": "markdown",
            "embedding_version": "v1"
        }
    },
    {
        "id": "1af999f9-4cff-4391-b789-1d350de18d35",
        "text": "Contains Nonbinding Recommendations\nSponsor..................................................................................................................................... 38. , 1 = 1. Considerations for Multicenter Clinical Investigations............................................................38. , 2 = 1. Considerations for Multicenter Clinical",
        "metadata": {
            "document_id": "ICD - Document 1.pdf",
            "chunk_index": 35,
            "source": "markdown",
            "embedding_version": "v1"
        }
    },
    {
        "id": "afea8746-99a0-4b9c-8f94-994ea850b3b7",
        "text": "Contains Nonbinding Recommendations\nInvestigations............................................................38. , 1 = 2. Sponsor Personnel........................................................................................................................ 39. , 2 = 2. Sponsor",
        "metadata": {
            "document_id": "ICD - Document 1.pdf",
            "chunk_index": 36,
            "source": "markdown",
            "embedding_version": "v1"
        }
    },
    {
        "id": "0bb8fe52-3d9c-4227-8417-fb05c4fdeb0e",
        "text": "Contains Nonbinding Recommendations\nPersonnel........................................................................................................................ 39. D. The",
        "metadata": {
            "document_id": "ICD - Document 1.pdf",
            "chunk_index": 37,
            "source": "markdown",
            "embedding_version": "v1"
        }
    },
    {
        "id": "e7346229-2f5d-4908-a007-ba426f210c2c",
        "text": "Contains Nonbinding Recommendations\nFDA........................................................................................................................................... 39, 1 = D. The",
        "metadata": {
            "document_id": "ICD - Document 1.pdf",
            "chunk_index": 38,
            "source": "markdown",
            "embedding_version": "v1"
        }
    },
    {
        "id": "09aba8df-cbb8-4a40-90f6-fe93e3f9a836",
        "text": "Contains Nonbinding Recommendations\nFDA........................................................................................................................................... 39. D. The",
        "metadata": {
            "document_id": "ICD - Document 1.pdf",
            "chunk_index": 39,
            "source": "markdown",
            "embedding_version": "v1"
        }
    },
    {
        "id": "97bd2dff-bc4f-4b85-b7e1-ce34f8e73f2e",
        "text": "Contains Nonbinding Recommendations\nFDA........................................................................................................................................... 39, 2 = D. The",
        "metadata": {
            "document_id": "ICD - Document 1.pdf",
            "chunk_index": 40,
            "source": "markdown",
            "embedding_version": "v1"
        }
    },
    {
        "id": "ea48c7d6-a4f6-411e-8e81-d0c6f46ac0d5",
        "text": "Contains Nonbinding Recommendations\nFDA........................................................................................................................................... 39. , 1 = 1. Investigational New Drugs and Biologics ..................................................................................40. , 2 = 1. Investigational New Drugs and",
        "metadata": {
            "document_id": "ICD - Document 1.pdf",
            "chunk_index": 41,
            "source": "markdown",
            "embedding_version": "v1"
        }
    },
    {
        "id": "13e874b8-ffc5-4a05-bd49-6c0d0dd70b30",
        "text": "Contains Nonbinding Recommendations\nBiologics ..................................................................................40. , 1 = 2. Investigational Medical Devices..................................................................................................41. , 2 = 2. Investigational Medical",
        "metadata": {
            "document_id": "ICD - Document 1.pdf",
            "chunk_index": 42,
            "source": "markdown",
            "embedding_version": "v1"
        }
    },
    {
        "id": "c6c9864c-558a-40bd-974b-5975a3f6bd2a",
        "text": "Contains Nonbinding Recommendations\nDevices..................................................................................................41. V., 1 = FREQUENTLY ASKED QUESTIONS.....................................................................................42. V., 2 = FREQUENTLY ASKED",
        "metadata": {
            "document_id": "ICD - Document 1.pdf",
            "chunk_index": 43,
            "source": "markdown",
            "embedding_version": "v1"
        }
    },
    {
        "id": "83d54f8a-8364-42c8-bc2f-197294e280df",
        "text": "Contains Nonbinding Recommendations\nQUESTIONS.....................................................................................42. , 1 = 1. What are some considerations for enrolling a child into a clinical investigation?.................42. , 2 = 1. What are some considerations for enrolling a child into a clinical investigation?.................42. , 1 = 2. Are there any additional protections required when enrolling children who are wards of the state?",
        "metadata": {
            "document_id": "ICD - Document 1.pdf",
            "chunk_index": 44,
            "source": "markdown",
            "embedding_version": "v1"
        }
    },
    {
        "id": "1236da2d-a3fe-439e-a1a4-14d661d4c188",
        "text": "Contains Nonbinding Recommendations\n............................................................................................................................................. 45. , 2 = 2. Are there any additional protections required when enrolling children who are wards of the state?",
        "metadata": {
            "document_id": "ICD - Document 1.pdf",
            "chunk_index": 45,
            "source": "markdown",
            "embedding_version": "v1"
        }
    },
    {
        "id": "79b8fbab-b10f-42cc-a9ab-5e9876fd824a",
        "text": "Contains Nonbinding Recommendations\n............................................................................................................................................. 45. , 1 = 3. What are some considerations for enrolling non-English speaking subjects? .......................46. , 2 = 3. What are some considerations for enrolling non-English speaking subjects? .......................46. , 1 = 4. What process should be followed when it is expected that subjects who do not understand English will",
        "metadata": {
            "document_id": "ICD - Document 1.pdf",
            "chunk_index": 46,
            "source": "markdown",
            "embedding_version": "v1"
        }
    },
    {
        "id": "cd222b48-eb58-444c-92bf-b05e4939f76d",
        "text": "Contains Nonbinding Recommendations\nbe enrolled? ............................................................................................................. 47. , 2 = 4. What process should be followed when it is expected that subjects who do not understand English will be enrolled? ............................................................................................................. 47",
        "metadata": {
            "document_id": "ICD - Document 1.pdf",
            "chunk_index": 47,
            "source": "markdown",
            "embedding_version": "v1"
        }
    },
    {
        "id": "49760d0b-e819-4793-ad03-0b731296ab8e",
        "text": "Guidance for IRBs, Clinical Investigators, and Sponsors 1\nThis guidance represents the current thinking of the Food and Drug Administration (FDA or Agency) on this topic.  It does not create any rights for any person and is not binding on FDA or the public.  You can use an alternative approach if it satisfies the requirements of the applicable statutes and regulations.  To discuss an alternative approach, contact the FDA staff responsible for this guidance as listed on the title page.",
        "metadata": {
            "document_id": "ICD - Document 1.pdf",
            "chunk_index": 48,
            "source": "markdown",
            "embedding_version": "v1"
        }
    },
    {
        "id": "c25c507a-7615-4131-8fe2-221b35f16395",
        "text": "I.  INTRODUCTION\nThis guidance is intended to assist institutional review boards (IRBs), clinical investigators, and sponsors in complying with FDA's informed consent regulations for clinical investigations.  This guidance supersedes FDA's guidance entitled ' A Guide to Informed Consent, ' issued in September 1998, and finalizes FDA's draft guidance entitled ' Informed Consent Information Sheet ,' issued in July 2014.  This document is structured to first present general guidance on FDA's regulatory requirements for informed consent and a discussion of the roles of IRBs, clinical investigators, sponsors, and FDA related to informed consent, followed by a series of frequently asked questions.",
        "metadata": {
            "document_id": "ICD - Document 1.pdf",
            "chunk_index": 49,
            "source": "markdown",
            "embedding_version": "v1"
        }
    },
    {
        "id": "a695a5bd-245d-4060-b5d7-465e1e94d132",
        "text": "I.  INTRODUCTION\nIn a final rule published on January 19, 2017, the Department of Health and Human Services (HHS) and other federal departments and agencies revised the Federal Policy for Protection of Human Subjects.  The final rule became effective in 2018 (codified for HHS at 45 CFR 46, subpart A; 'the 2018 Common Rule'). 2, 3 The 2018 Common Rule sets forth requirements for the protection of human subjects involved in research that is conducted or supported by federal departments or agencies that have adopted the Common Rule.  The revisions include significant changes to the provisions regarding informed consent. FDA is currently engaged in notice and comment rulemaking to harmonize its human subject protection\n1 This guidance document was developed by the Office of Clinical Policy (OCLiP), in coordination with the Center for Biologics Evaluation and Research (CBER), the Center for Devices and Radiological Health (CDRH), and the Center for Drug Evaluation and Research (CDER).",
        "metadata": {
            "document_id": "ICD - Document 1.pdf",
            "chunk_index": 50,
            "source": "markdown",
            "embedding_version": "v1"
        }
    },
    {
        "id": "9f13b3c0-274f-4ec5-b779-f675c9e920c4",
        "text": "I.  INTRODUCTION\n2 82 FR 7149, January 19, 2017; https://www.govinfo.gov/content/pkg/FR-2017-01-19/pdf/2017-01058.pdf.  In this guidance, this final rule will be referred to as the '2018 Common Rule'\n3 All references to the Code of Federal Regulations (CFR) throughout this document can be found at www.ecfr.gov.",
        "metadata": {
            "document_id": "ICD - Document 1.pdf",
            "chunk_index": 51,
            "source": "markdown",
            "embedding_version": "v1"
        }
    },
    {
        "id": "66cba305-d6c7-461f-9233-6bbcb81dad9d",
        "text": "Contains Nonbinding Recommendations\nregulations and the 2018 Common Rule to the extent practicable and consistent with other statutory provisions. 4 This guidance does not address possible future changes to the FDA's informed consent regulations that may be developed as part of our harmonization efforts.  FDA may revise this guidance document in the future to reflect any such changes and/or to address questions the Agency receives regarding informed consent.",
        "metadata": {
            "document_id": "ICD - Document 1.pdf",
            "chunk_index": 52,
            "source": "markdown",
            "embedding_version": "v1"
        }
    },
    {
        "id": "53431136-7ead-48ae-9f0f-338258cf8e72",
        "text": "Contains Nonbinding Recommendations\nFDA's informed consent requirements are set forth in FDA's regulations on Protection of Human Subjects (21 CFR part 50).  These regulations apply to clinical investigations regulated by FDA. 5, 6 Throughout this document we primarily provide guidance related to the requirements described in 21 CFR part 50; however, where appropriate we will describe additional regulations pertaining to informed consent found in FDA's regulations on Investigational New Drug Applications (21 CFR part 312) and Investigational Device Exemptions (21 CFR part 812).  The informed consent requirements in FDA regulations are not intended to preempt any applicable Federal, State, or local laws that require additional information to be disclosed for informed consent to be legally effective (21 CFR 50.25(d)).  If a clinical investigation 7 as defined at 21 CFR 50.3(c) is conducted or supported by HHS then the study may additionally be subject to 45 CFR part 46.  Where the regulations differ, the regulations that offer the greater protection to human subjects should be followed. 8",
        "metadata": {
            "document_id": "ICD - Document 1.pdf",
            "chunk_index": 53,
            "source": "markdown",
            "embedding_version": "v1"
        }
    },
    {
        "id": "defa4f3b-02bc-4a64-b596-cd74f2095a00",
        "text": "Contains Nonbinding Recommendations\nIn general, FDA's guidance documents, including this guidance, do not establish legally enforceable responsibilities. Instead, guidances describe the Agency's current thinking on a topic and should be viewed only as recommendations, unless specific regulatory or statutory requirements are cited. The use\n4 On September 28, 2022, FDA issued proposed rules to harmonize certain provisions of 21 CFR parts 50 and 56 with the 2018 Common Rule to the extent practicable and consistent with other statutory provisions (see 87 FR 58733 at https://www.federalregister.gov/documents/2022/09/28/2022-21088/protection-of-human-subjectsand-institutional-review-boards, and 87 FR 58752 at https://www.federalregister.gov/documents/2022/09/28/2022-21089/institutional-review-boards-cooperativeresearch).",
        "metadata": {
            "document_id": "ICD - Document 1.pdf",
            "chunk_index": 54,
            "source": "markdown",
            "embedding_version": "v1"
        }
    },
    {
        "id": "733855d6-e38c-4b5a-b048-c568c32c7624",
        "text": "Contains Nonbinding Recommendations\n5 21 CFR part 50 'applies to all clinical investigations regulated by the [FDA] under sections 505(i) and 520(g) of the Federal Food, Drug, and Cosmetic Act, as well as clinical investigations that support applications for research or marketing permits for products regulated by the [FDA], including foods, including dietary supplements, that bear a nutrient content claim or a health claim, infant formulas, food and color additives, drugs for human use, medical devices for human use, biological products for human use, and electronic products.' (21 CFR 50.1)\n6 IRB authority and responsibilities for reviewing informed consent forms are set forth in 21 CFR part 56.\n7 In this guidance document, the terms clinical investigation, study, research, and trial are used interchangeably\n8 See FDA 'Guidance for Sponsors, Investigators, and Institutional Review Board; Impact of Certain Provisions of the Revised Common Rule on FDA-Regulated Clinical Investigations' at https://www.fda.gov/regulatoryinformation/search-fda-guidance-documents/impact-certain-provisions-revised-common-rule-fda-regulatedclinical-investigations.",
        "metadata": {
            "document_id": "ICD - Document 1.pdf",
            "chunk_index": 55,
            "source": "markdown",
            "embedding_version": "v1"
        }
    },
    {
        "id": "7f266325-71c4-4de6-bff5-efe8ea80c0f4",
        "text": "Contains Nonbinding Recommendations\nof the word should in Agency guidance means that something is suggested or recommended, but not required.",
        "metadata": {
            "document_id": "ICD - Document 1.pdf",
            "chunk_index": 56,
            "source": "markdown",
            "embedding_version": "v1"
        }
    },
    {
        "id": "5376107c-dd38-416e-b370-28b9fc692580",
        "text": "II. SUMMARY OF THE CONSENT PROCESS\nTo many, the term informed consent is mistakenly viewed as synonymous with obtaining a subject's signature on the consent form; 9 however, obtaining documentation of a subject's informed consent is only part of the consent process.  Informed consent involves providing a prospective subject, or their legally authorized representative (LAR), with adequate information to allow for an informed decision about participation in the clinical investigation prior to enrollment.  Informed consent also involves facilitating the prospective subject's understanding of the information, providing adequate opportunity for the prospective subject to ask questions and to consider whether to participate, obtaining the prospective subject's voluntary agreement to participate prior to enrollment, and continuing to provide information as the clinical investigation progresses or as the enrolled subject or situation requires. 10\nExcept as provided in 21 CFR 50.23 and 50.24, 11 (see section III.A.1, 'Exceptions to Informed Consent'), no investigator may involve a human being as a subject in FDA-regulated research unless the investigator has obtained the legally effective informed consent of the subject or the subject's LAR (21\n9 In this guidance document, the terms informed consent form and informed consent document are used interchangeably.\n10 See 21 CFR 50.20.",
        "metadata": {
            "document_id": "ICD - Document 1.pdf",
            "chunk_index": 57,
            "source": "markdown",
            "embedding_version": "v1"
        }
    },
    {
        "id": "bea5954d-75f0-4a7e-9451-3121ea4b95e6",
        "text": "II. SUMMARY OF THE CONSENT PROCESS\n11 FDA has issued a proposed rule that, if finalized, would allow an exception from the requirement to obtain informed consent when a clinical investigation poses no more than minimal risk to the human subject and includes appropriate safeguards to protect the rights, safety, and welfare of human subjects. 83 FR 57378, November 15, 2018.  This proposed rule would implement new authorities provided in the 21 st Century Cures Act.  In the interim, FDA has issued guidance regarding IRB waiver or alteration of informed consent for certain clinical investigations involving no more than minimal risk.  See FDA 'Guidance for Sponsors, Investigators, and Institutional Review Boards; IRB Waiver or Alteration of Informed Consent for Clinical Investigations Involving No More Than Minimal Risk to Human Subjects,' available at https://www.fda.gov/regulatory-information/search-fda-guidancedocuments/irb-waiver-or-alteration-informed-consent-clinical-investigations-involving-no-more-minimal-risk.",
        "metadata": {
            "document_id": "ICD - Document 1.pdf",
            "chunk_index": 58,
            "source": "markdown",
            "embedding_version": "v1"
        }
    },
    {
        "id": "9b9e2833-faf4-4469-ac6f-f60aab537a7c",
        "text": "Contains Nonbinding Recommendations\nCFR 50.20). 12 To be legally effective, the informed consent process must satisfy the general requirements under 21 CFR 50.20 and include the relevant elements of informed consent described at 21 CFR 50.25 (see section III, 'FDA Informed Consent Requirements and Discussion').\nFDA considers advertising used to recruit subjects into the clinical trial to be the start of the ongoing consent process, and the information provided in any online or hard copy recruitment materials should be consistent with the informed consent document.  Generally, FDA recommends that any advertisement to recruit subjects be limited to the information the prospective subjects need to determine their interest and potential eligibility.  The FDA information sheet 'Recruiting Study Subjects' includes information regarding scripts for those who will interface with subjects to determine basic eligibility. 13",
        "metadata": {
            "document_id": "ICD - Document 1.pdf",
            "chunk_index": 59,
            "source": "markdown",
            "embedding_version": "v1"
        }
    },
    {
        "id": "4ac4f87d-d867-4cc8-aed0-139ec4a72f45",
        "text": "Contains Nonbinding Recommendations\nOnce a prospective subject is identified, and before research activities requiring prior consent occur, a person knowledgeable about the clinical investigation and capable of answering questions raised by the prospective subject should conduct a consent discussion.  The consent discussion and the consent form must contain information to allow prospective subjects to make an informed decision about participation in a clinical investigation and provide an opportunity for prospective subjects to ask questions about the clinical investigation and the information in the consent document (see section III, 'FDA Informed Consent Requirements and Discussion') (21 CFR 50.20 and 21 CFR 50.25). 14 The consent form serves several purposes, including helping to ensure that prospective subjects receive the required information, providing a \"take home\" reminder of the elements of the clinical investigation, providing contact information in case additional questions or concerns arise, and documenting prospective subjects' voluntary agreement to participate as well as the date of their agreement.\nThe informed consent process is an ongoing exchange of information throughout a subject's participation in a clinical trial and does not end after the consent form is signed.  For example, if new safety",
        "metadata": {
            "document_id": "ICD - Document 1.pdf",
            "chunk_index": 60,
            "source": "markdown",
            "embedding_version": "v1"
        }
    },
    {
        "id": "3d6bcf29-f703-4ad9-acd7-2bc4566ef1fb",
        "text": "Contains Nonbinding Recommendations\n12 As described in guidance, FDA intends to exercise enforcement discretion, under certain circumstances, with respect to its current regulations governing the requirement for informed consent when human specimens are used for FDA-regulated in vitro diagnostic (IVD) device investigations. See 'Guidance on Informed Consent for in Vitro Diagnostic Device Studies Using Leftover Human Specimens that are Not Individually Identifiable: Guidance for Sponsors, Institutional Review Boards, and Food and Drug Administration Staff', available at https://www.fda.gov/regulatory-information/search-fda-guidance-documents/guidance-informed-consent-vitrodiagnostic-device-studies-using-leftover-human-specimens-are-not\n13 See the FDA Information Sheet 'Recruiting Study Subjects,' available at https://www.fda.gov/regulatoryinformation/search-fda-guidance-documents/recruiting-study-subjects, for further information.\n14 The regulations allow use of a 'short form' consent form when the elements of informed consent are presented orally to the subject (21 CFR 50.27(b)(2)).  For a discussion of the short form written consent, see section III.E.4.b, 'Short Form.'",
        "metadata": {
            "document_id": "ICD - Document 1.pdf",
            "chunk_index": 61,
            "source": "markdown",
            "embedding_version": "v1"
        }
    },
    {
        "id": "6ec179e2-8382-46c8-80a3-76cc281f13e0",
        "text": "Contains Nonbinding Recommendations\ninformation or protocol changes occur during the conduct of the study, additional information may need to be given to the subject, and/or the subject may need additional opportunities to ask questions and receive answers throughout the clinical investigation (see section III.C.5, 'Providing Significant New Findings to Subjects,' and Frequently Asked Question #16).",
        "metadata": {
            "document_id": "ICD - Document 1.pdf",
            "chunk_index": 62,
            "source": "markdown",
            "embedding_version": "v1"
        }
    },
    {
        "id": "f4faf485-a86e-45ee-b44b-3f55c6f79cba",
        "text": "III.  FDA INFORMED CONSENT REQUIREMENTS AND DISCUSSION\nThe informed consent process and consent form must meet the general requirements of 21 CFR 50.20, and must include the basic elements of informed consent required by 21 CFR 50.25(a) (when used, a short form written consent document states that the elements of informed consent required by 21 CFR 50.25 have been presented orally; see section III.E.4.b 'Short Form' for more details).  If appropriate to the clinical investigation, one or more of the additional elements of informed consent at 21 CFR 50.25(b) must also be addressed.  For 'applicable clinical trials' as defined in 42 U.S.C. 282(j)(1)(A) initiated on or after March 7, 2012, an additional element of informed consent (i.e., inclusion of the specified statement regarding ClinicalTrials.gov) is required by 21 CFR 50.25(c). 15 The text of 21 CFR 50.20 and 21 CFR 50.25 is set out in italics below, followed by a discussion of each regulation.",
        "metadata": {
            "document_id": "ICD - Document 1.pdf",
            "chunk_index": 63,
            "source": "markdown",
            "embedding_version": "v1"
        }
    },
    {
        "id": "e8653ddd-3b3c-4219-b51f-918a4ca3fb5c",
        "text": "21 CFR 50.20:\n- Except as provided in 50.23, and 50.24, no investigator may involve a human being as a subject in research covered by these regulations unless the investigator has obtained the legally effective informed consent of the subject or the subject's legally authorized representative.\n- An investigator shall seek such consent only under circumstances that provide the prospective subject or the representative sufficient opportunity to consider whether or not to participate and that minimize the possibility of coercion or undue influence.\n- The information that is given to the subject or the representative shall be in language understandable to the subject or the representative.\n- No informed consent, whether oral or written, may include any exculpatory language through which the subject or the representative is made to waive or appear to waive any of the subject's legal rights, or releases or appears to release the investigator, the sponsor, the institution, or its agents from liability for negligence.\n15 For further information, see section III.D, 'Element of Informed Consent for 'Applicable Clinical Trials.''",
        "metadata": {
            "document_id": "ICD - Document 1.pdf",
            "chunk_index": 64,
            "source": "markdown",
            "embedding_version": "v1"
        }
    },
    {
        "id": "90c4061f-0788-4cdd-bcbb-b681696185f9",
        "text": "1. Exceptions to Informed Consent\nInformed consent is required for participation in FDA-regulated clinical investigations except under limited circumstances as described in 21 CFR 50.23 (involving certain life-threatening situations, military operations, or public health emergencies) and 21 CFR 50.24 (involving emergency research 16 ) (see 21 CFR 50.20).",
        "metadata": {
            "document_id": "ICD - Document 1.pdf",
            "chunk_index": 65,
            "source": "markdown",
            "embedding_version": "v1"
        }
    },
    {
        "id": "859484ff-e2c3-463e-a865-dd0eb3231ebe",
        "text": "1. Exceptions to Informed Consent\nWe note that, to implement statutory changes made to the Federal Food, Drug, and Cosmetic Act (FD&C) Act by section 3024 of the 21st Century Cures Act (Cures Act), FDA issued a proposed rule that, if finalized, would allow IRBs responsible for the review, approval, and continuing review of clinical investigations to approve an informed consent procedure that waives or alters certain informed consent elements or that waives the requirement to obtain informed consent for certain minimal risk clinical investigations. 17,18 In addition, FDA issued guidance explaining that until the Agency promulgates regulations implementing the Cures Act amendments to the FD&C Act, FDA does not intend to object to an IRB approving a consent procedure that does not include, or that alters, some or all of the elements of informed consent set forth in 21 CFR 50.25, or to an IRB waiving the requirements to obtain informed consent for certain minimal risk clinical investigations under the circumstances described in the guidance. 19 Nothing in FDA's informed consent regulations is intended to limit the authority of a physician to provide emergency medical care to the extent the physician is permitted to do so under applicable Federal, State, or local law",
        "metadata": {
            "document_id": "ICD - Document 1.pdf",
            "chunk_index": 66,
            "source": "markdown",
            "embedding_version": "v1"
        }
    },
    {
        "id": "8bda10f3-3c39-47f0-8830-f857c306ef50",
        "text": "1. Exceptions to Informed Consent\n(21 CFR 50.25(e)).",
        "metadata": {
            "document_id": "ICD - Document 1.pdf",
            "chunk_index": 67,
            "source": "markdown",
            "embedding_version": "v1"
        }
    },
    {
        "id": "0390f5d2-15f0-4500-8e75-f4d3e5200528",
        "text": "2. Coercion and Undue Influence\nThe conditions under which informed consent is sought and the relationship between the subject and the person obtaining consent should be carefully considered to minimize the possibility of coercion or undue influence (21 CFR 50.20).  According to the Belmont Report, 'Coercion occurs when an overt threat of harm is intentionally presented by one person to another in order to obtain compliance.  Undue influence,\n16 See \"Guidance for Institutional Review Boards, Clinical Investigators, and Sponsors; Exception from Informed Consent Requirements for Emergency Research,' available at https://www.fda.gov/regulatory-information/searchfda-guidance-documents/exception-informed-consent-requirements-emergency-research.\n17 See section 3024 of the Cures Act, Pub. L. 114-255, available at https://www.congress.gov/114/plaws/publ255/PLAW-114publ255.pdf.",
        "metadata": {
            "document_id": "ICD - Document 1.pdf",
            "chunk_index": 68,
            "source": "markdown",
            "embedding_version": "v1"
        }
    },
    {
        "id": "d563793b-68bc-4ef4-be5c-0d2f0fe1025e",
        "text": "2. Coercion and Undue Influence\n18 See 'Institutional Review Board Waiver or Alteration of Informed Consent for Minimal Risk Clinical Investigations,' (83 FR 57378, November 15, 2018) at https://www.govinfo.gov/content/pkg/FR-2018-1115/pdf/2018-24822.pdf.\n19 See 'Guidance for Sponsors, Investigators, and Institutional Review Boards; IRB Waiver of Alteration of Informed Consent for Clinical Investigations Involving No More Than Minimal Risk to Human Subjects,' available at https://www.fda.gov/regulatory-information/search-fda-guidance-documents/irb-waiver-or-alteration-informedconsent-clinical-investigations-involving-no-more-minimal-risk.",
        "metadata": {
            "document_id": "ICD - Document 1.pdf",
            "chunk_index": 69,
            "source": "markdown",
            "embedding_version": "v1"
        }
    },
    {
        "id": "ceb79189-59f8-45eb-97ec-db59a3e2b351",
        "text": "Contains Nonbinding Recommendations\nby contrast, occurs through an offer of an excessive, unwarranted, inappropriate or improper reward or other overture in order to obtain compliance.' 20\nFor example, if an employer seeks to enroll employees in a clinical investigation sponsored or conducted by the employer, the informed consent process should contain safeguards to ensure that participation is voluntary and that the possibility of undue influence or coercion by supervisors, peers, or others is minimized.  Similarly, because of a potential conflict of interest and the nature of the physician-patient relationship, 21 when the investigator is also the prospective subject's physician, for example, theinvestigator should ensure that the prospective subject understands that enrollment in the clinical investigation is voluntary, and that a decision to forgo enrollment will not adversely affect their medical care, in accordance with 21 CFR 50.25(a)(8).  The consent process and form should emphasize that an individual's participation is truly voluntary.",
        "metadata": {
            "document_id": "ICD - Document 1.pdf",
            "chunk_index": 70,
            "source": "markdown",
            "embedding_version": "v1"
        }
    },
    {
        "id": "12a183a0-0f1f-4f51-9385-5fad1f291434",
        "text": "Contains Nonbinding Recommendations\nNote that coercion and undue influence may be situational, and can affect any population, not just subject populations seen as vulnerable to coercion or undue influence.  For example, in a clinical investigation involving the collection of extra tissue samples during a planned surgical procedure, waiting to obtain informed consent until the prospective subject is in the preoperative area would generally fail to minimize the possibility of undue influence.  The possibility of undue influence could be addressed by first discussing the study with the prospective subject during a preoperative visit as part of the informed consent process.  The prospective subject could be told that the study will be reviewed with them again prior to the procedure and, after all questions are resolved, they will be asked to sign a consent form acknowledging their willingness to participate in the study at that time.",
        "metadata": {
            "document_id": "ICD - Document 1.pdf",
            "chunk_index": 71,
            "source": "markdown",
            "embedding_version": "v1"
        }
    },
    {
        "id": "b0f3f285-0c59-488c-ac76-3d35443ff817",
        "text": "Contains Nonbinding Recommendations\nIn addition, statements that claim investigational drugs and devices are safe or effective for the purposes for which they are being investigated are prohibited (21 CFR 312.7(a) and 21 CFR 812.7(d)).  Likewise, statements that overstate the possibility of benefit may unduly influence prospective subjects by leading them to incorrectly assume that it is known that the investigational product will be of benefit to them, influencing them to agree to participate when they might not have otherwise chosen to do so.  For example, wording that refers to the clinical investigation as a 'therapeutic trial' could contribute to a\n20 The Belmont Report was written by the National Commission for the Protection of Human Subjects of Biomedical and Behavioral Research.  The Commission, created as a result of the National Research Act of 1974, was charged with identifying the basic ethical principles that should underlie the conduct of biomedical and behavioral research involving human subjects and developing guidelines to assure that such research is conducted in accordance with those principles.  See Belmont Report, available at https://www.hhs.gov/ohrp/regulations-andpolicy/belmont-report/index.html.",
        "metadata": {
            "document_id": "ICD - Document 1.pdf",
            "chunk_index": 72,
            "source": "markdown",
            "embedding_version": "v1"
        }
    },
    {
        "id": "cdfb2c6e-a4d4-44fd-8d00-c156a50cefd0",
        "text": "Contains Nonbinding Recommendations\n21 For the purposes of this document physician means a medical doctor or other appropriate healthcare providers.\nprospective subject's misunderstanding that the trial will offer a direct benefit for their disease or condition.\nFurthermore, we generally recommend against including statements such as \"FDA has given permission for the clinical investigation to proceed\" or \"FDA has approved the clinical investigation' in the informed consent process, because such statements may suggest to subjects that the investigation has FDA's endorsement.  In addition, these statements may not be accurate for the particular clinical investigation at issue (see, e.g., 21 CFR 312.40(b) and 21 CFR 812.2(b)).",
        "metadata": {
            "document_id": "ICD - Document 1.pdf",
            "chunk_index": 73,
            "source": "markdown",
            "embedding_version": "v1"
        }
    },
    {
        "id": "322e881a-0115-4fcf-bbeb-8bc0f1772a24",
        "text": "Contains Nonbinding Recommendations\nFDA does not consider reimbursement for reasonable travel expenses to and from the clinical trial site (e.g., airfare, gas, tolls), and associated costs, such as parking and lodging, to raise issues related to coercion or undue influence.  Reimbursement for other expenses may be considered by an IRB on a caseby-case basis, and IRBs should consider whether the proposed remuneration could be an undue influence. Payment for participation in research should be just and fair.  This topic is also discussed under section III.B.3, 'Benefits.'",
        "metadata": {
            "document_id": "ICD - Document 1.pdf",
            "chunk_index": 74,
            "source": "markdown",
            "embedding_version": "v1"
        }
    },
    {
        "id": "b6e800b2-ef68-4596-980a-c05408d4a9a9",
        "text": "Contains Nonbinding Recommendations\nFinally, as discussed in FDA's Information Sheet, 'Guidance for Institutional Review Boards and Clinical Investigators, Payment and Reimbursement to Research Subjects,' paying research subjects in exchange for their participation is a common and, in general, acceptable practice. 22 FDA recognizes that payment to subjects for participation in clinical investigations, which is not specifically addressed by FDA regulations, may in some cases, raise difficult questions that should be addressed by IRBs.  For example, an IRB should address how much money research subjects should receive, and for what subjects should receive payment (e.g., their time, inconvenience, discomfort, or some other consideration).  However, FDA does not consider payment to research subjects for participating in research a benefit that can be used to justify risk when IRBs evaluate whether risks to subjects are reasonable in relation to anticipated benefit as required by 21 CFR 56.111(a)(2).  IRBs should review both the amount of payment and the proposed method and timing of disbursement to assure that they are not coercive and do not present undue influence (21 CFR 50.20).",
        "metadata": {
            "document_id": "ICD - Document 1.pdf",
            "chunk_index": 75,
            "source": "markdown",
            "embedding_version": "v1"
        }
    },
    {
        "id": "060a195c-0530-43ff-b6cd-c6a81bad0b7e",
        "text": "Contains Nonbinding Recommendations\nAs a general rule, FDA does not believe genuine offers of payment raise questions about coercion; however, an overt threat of harm presented in the guise of an offer of payment (e.g., a threat to withhold payment that had already been promised) would still be coercive.\n3. Language Understandable to the Subject or the Legally Authorized Representative\n22 See the FDA Information Sheet, 'Guidance for Institutional Review Boards and Clinical Investigators, Payment and Reimbursement to Research Subjects,' available at https://www.fda.gov/regulatory-information/search-fdaguidance-documents/payment-and-reimbursement-research-subjects.\nThe information given to the prospective subject, which includes both information provided orally during the consent discussion and written information in the consent form, must be in language understandable to the prospective subject or LAR (21 CFR 50.20).  'Understandable' means the information presented to prospective subject is in a language and at a level the subjects can comprehend (including an explanation of scientific and medical terms).",
        "metadata": {
            "document_id": "ICD - Document 1.pdf",
            "chunk_index": 76,
            "source": "markdown",
            "embedding_version": "v1"
        }
    },
    {
        "id": "2a7e4436-d2ee-48a2-b150-f5bcafab2fcb",
        "text": "4. Exculpatory Language\nThe consent process must not include exculpatory language through which a subject, or the LAR, is made to waive or appear to waive any of their legal rights, or release or appear to release the investigator, the sponsor, the institution, or its agents from liability for negligence (21 CFR 50.20).  FDA considers exculpatory language to be language that has the general effect of freeing or appearing to free an individual or an entity from malpractice, negligence, blame, fault, or guilt. 23\nThe following are examples of exculpatory language that would violate 21 CFR 50.20, and therefore cannot appear in consent forms:\n- I waive any possibility of compensation, including any right to sue for injuries that I may receive as a result of being in this study.\n- If you suffer an injury as a result of being in this study, neither the institution nor the investigator can assume financial responsibility or liability for the expenses of treatment for such injury.\nExamples of language that would not be considered exculpatory are included below (see also section III.B.6, 'Compensation and Medical Treatment in Event of Injury'):",
        "metadata": {
            "document_id": "ICD - Document 1.pdf",
            "chunk_index": 77,
            "source": "markdown",
            "embedding_version": "v1"
        }
    },
    {
        "id": "f5bc7fe6-151b-4465-be14-0cd752ae4a5f",
        "text": "4. Exculpatory Language\n- You do not give up any of your legal rights by being in this study, and you may choose to pursue legal action if you are injured by being in the study.\n- If you are injured as a result of being in this study, paying for the cost of your medical care will be your responsibility or that of your health insurance company.  However, signing this form does not stop you from pursuing legal action for the injury.\n23 For additional discussion of exculpatory language, see the joint draft guidance from the HHS Office for Human Research Protections (OHRP) and FDA, 'Guidance on Exculpatory Language in Informed Consent,' available at https://www.fda.gov/regulatory-information/search-fda-guidance-documents/exculpatory-language-informedconsent.  When finalized the guidance will represent FDA's current thinking on this issue. When finalized, the examples in the draft may be revised.",
        "metadata": {
            "document_id": "ICD - Document 1.pdf",
            "chunk_index": 78,
            "source": "markdown",
            "embedding_version": "v1"
        }
    },
    {
        "id": "db39d54f-cbb4-47cb-bc81-41669b5a4dd8",
        "text": "B. Basic Elements of Informed Consent\nAs discussed in this section, FDA regulations identify eight basic elements of informed consent to be provided to the subject (21 CFR 50.25(a)).  The text of each of the eight elements is italicized below, followed by a discussion of the element. As discussed in section III.E.4.b 'Short Form', when a short form written consent document is used, the document must state that the elements of informed consent required by 21 CFR 50.25 have been presented orally to the subject or the subject's LAR (21 CFR 50.27(b)(2)).\n- (a) Basic elements of informed consent.  In seeking informed consent, the following information shall be provided to each subject:",
        "metadata": {
            "document_id": "ICD - Document 1.pdf",
            "chunk_index": 79,
            "source": "markdown",
            "embedding_version": "v1"
        }
    },
    {
        "id": "176d458b-9ec4-4e70-89a4-9280fad0191f",
        "text": "1. Description of Clinical Investigation\nA statement that the study involves research, an explanation of the purposes of the research and the expected duration of the subject's participation, a description of the procedures to be followed, and identification of any procedures which are experimental. (21 CFR 50.25(a)(1))\nA clear statement that the clinical investigation involves research is important to make prospective subjects aware that, although preliminary data (bench, animal, pilot studies, literature) may exist, the purpose of the subject's participation is primarily to contribute to research (for example, to evaluate the safety and effectiveness of the test article or to evaluate a different dose or route of administration of an approved drug), rather than to their own medical treatment.",
        "metadata": {
            "document_id": "ICD - Document 1.pdf",
            "chunk_index": 80,
            "source": "markdown",
            "embedding_version": "v1"
        }
    },
    {
        "id": "7c5bb2f5-0ac8-4865-a03d-02678c8c12cb",
        "text": "1. Description of Clinical Investigation\nFDA recommends that when discussing the required elements of informed consent with prospective subjects, there should first be a discussion of the care a patient would likely receive if not part of the research, if relevant, and then the potential subject should be provided with information about the research.  This sequence allows prospective subjects to understand how the research differs from the care they might otherwise receive.  The description of the clinical investigation should identify tests or procedures required by the protocol that would not be part of their care outside of the research; for example, drawing blood samples for a pharmacokinetic study.  Note that all experimental procedures must be identified as such (21 CFR 50.25(a)(1)).  Procedures related solely to research must be explained (for example, protocol-driven versus individualized dosing, randomized assignment to treatment, blinding of subject and investigator, and receipt of placebo if the study is placebo-controlled) (21 CFR 50.25(a)(1)).  In some cases, tests or procedures that would be considered part of usual clinical care will not be performed on study participants; when applicable, this should be discussed as part of the informed consent process.",
        "metadata": {
            "document_id": "ICD - Document 1.pdf",
            "chunk_index": 81,
            "source": "markdown",
            "embedding_version": "v1"
        }
    },
    {
        "id": "4cdaca13-2be5-4c6b-abd3-6800984390cb",
        "text": "Contains Nonbinding Recommendations\nThe description of the clinical investigation must describe the test article (e.g., the investigational product under study) and, if used in the study, the control (21 CFR 50.25(a)(1)).  The description should include relevant information on what is known about both the test article and the control.  For example, the description should indicate whether the test article is approved or cleared 24 for marketing and describe the use(s) for which it has been approved or cleared.  The description should also provide relevant information about any control used in the study: for example, whether the control is FDA approved or cleared for marketing, considered a medically recognized standard of care 25 , or is a placebo (including an explanation of what a placebo is).  The information provided about the test article and control should include appropriate and reliable information about the potential benefits and risks of each, to the extent such information is available.",
        "metadata": {
            "document_id": "ICD - Document 1.pdf",
            "chunk_index": 82,
            "source": "markdown",
            "embedding_version": "v1"
        }
    },
    {
        "id": "e1158be6-c606-44c8-9898-9618a8ad6476",
        "text": "Contains Nonbinding Recommendations\nFor clinical investigations involving the comparison of an investigational product to one or more standards of care, it may be acceptable to describe the most common risks and benefits of the standard(s) of care in the consent form and provide additional information that may be relevant to a particular subject as part of the consent discussion, if appropriate.\nThe consent process should outline what the subject's participation will involve in order to comply with the protocol, for example, the number of clinic visits, maintenance of diaries, and medical or dietary restrictions (including the need to avoid specific medications or activities, such as participation in other clinical investigations 26 ).  If describing every procedure would make the consent form too lengthy or detailed, FDA recommends providing the general procedures in the consent form with an addendum describing the details of the study procedures to be performed at each visit.  It may be helpful to provide a chart outlining what happens at each study visit to simplify the consent form and assist the prospective subject in understanding what participation in the clinical investigation will involve.  FDA believes that removing procedural details from the consent form will reduce its length, enhance its readability, and allow the consent document to focus on content related to the risks and anticipated benefits, if any.",
        "metadata": {
            "document_id": "ICD - Document 1.pdf",
            "chunk_index": 83,
            "source": "markdown",
            "embedding_version": "v1"
        }
    },
    {
        "id": "95d1b0bb-2e23-4e5a-8bd9-fbfbc7ec5268",
        "text": "Contains Nonbinding Recommendations\nThe informed consent process must clearly describe the expected duration of the subject's participation in the clinical investigation (see 21 CFR 50.25(a)(1)), which includes their active participation as well as\n24 For purposes of this guidance, when 'approved or cleared' is used in discussing devices, the terms refer to FDA permitting the marketing of a device via the premarket approval, premarket notification (510(k)), De Novo classification, or Humanitarian Device Exemption (HDE) pathways.\n25 For the purposes of this guidance only, FDA generally would consider a medically recognized standard of care to be one evidenced by publication in a peer reviewed journal as a generally recognized standard of care or recognition by a professional medical society (e.g., in a clinical guideline).\n26 For additional information see Frequently Asked Question #11, 'Can a subject participate in more than one clinical investigation simultaneously?'\nlong-term follow-up, if appropriate.  Prospective subjects must be informed of the procedures that will occur during such follow-up (21 CFR 50.25(a)(1)), which may be provided in a chart as described above.",
        "metadata": {
            "document_id": "ICD - Document 1.pdf",
            "chunk_index": 84,
            "source": "markdown",
            "embedding_version": "v1"
        }
    },
    {
        "id": "c58dd19d-6910-4068-858e-7845d64c9615",
        "text": "2. Risks and Discomforts\nA description of any reasonably foreseeable risks or discomforts to the subject. (21 CFR 50.25(a)(2))",
        "metadata": {
            "document_id": "ICD - Document 1.pdf",
            "chunk_index": 85,
            "source": "markdown",
            "embedding_version": "v1"
        }
    },
    {
        "id": "9b6c03a0-2afa-4458-970f-cd5a6d9d455a",
        "text": "2. Risks and Discomforts\nThe informed consent process must describe the reasonably foreseeable risks or discomforts to the subject.  This includes risks or discomforts of tests, interventions and procedures required by the protocol (including protocol-specified standard medical procedures, exams, and tests), with a particular focus on those that carry significant risk of morbidity or mortality.  Possible risks or discomforts due to changes to a subject's medical care (e.g., by changing the subject's stable medication regimen or by stopping the subject's current treatment and randomizing them to either the investigational drug or placebo) should also be addressed.  Where relevant, participants should also be made aware of the possibility of unintended disclosures of private information and be provided with an explanation of measures to protect a subject's privacy and data, and limitations to those measures. 27 The explanation of potential risks of the test article and control, if any, and an assessment of the likelihood of these risks occurring should be based on reliable and accurate information presented in the protocol, investigator's brochure, labeling, and/or previous research reports.",
        "metadata": {
            "document_id": "ICD - Document 1.pdf",
            "chunk_index": 86,
            "source": "markdown",
            "embedding_version": "v1"
        }
    },
    {
        "id": "4dbab17c-483e-473e-84f0-9637e6244d25",
        "text": "2. Risks and Discomforts\nReasonably foreseeable discomforts to the subject must also be described (21 CFR 50.25(a)(2)).  For example, the consent form should disclose that the subject may be uncomfortable having to stay in one position or experience claustrophobia-like symptoms during an MRI. For clinical investigations involving the comparison of an investigational product to one or more standards of care, it may be acceptable to describe the more common and significant risks and discomforts of the standard of care in the informed consent form and provide additional risk information, as appropriate, as part of the consent discussion.",
        "metadata": {
            "document_id": "ICD - Document 1.pdf",
            "chunk_index": 87,
            "source": "markdown",
            "embedding_version": "v1"
        }
    },
    {
        "id": "b59047e9-3cc1-42f8-82f0-ebbbb6350438",
        "text": "2. Risks and Discomforts\nAny reasonably foreseeable risks or discomforts to the subject need to be described in the informed consent form; however, it is not necessary to describe all possible risks, especially if doing so could make the form overwhelming for subjects to read.  Information on risks that are more likely to occur and those that are serious should be described so that prospective subjects can understand the nature of the risk. The discussion may include information on whether a risk is reversible, and the probability of the risk based on existing data.  Information on what may be done to mitigate serious risks, and risks and discomforts more likely to occur, should also be considered for inclusion.\n27 Note, 21 CFR 56.111(a)(7) requires IRBs to determine, where appropriate, that there are adequate provisions to protect the privacy of subjects and to maintain the confidentiality of data.",
        "metadata": {
            "document_id": "ICD - Document 1.pdf",
            "chunk_index": 88,
            "source": "markdown",
            "embedding_version": "v1"
        }
    },
    {
        "id": "a4f614dc-3361-4280-bc35-1eb673fc2a3c",
        "text": "Contains Nonbinding Recommendations\nThe description should not understate the probability and magnitude of the reasonably foreseeable risks and discomforts.  If applicable, the consent document should include a description of the reasonably foreseeable risks to the subject, but also the potential for risk to 'others' (for example, radiation therapy where close proximity to subjects post-procedure may create some risk to others).  In situations where there may be a risk to others, efforts to mitigate the potential risk (e.g., using separate bathrooms) may be included in the consent document or provided in a separate document and given to the subject during the consent discussion.",
        "metadata": {
            "document_id": "ICD - Document 1.pdf",
            "chunk_index": 89,
            "source": "markdown",
            "embedding_version": "v1"
        }
    },
    {
        "id": "c88649f5-7f85-4dd5-92a7-32f7fd696c53",
        "text": "Contains Nonbinding Recommendations\nWhen appropriate, a statement must be included that a particular treatment or procedure may involve currently unforeseeable risks to the subject (or to the subject's embryo or fetus, if the subject is or may become pregnant) (21 CFR 50.25(b)(1); see section III.C.1, 'Unforeseeable Risks').  If unanticipated risks are reported during the investigation, the informed consent discussion and documents may need to be updated with the additional risks (21 CFR 50.25(a)(2); see Frequently Asked Question #16).",
        "metadata": {
            "document_id": "ICD - Document 1.pdf",
            "chunk_index": 90,
            "source": "markdown",
            "embedding_version": "v1"
        }
    },
    {
        "id": "94a1ab2f-32cd-4dfb-aa96-08d66ae512d9",
        "text": "3. Benefits\nA description of any benefits to the subject or to others which may reasonably be expected from the research. (21 CFR 50.25(a)(3))",
        "metadata": {
            "document_id": "ICD - Document 1.pdf",
            "chunk_index": 91,
            "source": "markdown",
            "embedding_version": "v1"
        }
    },
    {
        "id": "bbf57e85-0616-4c88-85f1-53496fcd8753",
        "text": "3. Benefits\nPotential benefits should be explained in terms of any direct impact to the prospective subject, in addition to the anticipated societal benefit of the research.  The description of potential benefits to the subject from the use of the test article (and control, if appropriate) should include appropriate details, and should be clear, balanced, and based on reliable information to the extent such information is available.  For clinical investigations involving the comparison of an investigational product to one or more standards of care, it may be acceptable to generally describe the benefits of the standard of care in the informed consent form and provide more specific information about the standard of care as part of the consent discussion rather than in the consent document.  This element requires a description of the potential benefits not only to the subject (for example, 'This product is intended to decrease XXX; however, we cannot guarantee that you will receive any benefit from it or from being in the study.'), but also to 'others' (for example, 'Your participation in this research may not benefit you, but information learned from this study may benefit patients with your disease or condition in the future.').",
        "metadata": {
            "document_id": "ICD - Document 1.pdf",
            "chunk_index": 92,
            "source": "markdown",
            "embedding_version": "v1"
        }
    },
    {
        "id": "4b4f7fa7-5ca2-49ed-b180-77136eb73188",
        "text": "3. Benefits\nOverly optimistic representations of the benefits of the test article being studied in the clinical investigation may be misleading and may violate FDA regulations that prohibit promotion of investigational drugs and devices (21 CFR 312.7 and 21 CFR 812.7).  Where the purpose of the study is to determine the safety and/or effectiveness of the test article, there is usually significant uncertainty regarding whether, and to what extent, the test article provides a benefit.  If there is no potential for direct",
        "metadata": {
            "document_id": "ICD - Document 1.pdf",
            "chunk_index": 93,
            "source": "markdown",
            "embedding_version": "v1"
        }
    },
    {
        "id": "c3f7b246-2a27-417f-90f1-859a4c569e21",
        "text": "Contains Nonbinding Recommendations\nbenefit to the prospective subject, which may be the case, for example, in a phase I study in healthy volunteers, this point should be clearly stated.  An example of a way in which to describe in the consent document that an investigational product does not have direct benefits to participating subjects would be to state 'There are no direct benefits to you from taking part in this study.'\nIf payments, including reimbursement for research-related expenses incurred by subjects due to participation, are provided, the consent process should not identify them as benefits. 28",
        "metadata": {
            "document_id": "ICD - Document 1.pdf",
            "chunk_index": 94,
            "source": "markdown",
            "embedding_version": "v1"
        }
    },
    {
        "id": "fc122cd8-3b57-4514-a13a-93b61ae20851",
        "text": "4. Alternative Procedures or Treatments\nA disclosure of appropriate alternative procedures or courses of treatment, if any, that might be advantageous to the subject. (21 CFR 50.25(a)(4))\nTo enable an informed decision about taking part in a clinical investigation, consent forms must disclose appropriate alternatives to entering the clinical investigation, if any, that might be advantageous to the subject (21 CFR 50.25(a)(4)).  Prospective subjects must be informed of the appropriate alternatives available to them, including a description of the care they would be likely to receive if they choose not to participate in the research.  This includes alternatives such as approved therapies for the patient's disease or condition, other forms of therapy (e.g., surgical) or diagnosis, and when appropriate, supportive care with no disease-directed therapy.  This disclosure must include a description of the current medically recognized standard of care, particularly in studies of medical products intended to treat or diagnose serious diseases or conditions.  The current medically recognized standard of care may include uses or treatment regimens for a legally marketed drug or device that are not included in the product's approved or cleared uses.",
        "metadata": {
            "document_id": "ICD - Document 1.pdf",
            "chunk_index": 95,
            "source": "markdown",
            "embedding_version": "v1"
        }
    },
    {
        "id": "1875d1cc-5009-4884-807d-a918e16b4413",
        "text": "4. Alternative Procedures or Treatments\nWhen describing in the consent form an unapproved use or treatment regimen of an approved or cleared drug or device that the sponsor markets, and such use or treatment regimen is a part of the medically recognized standard of care, the consent form can provide factual information concerning the unapproved use or treatment regimen of the drug or device. However, this information should not be presented in a promotional manner.  If a sponsor has questions related to this issue, they may contact FDA for feedback. 29\n28 See the FDA Information Sheet 'Payment and Reimbursement to Research Subjects,' available at https://www.fda.gov/regulatory-information/search-fda-guidance-documents/payment-and-reimbursementresearch-subjects.",
        "metadata": {
            "document_id": "ICD - Document 1.pdf",
            "chunk_index": 96,
            "source": "markdown",
            "embedding_version": "v1"
        }
    },
    {
        "id": "0fb53731-d6bc-4a24-9130-141899101740",
        "text": "4. Alternative Procedures or Treatments\n29 As FDA has recognized in prior guidance, unapproved new uses or treatment regimens for approved or cleared drugs or devices may be important and may even constitute medically recognized standard of care.  See FDA 'Guidance for Industry; Good Reprint Practices for the Distribution of Medical Journal Articles and Medical or Scientific Reference Publications on Unapproved New Uses of Approved Drugs and Approved or Cleared Medical Devices,' available at https://downloads.regulations.gov/FDA-2008-D-0053-0127/content.pdf.",
        "metadata": {
            "document_id": "ICD - Document 1.pdf",
            "chunk_index": 97,
            "source": "markdown",
            "embedding_version": "v1"
        }
    },
    {
        "id": "05c0e42d-753b-49a3-80b2-09e6734337a8",
        "text": "Contains Nonbinding Recommendations\nA statement identifying alternative therapies and indicating that the alternatives will be discussed by the clinical investigator in more detail, if appropriate, may be used if there is more than one alternative.  FDA recommends that treatment options lacking evidence of therapeutic value not be included.  If additional alternative procedures or courses of treatment become available during the course of the clinical investigation, the informed consent discussion and documents may need to be updated (see 21 CFR 50.25(a)(4) and 50.25(b)(5) and Frequently Asked Question #16).",
        "metadata": {
            "document_id": "ICD - Document 1.pdf",
            "chunk_index": 98,
            "source": "markdown",
            "embedding_version": "v1"
        }
    },
    {
        "id": "57fa9803-c471-4f5c-8809-debd37791346",
        "text": "Contains Nonbinding Recommendations\nWhen disclosing appropriate alternative procedures or courses of treatment, FDA recommends that a description of any reasonably foreseeable risks or discomforts and potential benefits associated with these alternatives should be disclosed during the informed consent process, although not necessarily included in the written informed consent document.  Where such descriptions or disclosures can contain quantified comparative estimates of the reasonably foreseeable risks or discomforts and potential benefits (e.g., from the clinical literature) between the alternatives, they should do so.  The Agency does not believe that providing such quantified comparative estimates for every case would be realistic or appropriate. 30 Where such well-defined estimates are not possible, the Agency believes that a description of the risks and benefits should be sufficient.  While this should be more than just a list of alternatives, a full risk/benefit explanation of alternatives may not be appropriate to include in the written document. However, the person(s) obtaining the prospective subject's consent should be able to discuss available alternatives and answer the prospective subject's questions.",
        "metadata": {
            "document_id": "ICD - Document 1.pdf",
            "chunk_index": 99,
            "source": "markdown",
            "embedding_version": "v1"
        }
    },
    {
        "id": "f974d64d-53f5-4c11-9e48-9b5223bb244e",
        "text": "Contains Nonbinding Recommendations\nIt may be appropriate to refer the subject to their primary care provider or another healthcare professional who can more fully discuss the alternatives, for example, when alternatives include various combinations of treatments such as radiation, surgery, and chemotherapy for some cancers.  Such discussions with an appropriate healthcare professional should be completed prior to the subject signing and dating the consent form.\nWhile an individual subject may be eligible for more than one clinical investigation, that determination and the decision as to which trial would be most appropriate for a particular subject would need to be made on a case-by-case basis.  A discussion of other trials for which the subject may be eligible would generally be more appropriate to address as part of the informed consent discussion, rather than the\n30 Federal Register , 'Protection of Human Subjects; Informed Consent' (46 FR 8942, January 27, 1981), available at https://www.fda.gov/science-research/clinical-trials-and-human-subject-protection/protection-human-subjectsinformed-consent; see response to comment 23.\ninformed consent document. 31 The subject may also wish to seek input from a primary care or other healthcare provider on this issue.",
        "metadata": {
            "document_id": "ICD - Document 1.pdf",
            "chunk_index": 100,
            "source": "markdown",
            "embedding_version": "v1"
        }
    },
    {
        "id": "7ec53883-996d-4a34-bfe9-b8fc8770304e",
        "text": "Contains Nonbinding Recommendations\nAs applicable, the informed consent process should advise that participation in one clinical investigation may preclude an individual's eligibility to participate in other clinical investigations.  When there are multiple clinical investigations for evaluating the treatment of a particular disease for which a subject may be eligible, the sequence in which a subject may participate in the clinical investigations may be important and should be discussed with the prospective subject.  For example, participation in a study of a drug for a specific therapeutic category may be an exclusion criterion for another study.  The prospective subject may wish to discuss the study with their primary care provider, if appropriate.",
        "metadata": {
            "document_id": "ICD - Document 1.pdf",
            "chunk_index": 101,
            "source": "markdown",
            "embedding_version": "v1"
        }
    },
    {
        "id": "3b937898-af0d-4945-91e0-286b257c3e5a",
        "text": "5. Confidentiality\nA statement describing the extent, if any, to which confidentiality of records identifying the subject will be maintained and that notes the possibility that the Food and Drug Administration may inspect the records. (21 CFR 50.25(a)(5))\nThe consent process must describe the extent to which confidentiality of records identifying subjects will be maintained (21 CFR 50.25(a)(5)) and should identify all entities, for example, the study sponsor, the research team, regulatory agencies, and/or ethics committee members, who may gain access to the records relating to the clinical investigation.  The consent process must also note the possibility that FDA may inspect records (21 CFR 50.25(a)(5)) and should not state or imply that FDA needs permission from the subject for access to the records.  Under the Health Insurance Portability and Accountability Act (HIPAA) Privacy Rule, FDA does not need permission to inspect records containing protected health information (45 CFR 164.512).  FDA may inspect study records to assess investigator compliance with the study protocol and the validity of the data reported by the sponsor.",
        "metadata": {
            "document_id": "ICD - Document 1.pdf",
            "chunk_index": 102,
            "source": "markdown",
            "embedding_version": "v1"
        }
    },
    {
        "id": "48c6d42f-dda5-4bdc-a62b-241ac9da1e6d",
        "text": "5. Confidentiality\nFDA may inspect and copy records relating to a clinical investigation (see, e.g., sections 704(a) and 704(e) of the FD&C Act, 21 CFR 56.115(b), 312.58(a), 312.68, and 812.145(b)).  FDA generally will not copy records that include the subject's name unless it is necessary to do so for the reasons described in 21 CFR 312.68 and 812.145, such as when there is reason to question whether the records represent the actual cases studied or results obtained.  When FDA requires subject names or other information that could connect the individual subject with the personal health information contained in the record, FDA will generally treat such information as confidential, but on rare occasions, FDA may be required to\n31 For additional advice regarding the need to avoid coercion and undue influence during the informed consent process, see Section III.A.2.",
        "metadata": {
            "document_id": "ICD - Document 1.pdf",
            "chunk_index": 103,
            "source": "markdown",
            "embedding_version": "v1"
        }
    },
    {
        "id": "6c1880f3-822c-4891-a42c-e05ebe2f35b3",
        "text": "Contains Nonbinding Recommendations\ndisclose this information to third parties, for example, if required by a court of law (see 5 U.S.C. 552(b)(6); see also 21 CFR 20.63(a) and 20.83(a)-(b)).  Therefore, the consent process should not promise or imply absolute confidentiality with regard to records that may be inspected by FDA. 32",
        "metadata": {
            "document_id": "ICD - Document 1.pdf",
            "chunk_index": 104,
            "source": "markdown",
            "embedding_version": "v1"
        }
    },
    {
        "id": "a964f92c-36aa-4915-aa57-308957350759",
        "text": "6. Compensation and Medical Treatment in Event of Injury\nFor research involving more than minimal risk, an explanation as to whether any compensation and an explanation as to whether any medical treatments are available if injury occurs and, if so, what they consist of, or where further information may be obtained. (21 CFR 50.25(a)(6))\nFor clinical investigations involving more than minimal risk, the informed consent process must describe any compensation and medical treatments available to subjects if injury occurs 33 (21 CFR 50.25(a)(6)). Because available compensation and medical treatments may vary depending on the medical circumstances of the individual subject or the policies of the institution, the consent process should include an explanation to subjects of where they may obtain further information.  An example of an adequate statement is:\n'The sponsor has made plans to pay for medical costs related to research-related injuries' followed by an explanation of how to obtain further information.\nIf no compensation is available, the consent process should include a statement such as: 34",
        "metadata": {
            "document_id": "ICD - Document 1.pdf",
            "chunk_index": 105,
            "source": "markdown",
            "embedding_version": "v1"
        }
    },
    {
        "id": "beec90e3-e150-44ab-a561-061c9f574476",
        "text": "6. Compensation and Medical Treatment in Event of Injury\n32 When appropriate, a sponsor may request a discretionary Certificate of Confidentiality (CoC).  A CoC generally prohibits a researcher from disclosing identifiable, sensitive information about the research participant, created or compiled for purposes of the research, in any Federal, State, or local civil, criminal, administrative, legislative, or other proceeding.  There are some exceptions to the prohibition on disclosure of such information.  See FDA guidance 'Certificates of Confidentiality,' available at https://www.fda.gov/media/132966/download.\n33 Investigators should ensure that subjects have access to reasonable medical care for medical problems arising during their participation in the clinical investigation that are, or could be, related to the study intervention.  See pages 7-8 of FDA's 'Guidance for Industry Investigator Responsibilities - Protecting the Rights, Safety, and Welfare of Study Subjects,' available at https://www.fda.gov/regulatory-information/search-fda-guidancedocuments/investigator-responsibilities-protecting-rights-safety-and-welfare-study-subjects.",
        "metadata": {
            "document_id": "ICD - Document 1.pdf",
            "chunk_index": 106,
            "source": "markdown",
            "embedding_version": "v1"
        }
    },
    {
        "id": "d248173d-bef6-4e66-8ddc-97b047a32844",
        "text": "6. Compensation and Medical Treatment in Event of Injury\n34 For additional discussion of exculpatory language, see the joint draft guidance from OHRP and FDA, 'Guidance on Exculpatory Language in Informed Consent,' which, when final, will represent FDA's current thinking on this topic, available at https://www.fda.gov/regulatory-information/search-fda-guidance-documents/exculpatorylanguage-informed-consent.",
        "metadata": {
            "document_id": "ICD - Document 1.pdf",
            "chunk_index": 107,
            "source": "markdown",
            "embedding_version": "v1"
        }
    },
    {
        "id": "b1a70a00-f646-4c41-83b5-ba52f2969fe7",
        "text": "Contains Nonbinding Recommendations\n'Because of hospital policy, the hospital is not able to pay for your medical care if you are injured as a result of being in this study.  If you are injured as a result of being in this study, you or your insurance will be responsible for paying your medical expenses.  However, you do not give up any of your legal rights by being in this study, and you may choose to pursue legal action if you are injured by being in the study.'\nSee section III.A.4, 'Exculpatory Language', for additional information.",
        "metadata": {
            "document_id": "ICD - Document 1.pdf",
            "chunk_index": 108,
            "source": "markdown",
            "embedding_version": "v1"
        }
    },
    {
        "id": "74d21034-b1d8-4286-be6d-d9ac98f2cdbb",
        "text": "7. Contacts\nAn explanation of whom to contact for answers to pertinent questions about the research and research subjects' rights, and whom to contact in the event of a research-related injury to the subject. (21 CFR 50.25(a)(7))",
        "metadata": {
            "document_id": "ICD - Document 1.pdf",
            "chunk_index": 109,
            "source": "markdown",
            "embedding_version": "v1"
        }
    },
    {
        "id": "1c1d6efc-69cf-4456-ae9d-315940cf0b62",
        "text": "7. Contacts\nThe consent document (or oral presentation, if a short form is used) must provide information on how to contact an appropriate individual for questions about the clinical investigation and the subjects' rights, and whom to contact in the event that a research-related injury to the subject occurs (21 CFR 50.25(a)(7)). This information should include contact names (or offices), email addresses, and their telephone numbers. FDA recommends that the individual or office named for questions about subjects' rights not be part of the investigational team, because subjects may be hesitant to report specific concerns or identify possible problems to someone who is part of the investigational team.  Therefore, an appropriate contact for subjects' rights questions may be the IRB Office, the facility's Patient Advocate Office, or other staff with training regarding the rights of clinical trials subjects.  In addition, the consent process should include information on whom to contact and what to do in the event of an emergency, including 24-hour contact information, if appropriate. 35",
        "metadata": {
            "document_id": "ICD - Document 1.pdf",
            "chunk_index": 110,
            "source": "markdown",
            "embedding_version": "v1"
        }
    },
    {
        "id": "a532af72-85b9-442c-bf01-40a5f9aca58f",
        "text": "7. Contacts\nIf contact information changes during the clinical investigation, then the new contact information must be provided to the subject (21 CFR 50.25(a)(7)).  This may be done through a variety of ways, for example, a card providing the relevant contact information for the clinical investigation may be given to the subject during a visit or mailed to the subject in an envelope to protect the subject's privacy.",
        "metadata": {
            "document_id": "ICD - Document 1.pdf",
            "chunk_index": 111,
            "source": "markdown",
            "embedding_version": "v1"
        }
    },
    {
        "id": "28448f4b-a17f-4226-9709-8f0cce63c6a4",
        "text": "8. Voluntary Participation\n35 See pages 7-8 of FDA's 'Guidance for Industry Investigator Responsibilities - Protecting the Rights, Safety, and Welfare of Study Subjects,' available at https://www.fda.gov/regulatory-information/search-fda-guidancedocuments/investigator-responsibilities-protecting-rights-safety-and-welfare-study-subjects.",
        "metadata": {
            "document_id": "ICD - Document 1.pdf",
            "chunk_index": 112,
            "source": "markdown",
            "embedding_version": "v1"
        }
    },
    {
        "id": "c5881ad5-6a37-4e39-9762-fe9c031cbefd",
        "text": "Contains Nonbinding Recommendations\nA statement that participation is voluntary, that refusal to participate will involve no penalty or loss of benefits to which the subject is otherwise entitled, and that the subject may discontinue participation at any time without penalty or loss of benefits to which the subject is otherwise entitled. (21 CFR 50.25(a)(8))",
        "metadata": {
            "document_id": "ICD - Document 1.pdf",
            "chunk_index": 113,
            "source": "markdown",
            "embedding_version": "v1"
        }
    },
    {
        "id": "f7fa6778-751e-4f51-8798-26e258f8a92b",
        "text": "Contains Nonbinding Recommendations\nThis element requires that subjects be informed that they may decline to take part in the clinical investigation or may stop participation at any time without penalty or loss of benefits to which subjects are entitled (21 CFR 50.25(a)(8)).  Language that limits the subject's right to decline to participate or withdraw from the clinical investigation must not be used.  If special procedures should be followed for the subject to withdraw from the clinical investigation, the consent process must outline and explain the procedures (21 CFR 50.25(b)(4); see section III.C.4, 'Consequences of Subject's Decision to Withdraw'). Written withdrawal from the study by the subject is not a requirement. When possible, the site staff should document the withdrawal and the date it occurred.   Note, when a subject withdraws from a study conducted under an investigational new drug application (IND) or investigational device exemption (IDE), the data collected on the subject to the point of withdrawal remains part of the study database and may not be removed. 36",
        "metadata": {
            "document_id": "ICD - Document 1.pdf",
            "chunk_index": 114,
            "source": "markdown",
            "embedding_version": "v1"
        }
    },
    {
        "id": "eaa96a42-9db5-469a-90ab-38650ee8ae79",
        "text": "C. Additional Elements of Informed Consent\nFDA regulations identify six additional elements of informed consent to be provided to each subject, when appropriate.  (21 CFR 50.25(b))\n- (b) Additional elements of informed consent.  When appropriate, one or more of the following elements of information shall also be provided to each subject:\nThe following elements are appropriate to provide to prospective subjects when the IRB determines the information is material to prospective subjects' decisions to participate:",
        "metadata": {
            "document_id": "ICD - Document 1.pdf",
            "chunk_index": 115,
            "source": "markdown",
            "embedding_version": "v1"
        }
    },
    {
        "id": "b2719eb6-3d14-4979-a841-3d63b83b6611",
        "text": "1. Unforeseeable Risks\nA statement that the particular treatment or procedure may involve risks to the subject (or to the embryo or fetus, if the subject is or may become pregnant) which are currently unforeseeable. (21 CFR 50.25(b)(1))\n36 See, 'Guidance for Sponsors, Clinical Investigators, and IRBs; Data Retention When Subjects Withdraw from FDARegulated Clinical Trials,' at https://www.fda.gov/regulatory-information/search-fda-guidance-documents/dataretention-when-subjects-withdraw-fda-regulated-clinical-trials.",
        "metadata": {
            "document_id": "ICD - Document 1.pdf",
            "chunk_index": 116,
            "source": "markdown",
            "embedding_version": "v1"
        }
    },
    {
        "id": "1111f405-be44-4b5c-9e1d-a829ab680e8d",
        "text": "Contains Nonbinding Recommendations\nWhen appropriate, the consent process must contain a statement that the particular test article or procedure may involve risks to subjects (or to the embryo or fetus, if the subject is or may become pregnant) that are currently unforeseeable (21 CFR 50.25(b)(1)).  If long-term safety studies (such as bench and animal testing 37 ) are not completed, the informed consent process should explain that researchers have not completed studies that may identify potential risks (e.g., carcinogenicity or teratogenicity studies), and that there may be potential risks to subjects (or to the embryo or fetus, if the subject is or may become pregnant) that are currently unforeseeable (21 CFR 50.25(b)(1)).  Sponsors may want to consider whether appropriate birth control measures and notifying the investigator of pregnancy should be included in the protocol and addressed in the informed consent document.",
        "metadata": {
            "document_id": "ICD - Document 1.pdf",
            "chunk_index": 117,
            "source": "markdown",
            "embedding_version": "v1"
        }
    },
    {
        "id": "84d4fbee-af25-43a3-af50-1a976f6faa32",
        "text": "2. Involuntary Termination of Subject's Participation\nAnticipated circumstances under which the subject's participation may be terminated by the investigator without regard to the subject's consent. (21 CFR 50.25(b)(2))",
        "metadata": {
            "document_id": "ICD - Document 1.pdf",
            "chunk_index": 118,
            "source": "markdown",
            "embedding_version": "v1"
        }
    },
    {
        "id": "2b90fc94-98c7-4d6e-80a3-c24c98597327",
        "text": "2. Involuntary Termination of Subject's Participation\nWhen appropriate, the consent process must inform the subject of anticipated circumstances under which the investigator may end the subject's participation without the subject's consent (21 CFR 50.25(b)(2)). Such circumstances may arise if, for example, the subject is unable to comply with procedures required by the clinical investigation, if the subject meets discontinuation criteria for continuing in the study, or if the site withdraws from the study.  A simple statement that the investigator or sponsor may withdraw the subject from participation at any time is inadequate and does not inform the subject of anticipated circumstances that may trigger their withdrawal from the clinical investigation.  For example, the consent process may inform the subject that the investigator may withdraw the subject's participation in the clinical investigation if the subject does not follow the instructions given to them by the investigator, such as repeatedly failing to return for protocol-required clinic visits or repeatedly failing to follow dosing or device instructions.  If a subject is withdrawn from the study, the clinical investigator should explain to the subject the reasons for withdrawal, discuss other available treatment or research options, and, if appropriate, discuss plans to follow the subject after withdrawal for side effects.",
        "metadata": {
            "document_id": "ICD - Document 1.pdf",
            "chunk_index": 119,
            "source": "markdown",
            "embedding_version": "v1"
        }
    },
    {
        "id": "2dabf198-c6e0-4d90-b52a-b9df8a2932c5",
        "text": "2. Involuntary Termination of Subject's Participation\nThe subject should also be informed as to how the data that have already been collected will be handled.",
        "metadata": {
            "document_id": "ICD - Document 1.pdf",
            "chunk_index": 120,
            "source": "markdown",
            "embedding_version": "v1"
        }
    },
    {
        "id": "c8e2728c-f438-4e34-84fe-38298df9f984",
        "text": "3. Additional Costs to Subject\nAny additional costs to the subject that may result from participation in the research. (21 CFR 50.25(b)(3))\n37 FDA supports the principles of the '3Rs,' to reduce, refine, and replace animal use in testing when feasible.  FDA encourages sponsors to consult with the relevant review division if it they wish to use a non-animal testing method they believe is suitable, adequate, validated, and feasible.  FDA will consider if such an alternative method is adequate to meet the regulatory need.",
        "metadata": {
            "document_id": "ICD - Document 1.pdf",
            "chunk_index": 121,
            "source": "markdown",
            "embedding_version": "v1"
        }
    },
    {
        "id": "375dd3c0-e328-4a62-afb3-0f57f699d735",
        "text": "Contains Nonbinding Recommendations\nIf subjects might incur additional expense as a result of taking part in the clinical investigation, the consent process must explain the added costs (21 CFR 50.25(b)(3)).  FDA recommends that any additional cost that may be charged to the subject, the subject's insurance, or other reimbursement mechanism be explained as part of the informed consent process.  Subjects should be made aware that insurance or other reimbursement mechanisms might not fund the medical care they receive as a result of participating in a clinical investigation even when the care is the standard care they would otherwise receive if not participating in a clinical investigation. 38",
        "metadata": {
            "document_id": "ICD - Document 1.pdf",
            "chunk_index": 122,
            "source": "markdown",
            "embedding_version": "v1"
        }
    },
    {
        "id": "a6508544-0bdd-4322-93cc-52128fdc5949",
        "text": "Contains Nonbinding Recommendations\nAdditionally, insurance or other forms of reimbursement might not pay for care related to complications or injuries arising from participation in a clinical investigation (see section III.B.6, 'Compensation and Medical Treatments in Event of Injury').  If the subject's insurance is charged and there are deductibles or copayments, the subject should be informed of whether they will be responsible for these costs.  If funds will be available to cover costs not covered by insurance or other forms of reimbursement, the consent form should describe how these funds will be made available to subjects or direct subjects on how to obtain further information.  Because these issues may be complex, it may be appropriate to refer the subject to a knowledgeable financial counselor or reimbursement specialist to explain the costs and the insurance and reimbursement issues prior to signing the consent form.",
        "metadata": {
            "document_id": "ICD - Document 1.pdf",
            "chunk_index": 123,
            "source": "markdown",
            "embedding_version": "v1"
        }
    },
    {
        "id": "fa9c1f25-3b73-427e-b3e2-5115b4dfc1e4",
        "text": "Contains Nonbinding Recommendations\nIn some cases, the cost of an investigational product may be charged to the subject.  In clinical investigations involving investigational devices, the sponsor is permitted to recover the costs of research, development, manufacture, and handling of investigational devices (see 21 CFR 812.7(b)).  FDA may authorize sponsors in certain clinical investigations of drugs to recover the direct costs of making the investigational drug available, such as costs to manufacture, ship, and handle (e.g., store) the drug (see 21 CFR 312.8). 39 When these costs are passed to the subject, the consent process must identify these costs (21 CFR 50.25(b)(3)).\n38 The Patient Protection and Affordable Care Act added section 2709 to the Public Health Service Act (42 U.S.C. 300gg-8).  Among other things, this provision prohibits a group health plan or health insurance issuer in the group and individual health insurance market from denying certain individuals' participation in certain clinical trials and from denying or limiting coverage of routine patient costs for items or services furnished in connection with participation in such trials.",
        "metadata": {
            "document_id": "ICD - Document 1.pdf",
            "chunk_index": 124,
            "source": "markdown",
            "embedding_version": "v1"
        }
    },
    {
        "id": "39786330-1be3-4d65-81cf-974f8e099872",
        "text": "Contains Nonbinding Recommendations\n39 See 'Guidance for Institutional Review Boards and Clinical Investigators, Charging for Investigational Products,' available at https://www.fda.gov/regulatory-information/search-fda-guidance-documents/charginginvestigational-products, and 'Guidance for Industry, Charging for Investigational Drugs Under an IND - Questions and Answers,' available at https://www.fda.gov/regulatory-information/search-fda-guidancedocuments/charging-investigational-drugs-under-ind-questions-and-answers.  Also, sponsors of expanded access INDs and treatment protocols that meet certain requirements may recover other costs than these direct costs.  See 21 CFR 312.8(d)(2).",
        "metadata": {
            "document_id": "ICD - Document 1.pdf",
            "chunk_index": 125,
            "source": "markdown",
            "embedding_version": "v1"
        }
    },
    {
        "id": "9ec9b82c-39b2-4101-946a-e1b7d6677670",
        "text": "Contains Nonbinding Recommendations\nBeyond the costs directly related to participation in the research, it may be appropriate to identify additional costs that may be incurred, such as any costs associated with participation in the clinical investigation, e.g., time off from work, child or elder care, or transportation costs.  To aid the prospective subject in understanding these additional costs, the consent process should describe the protocol requirements in sufficient detail (e.g., number and duration of study site visits and procedures) to enable subjects to appreciate how much time they may need to take away from work, child care, or elder care. Prospective subjects should be made aware of direct and indirect costs of participation and informed as to what extent these costs will be covered by the sponsor versus paid by the subject (see section III.A.2, 'Coercion and Undue Influence').",
        "metadata": {
            "document_id": "ICD - Document 1.pdf",
            "chunk_index": 126,
            "source": "markdown",
            "embedding_version": "v1"
        }
    },
    {
        "id": "856f6a1e-e211-4912-9d62-aa320a5e4b0e",
        "text": "4. Consequences of Subject's Decision to Withdraw\nThe consequences of a subject's decision to withdraw from the research and procedures for orderly termination of participation by the subject. (21 CFR 50.25(b)(4))\nWhen appropriate, the consent process must describe the consequences of a subject's decision to withdraw from the clinical investigation and the procedures for orderly termination of participation by the subject (21 CFR 50.25(b)(4)).  For example, when withdrawal from a clinical investigation may adversely affect the subject, the informed consent process must explain the withdrawal procedures that are recommended in order to ensure the subject's safety and should specifically state why the withdrawal procedures are important to the subject's welfare.  For some clinical investigations, an intervention should be withdrawn gradually, or the investigator may recommend follow-up to ensure the subject's safety when an investigational intervention is prematurely terminated due to a subject's withdrawal.  In these cases, the consent process must explicitly inform the subject of the potential adverse effects of premature termination of the investigational intervention.  Prospective subjects should be made aware of the number of visits and approximate time required for participation in the study to help them determine if they are able to make the commitment to complete the study.",
        "metadata": {
            "document_id": "ICD - Document 1.pdf",
            "chunk_index": 127,
            "source": "markdown",
            "embedding_version": "v1"
        }
    },
    {
        "id": "6ba7452d-b31b-4718-9160-fb24b7f9d000",
        "text": "4. Consequences of Subject's Decision to Withdraw\nWhen appropriate, it may be reasonable to counsel prospective subjects that they should not participate in the trial if they do not foresee staying in the study. If applicable, the consent process must explain whether a subject who withdraws early will receive future study payments. 40 The subject should also be informed as to how the data that have already been collected will be handled (see also section III.B.8, 'Voluntary Participation').\n40 For further information about the timing of payments to research participants see the 'Guidance for Institutional Review Boards and Clinical Investigators, Information Sheet: Payment and Reimbursement to Research Subjects,' available at Payment and Reimbursement to Research Subjects | FDA.",
        "metadata": {
            "document_id": "ICD - Document 1.pdf",
            "chunk_index": 128,
            "source": "markdown",
            "embedding_version": "v1"
        }
    },
    {
        "id": "17598cc9-14da-4ff7-8b88-c21cb98a5e8c",
        "text": "5. Providing Significant New Findings to Subjects\nA statement that significant new findings developed during the course of the research which may relate to the subject's willingness to continue participation will be provided to the subject. (21 CFR 50.25(b)(5))",
        "metadata": {
            "document_id": "ICD - Document 1.pdf",
            "chunk_index": 129,
            "source": "markdown",
            "embedding_version": "v1"
        }
    },
    {
        "id": "2cf2c85a-40b6-4ba7-b77e-77eef90f0a09",
        "text": "5. Providing Significant New Findings to Subjects\nThe consent process must, when appropriate, include a statement that significant new findings that may relate to the subject's willingness to continue participation, such as new risk information, will be provided to the subject (21 CFR 50.25(b)(5)).  Significant new findings may include an unexpected adverse event, an adverse event occurring at greater frequency or severity than previously stated in the consent process, results from interim analyses (in some cases), additional alternative procedures or courses of treatment that become available during the course of the clinical investigation, and information from other clinical trials about the effectiveness of the investigational product, the comparator, or other products for the same indication.  FDA encourages the inclusion of this statement in the consent form for clinical investigations where knowledge of risk is limited, for example, clinical investigations involving the first use of an investigational product in humans, novel therapies, and new molecular entities, or complex clinical investigations that involve significant risk.  Where there are significant new findings, the IRB should consider whether enrolled subjects should be contacted to determine if this information impacts their decision to continue participation in the clinical investigation (see Frequently Asked Question #16).",
        "metadata": {
            "document_id": "ICD - Document 1.pdf",
            "chunk_index": 130,
            "source": "markdown",
            "embedding_version": "v1"
        }
    },
    {
        "id": "c2a81d2b-7fdd-48a5-accb-86b9aae5bc4f",
        "text": "6. Number of Subjects\nThe approximate number of subjects involved in the study. (21 CFR 50.25(b)(6))\nWhen appropriate, the informed consent process must state the approximate number of subjects involved in the clinical investigation (21 CFR 50.25(b)(6)).  For example, a subject's decision whether or not to participate in the study may be influenced by knowledge that the clinical investigation is a small initial trial of the product (such as a phase 1 or 2 drug clinical investigation or a device feasibility clinical investigation where only a small number of subjects participate).",
        "metadata": {
            "document_id": "ICD - Document 1.pdf",
            "chunk_index": 131,
            "source": "markdown",
            "embedding_version": "v1"
        }
    },
    {
        "id": "6a0b11bb-2bce-4d17-bb5d-152a2e743a74",
        "text": "D. Element of Informed Consent for 'Applicable Clinical Trials' 41\nWhen seeking informed consent for applicable clinical trials, as defined in 42 U.S.C. 282(j)(1)(A), the following statement shall be provided to each clinical trial subject in informed consent documents and processes.  This will notify the clinical trial subject that clinical trial\n41 For further information, see FDA's 'Guidance for Sponsors, Investigators, and Institutional Review Boards, Questions and Answers on Informed Consent Elements, 21 CFR  50.25(c)' available at https://www.fda.gov/regulatory-information/search-fda-guidance-documents/questions-and-answers-informedconsent-elements-21-cfr-ss-5025c?source=govdelivery.",
        "metadata": {
            "document_id": "ICD - Document 1.pdf",
            "chunk_index": 132,
            "source": "markdown",
            "embedding_version": "v1"
        }
    },
    {
        "id": "87cf8eab-0a60-4eda-b912-20e268e30e7d",
        "text": "Contains Nonbinding Recommendations\ninformation has been or will be submitted for inclusion in the clinical trial registry databank under paragraph (j) of section 402 of the Public Health Service Act.  The statement is: 'A description of this clinical trial will be available on https://www.ClinicalTrials.gov, as required by U.S. Law.  This Web site will not include information that can identify you.  At most, the Web site will include a summary of the results.  You can search this Web site at any time.' (21 CFR 50.25(c))\nAll informed consent forms for 'applicable clinical trials' 42 initiated on or after March 7, 2012, must contain the above quoted statement, which cannot be modified (21 CFR 50.25(c)). 43 However, additional explanation may be provided, if appropriate.  For example, with respect to clinical trials involving investigational devices, an additional statement could be added that information about device trials might not be made publicly available until after a product is cleared or approved by FDA.",
        "metadata": {
            "document_id": "ICD - Document 1.pdf",
            "chunk_index": 133,
            "source": "markdown",
            "embedding_version": "v1"
        }
    },
    {
        "id": "135ef843-4f18-4408-9496-c1ca98fbc5be",
        "text": "1.  Requirement for Written Documentation of Informed Consent\n- (a) Except as provided in  56.109(c), informed consent shall be documented by the use of a written consent form approved by the IRB and signed and dated by the subject or the subject's legally authorized representative at the time of consent.  A copy shall be given to the person signing the form. (21 CFR 50.27(a))\nInformed consent must be documented by a signed and dated written consent form except under two specific circumstances as described in FDA's regulations at 21 CFR 56.109(c) 44 (21 CFR 50.27).  When\n42 For the definition of 'applicable clinical trial,' see 42 USC 282(j)(1)(A) and 42 CFR 11.10(a).  It is the responsibility of sponsors and investigators to determine if their clinical trial meets the definition of an 'applicable clinical trial' and to ensure compliance with the most current applicable statutory and regulatory requirements.  Information on \"applicable clinical trials\" is available at https://clinicaltrials.gov/ct2/manage-recs/fdaaa.\n43 Note that this statement is not required for child assent.",
        "metadata": {
            "document_id": "ICD - Document 1.pdf",
            "chunk_index": 134,
            "source": "markdown",
            "embedding_version": "v1"
        }
    },
    {
        "id": "e192ce34-a333-43ec-920c-dded6c84e68f",
        "text": "1.  Requirement for Written Documentation of Informed Consent\n44 21 CFR 56.109(c) states, ' An IRB shall require documentation of informed consent in accordance with section 50.27 of this chapter, except as follows:\n' (1) The IRB may, for some or all subjects, waive the requirement that the subject, or the subject's legally authorized representative, sign a written consent form if it finds that the research presents no more than minimal risk of harm to subjects and involves no procedures for which written consent is normally required outside the research context; or\n' (2) The IRB may, for some or all subjects, find that the requirements in 50.24 of this chapter for an exception from informed consent for emergency research are met.'",
        "metadata": {
            "document_id": "ICD - Document 1.pdf",
            "chunk_index": 135,
            "source": "markdown",
            "embedding_version": "v1"
        }
    },
    {
        "id": "43e9100f-bbe9-47c5-8218-045c3333df1d",
        "text": "Contains Nonbinding Recommendations\nwritten informed consent is required, the use of electronic, including digital, signatures are permitted under FDA's regulations, provided it is in compliance with applicable regulations. 45\nIn the event that an IRB waives the requirement for documentation of informed consent (under 21 CFR 56.109(c)(1)), FDA recommends that the elements of informed consent be reviewed verbally with the subject or the subject's LAR.  Additionally, the IRB may require the investigator to provide subjects with a written statement regarding the clinical investigation (21 CFR 56.109(d)).  See section III. E.2, 'Alternative Methods of Obtaining Informed Consent' below for additional information regarding documentation of consent.  FDA recommends that when an IRB waives the documentation requirement for informed consent in circumstances where there is minimal risk of harm under 21 CFR 56.109(c)(1), the consent process and discussion be described and noted in subject case histories required to be maintained under 21 CFR 312.62(b) or 21 CFR 812.140(a)(3). 46",
        "metadata": {
            "document_id": "ICD - Document 1.pdf",
            "chunk_index": 136,
            "source": "markdown",
            "embedding_version": "v1"
        }
    },
    {
        "id": "406fa836-9277-491f-ba1b-1af499cde1d3",
        "text": "2. Alternative Methods of Obtaining Informed Consent\nTraditionally, informed consent has been obtained and documented in a face-to-face interview using paper consent forms.  Technologies are available that may serve as an alternative to the paper consent form in the informed consent process. 47 Parties interested in pursuing alternative methods of obtaining informed consent should discuss their plan with their IRB and are welcome to contact FDA as needed for advice. 48\nEven in the context of paper consent forms, there may be certain circumstances when an alternative to a face-to-face consent discussion may be appropriate.  For example, such an alternative may be appropriate\n45 See 21 CFR part 11, 'Electronic Records; Electronic Signatures' and FDA guidance entitled, ' Guidance for Industry Part 11, Electronic Records; Electronic Signatures - Scope and Application ,' available at https://www.fda.gov/regulatory-information/search-fda-guidance-documents/part-11-electronic-recordselectronic-signatures-scope-and-application.",
        "metadata": {
            "document_id": "ICD - Document 1.pdf",
            "chunk_index": 137,
            "source": "markdown",
            "embedding_version": "v1"
        }
    },
    {
        "id": "ab617bdf-c62d-4c47-9bc6-a3907935d20b",
        "text": "2. Alternative Methods of Obtaining Informed Consent\n46 Documentation requirements related to emergency research, as mentioned in 21 CFR 56.109(c)(2), can be found in 21 CFR 50.24.  Discussion of these studies is in a separate guidance, 'Guidance for Institutional Review Boards, Clinical Investigators, and Sponsors; Exception from Informed Consent Requirements for Emergency Research,' available at https://www.fda.gov/regulatory-information/search-fda-guidance-documents/exception-informedconsent-requirements-emergency-research.\n47 For additional information on alternative methods of obtaining informed consent, please see 'Guidance for Institutional Review Boards, Investigators, and Sponsors, Use of Electronic Informed Consent in Clinical Investigations,' available at https://www.fda.gov/regulatory-information/search-fda-guidance-documents/useelectronic-informed-consent-clinical-investigations-questions-and-answers, and FDA's MyStudies Application (App) at https://www.fda.gov/drugs/science-and-research-drugs/covid-mystudies-application-app.",
        "metadata": {
            "document_id": "ICD - Document 1.pdf",
            "chunk_index": 138,
            "source": "markdown",
            "embedding_version": "v1"
        }
    },
    {
        "id": "095999b4-4765-4d51-9305-02166c582a2a",
        "text": "2. Alternative Methods of Obtaining Informed Consent\n48 Questions related to alternative methods of obtaining informed consent can be directed to the Office of Clinical Policy at gcpquestions@fda.hhs.gov.",
        "metadata": {
            "document_id": "ICD - Document 1.pdf",
            "chunk_index": 139,
            "source": "markdown",
            "embedding_version": "v1"
        }
    },
    {
        "id": "33ff59d3-2636-4145-a487-34cc2ba8372b",
        "text": "Contains Nonbinding Recommendations\nwhen the subject or the subject's LAR is unable to visit the investigational site to sign the consent form, or if the screening procedures for the clinical investigation require prior activity, such as fasting, that requires consent but does not require a visit to the investigational site. 49 When written documentation of informed consent is required, informed consent cannot be obtained and documented by oral communication through the telephone alone.",
        "metadata": {
            "document_id": "ICD - Document 1.pdf",
            "chunk_index": 140,
            "source": "markdown",
            "embedding_version": "v1"
        }
    },
    {
        "id": "77229d34-e7aa-433b-99b7-c7c820f5add6",
        "text": "Contains Nonbinding Recommendations\nMethods other than a face-to-face consent discussion may be acceptable if those methods allow for an adequate exchange of information and documentation, and a method to ensure that the signer of the consent form is the person who plans to enroll as a subject in the clinical investigation or is the LAR of the subject.  For example, the consent form may be sent to the subject or the subject's LAR by facsimile or e-mail, and the consent discussion may then be conducted by telephone/videoconference when the subject or subject's LAR can access the consent form during the discussion.  After the consent discussion, the subject or the subject's LAR can manually or electronically sign and date the consent form and return the document to the clinical investigator through a secure electronic method, such as by scanning the consent form and returning it through a secure e-mail account, or by posting it to a secure internet address.  Alternatively, the subject may bring the signed and dated consent form to their next visit to the clinical site or mail it to the clinical investigator.",
        "metadata": {
            "document_id": "ICD - Document 1.pdf",
            "chunk_index": 141,
            "source": "markdown",
            "embedding_version": "v1"
        }
    },
    {
        "id": "d5d9b7cf-8b4c-4573-80b4-75a557d86cfa",
        "text": "Contains Nonbinding Recommendations\nThe signed document must be maintained as part of the subject's case history required under 21 CFR 312.62(b) and 812.140(a)(3).  In addition, the person signing the consent form must receive a copy of the consent form (21 CFR 50.27(a)).  Although FDA regulations do not require the subject's copy to be a signed copy, FDA recommends that a copy of the signed consent form be provided (see section III.E.3, 'Requirement for Dating Consent Form'). 50 In situations in which the signed document cannot be retrieved for filing in the study records (e.g., because the subject is in strict isolation due to a highly transmissible infectious disease), and electronic consent is not available, it is acceptable to retain for the study records a photographic image of the signed consent form along with an attestation by the person entering the photograph into the study records that states how the photograph was obtained and that it is a photograph of the informed consent form signed by the subject.",
        "metadata": {
            "document_id": "ICD - Document 1.pdf",
            "chunk_index": 142,
            "source": "markdown",
            "embedding_version": "v1"
        }
    },
    {
        "id": "826f29b6-0e84-47d7-8a63-c8e324324318",
        "text": "Contains Nonbinding Recommendations\nFor studies involving no more than minimal risk, and no procedures for which written consent is normally required outside the research context, oral consent from a subject or a subject's LAR is permissible under 21 CFR 56.109(c).  When oral consent is used, FDA recommends that the consent process and discussion\n49 See 'Guidance for Institutional Review Boards and Clinical Investigators: Information Sheet - Screening Tests Prior to Study Enrollment,' available at https://www.fda.gov/regulatory-information/search-fda-guidancedocuments/screening-tests-prior-studyenrollment#:~:text=While%20an%20investigator%20may%20discuss%20availability%20of%20studies,eligibility%20 for%20research%2C%20including%20withdrawal%20from%20medication%20%28wash-out%29.",
        "metadata": {
            "document_id": "ICD - Document 1.pdf",
            "chunk_index": 143,
            "source": "markdown",
            "embedding_version": "v1"
        }
    },
    {
        "id": "fbfed042-86ca-4495-bb20-0798634c4e7b",
        "text": "Contains Nonbinding Recommendations\n50 See FDA's guidance 'E6(R2) Good Clinical Practice: Integrated Addendum to ICH E6(R1)' Section 4.8.11; available at https://www.fda.gov/regulatory-information/search-fda-guidance-documents/e6r2-good-clinical-practiceintegrated-addendum-ich-e6r1.\nbe described and noted in subject case histories required to maintained under 21 CFR 312.62(b) or 21 CFR 812.140(a)(3).",
        "metadata": {
            "document_id": "ICD - Document 1.pdf",
            "chunk_index": 144,
            "source": "markdown",
            "embedding_version": "v1"
        }
    },
    {
        "id": "45c157b9-d2bb-4234-9663-4198a4c4363a",
        "text": "3. Requirement for Dating Consent Form\nIn addition to signing the consent form, the subject or the subject's LAR must enter the date of signature on the form (21 CFR 50.27(a)) to allow confirmation that the subject or the subject's LAR provided consent prior to participation in the clinical investigation, as required by 21 CFR 50.20.  In those cases where the subject provides consent on the same day 51 that they begin participation in the clinical investigation, the subject's case history must document that the subject provided consent prior to participation in the research for studies conducted under an IND or IDE, (312.62(b) and 812.140(a)(3)), and the subject's case history should contain the signed and dated consent form.  Although FDA regulations do not require the subject's copy to be a signed copy, FDA recommends that a copy of the signed consent form be provided.",
        "metadata": {
            "document_id": "ICD - Document 1.pdf",
            "chunk_index": 145,
            "source": "markdown",
            "embedding_version": "v1"
        }
    },
    {
        "id": "960b44a0-7337-4148-bd55-feb3df6f140c",
        "text": "4. Forms for Documentation of Informed Consent\nUnder 21 CFR 50.27:\n- (b) Except as provided in  56.109(c), the consent form may be either of the following:\n- (1)  A written consent document that embodies the elements of informed consent required by  50.25.  This form may be read to the subject or the subject's legally authorized representative, but, in any event, the investigator shall give either the subject or the representative adequate opportunity to read it before it is signed.\n- (2)  A short form written consent document stating that the elements of informed consent required by  50.25 have been presented orally to the subject or the subject's legally authorized representative.  When this method is used, there shall be a witness to the oral presentation. Also, the IRB shall approve a written summary of what is to be said to the subject or the representative.  Only the short form itself is to be signed by the subject or the representative. However, the witness shall sign both the short form and a copy of the summary, and the",
        "metadata": {
            "document_id": "ICD - Document 1.pdf",
            "chunk_index": 146,
            "source": "markdown",
            "embedding_version": "v1"
        }
    },
    {
        "id": "7310d7cb-9853-426e-80b6-d46e84c4f946",
        "text": "4. Forms for Documentation of Informed Consent\n51 Prospective subjects should have sufficient opportunity and time to consider enrollment in the research, such that coercion and undue influence are minimized.  See section III.A.2, 'Coercion and Undue Influence'.",
        "metadata": {
            "document_id": "ICD - Document 1.pdf",
            "chunk_index": 147,
            "source": "markdown",
            "embedding_version": "v1"
        }
    },
    {
        "id": "9d847868-4251-4258-9514-06d4b90b22f5",
        "text": "Contains Nonbinding Recommendations\nperson actually obtaining the consent shall sign a copy of the summary.  A copy of the summary shall be given to the subject or the representative, in addition to a copy of the short form.\nThe regulations provide for obtaining written informed consent by two different methods:  a long form that embodies all the elements of informed consent (see 21 CFR 50.25), or a short form that states that the elements of informed consent have been presented orally to the subject or the subject's LAR.",
        "metadata": {
            "document_id": "ICD - Document 1.pdf",
            "chunk_index": 148,
            "source": "markdown",
            "embedding_version": "v1"
        }
    },
    {
        "id": "81194c82-b751-4ce8-b11c-869ce097e936",
        "text": "a. Long Form\nAs stated above, the long form must incorporate all the elements of informed consent as required under 21 CFR 50.25.  When the long form is used, a copy must be provided to the person signing the form, that is, the subject or the subject's LAR (21 CFR 50.27(a)).",
        "metadata": {
            "document_id": "ICD - Document 1.pdf",
            "chunk_index": 149,
            "source": "markdown",
            "embedding_version": "v1"
        }
    },
    {
        "id": "25509d1c-4a59-465f-b053-78e370361e93",
        "text": "b. Short Form\nAn IRB may approve a short form to be used in appropriate situations where the elements of informed consent required by 21 CFR 50.25 are presented orally to the subject or the subject's LAR (21 CFR 50.27(b)(2)).  For example, IRBs may consider approving the use of a short form in situations where the subject or the subject's LAR is unable to read due to low literacy or visual impairment. 52\nWhen the short form is used, the IRB is required to approve a written summary of the information to be presented orally (21 CFR 50.27(b)(2)).  The information presented orally should be as thorough as the",
        "metadata": {
            "document_id": "ICD - Document 1.pdf",
            "chunk_index": 150,
            "source": "markdown",
            "embedding_version": "v1"
        }
    },
    {
        "id": "a381ed22-e5c2-4073-922f-89afe7a891db",
        "text": "b. Short Form\n52 For additional information see Frequently Asked Question #6, 'What should be considered when enrolling subjects with low literacy and numeracy?' and Frequently Asked Question #7, 'What should be considered when enrolling subjects with physical or sensory disabilities?'  In addition, for information on enrolling individuals with limited English proficiency see Frequently Asked Question #3, 'What are some considerations for enrolling nonEnglish speaking subjects?', Frequently Asked Question #4, 'What process should be followed when it is expected that subjects who do not understand English will be enrolled?', and Frequently Asked Question #5, 'What process should be followed when the enrollment of subjects who do not understand English, or who are limited English proficient, is not expected?'",
        "metadata": {
            "document_id": "ICD - Document 1.pdf",
            "chunk_index": 151,
            "source": "markdown",
            "embedding_version": "v1"
        }
    },
    {
        "id": "a9f98e28-293d-4d96-a8a3-b2c52864530f",
        "text": "Contains Nonbinding Recommendations\ninformation contained in the long form. 53 A copy of the short form and the written summary must be given to the person signing the form (that is, the subject or the subject's LAR) (21 CFR 50.27(b)(2)).\nUse of the short form requires that there be a witness to the oral presentation of information to the subject or the subject's LAR (21 CFR 50.27(b)(2)).  FDA recommends that an impartial third party not otherwise connected with the clinical investigation (for example, clinical staff not involved in the research, a patient advocate or an independent interpreter) serve as the witness.  The witness must be present physically or by some other means, for example, by phone or video conference, during the oral presentation, not just the signing of the consent form (21 CFR 50.27(b)(2)).  The purpose of the witness is generally to attest to the voluntariness of the subject's consent and the adequacy of the consent process by ensuring that the information was accurately conveyed and that the subject's questions were answered.",
        "metadata": {
            "document_id": "ICD - Document 1.pdf",
            "chunk_index": 152,
            "source": "markdown",
            "embedding_version": "v1"
        }
    },
    {
        "id": "80abbaed-c1d9-4de5-bea1-5d8a731b3169",
        "text": "Contains Nonbinding Recommendations\nThe subject or the subject's LAR signs and dates only the short form (21 CFR 50.27(a) and (b)(2)).  The witness must sign both the short form and the summary, and the person obtaining consent must sign the summary (21 CFR 50.27(b)(2)).  Due to the additional requirements of having a witness and providing a written summary of the consent discussion, use of the short form may not ease or expedite the consent process.",
        "metadata": {
            "document_id": "ICD - Document 1.pdf",
            "chunk_index": 153,
            "source": "markdown",
            "embedding_version": "v1"
        }
    },
    {
        "id": "79427ce4-a7c3-4a33-96d8-9d26404839c7",
        "text": "IV.  RESPONSIBILITIES FOR INFORMED CONSENT\nIRBs, clinical investigators, and sponsors share responsibility for ensuring that the informed consent form and process is adequate and meets FDA's regulatory requirements.  The regulatory requirements represent the minimum information to be provided to prospective subjects for informed consent.  The consent form should also incorporate any additional information that may affect subjects' rights and welfare or willingness to participate in the clinical research.  For example, information about certain financial relationships and interests may be important to the subject (see section IV.A.1, \"Review of All Informed Consent Materials\" and section IV.B.2, \"Financial Relationships and Interests\").",
        "metadata": {
            "document_id": "ICD - Document 1.pdf",
            "chunk_index": 154,
            "source": "markdown",
            "embedding_version": "v1"
        }
    },
    {
        "id": "5e1c5957-11b8-4170-983e-1f0a37ad7396",
        "text": "IV.  RESPONSIBILITIES FOR INFORMED CONSENT\n53 See the response to Comment 52 in the preamble to the 1981 final rule issuing regulations for the protection of human subjects (46 FR 8942, January 27, 1981); https://www.fda.gov/science-research/clinical-trials-and-humansubject-protection/protection-human-subjects-informed-consent: 'The fact that a short form is used to document informed consent does not mean that the subject will get less information than if handed a long, detailed written documentAll the 'form' provides [whether long or short] is evidence that the information required by 50.25 has been provided to a prospective subject.'",
        "metadata": {
            "document_id": "ICD - Document 1.pdf",
            "chunk_index": 155,
            "source": "markdown",
            "embedding_version": "v1"
        }
    },
    {
        "id": "6f4f5190-d06c-4c6c-bc33-465db1e2bc4d",
        "text": "A. The IRB\nFDA requires that an IRB review and have authority to approve, require modifications in (to secure approval), or disapprove all research activities covered by the IRB regulations (21 CFR 56.109(a)).  A critical part of this responsibility is for the IRB to review and approve a consent form that complies with applicable regulatory requirements at 21 CFR part 50 and to help ensure there is an adequate informed consent process that protects the rights and welfare of subjects participating in clinical investigations (21 CFR 56.109 and 56.111).  Below are specific areas that IRBs should consider:",
        "metadata": {
            "document_id": "ICD - Document 1.pdf",
            "chunk_index": 156,
            "source": "markdown",
            "embedding_version": "v1"
        }
    },
    {
        "id": "4114e629-4167-47b3-a74b-d153f53d2537",
        "text": "1. Review of All Informed Consent Materials\nIRBs must review all materials used in the informed consent process (see 21 CFR 56.109(a)-(b) and 56.111(a)(4)-(5)). 54 This includes recruitment materials 55 , such as advertisements, and information provided in addition to the informed consent form (for example, a chart explaining what to expect at each study visit or a document explaining the costs to subjects).  The IRB's review is to ensure that information given to subjects as part of the consent process is in accordance with the requirements of 21 CFR part 50 (see 21 CFR 56.109 and 56.111(a)(4)-(5)).\nWhen reviewing clinical investigations, IRBs must ensure that the consent process minimizes the possibility of coercion and undue influence (21 CFR 50.20 and 56.111(a)(4)).  When a clinical",
        "metadata": {
            "document_id": "ICD - Document 1.pdf",
            "chunk_index": 157,
            "source": "markdown",
            "embedding_version": "v1"
        }
    },
    {
        "id": "cd513071-0baf-4261-ba62-6c5706745a09",
        "text": "1. Review of All Informed Consent Materials\n54 IRBs are not required under 21 CFR part 56 to review stand-alone HIPAA authorizations, so long as an IRB's written procedures, adopted pursuant to 21 CFR 56.108(a), do not require such review and approval.  See page 8 of FDA's 'Guidance for Industry IRB Review of Stand-Alone HIPAA Authorizations Under FDA Regulations' (available at https://www.fda.gov/regulatory-information/search-fda-guidance-documents/irb-review-standalone-hipaa-authorizations-under-fda-regulations).",
        "metadata": {
            "document_id": "ICD - Document 1.pdf",
            "chunk_index": 158,
            "source": "markdown",
            "embedding_version": "v1"
        }
    },
    {
        "id": "00fa7e91-81e3-4f9d-b6fd-b09c804b9eb1",
        "text": "1. Review of All Informed Consent Materials\n55 As described in the FDA Information Sheet 'Recruiting Study Subjects' (available at https://www.fda.gov/regulatory-information/search-fda-guidance-documents/recruiting-study-subjects), FDA considers advertising, including but not necessarily limited to newspaper, radio, TV, bulletin boards, posters, flyers, and internet postings, to be part of the consent process.  However, FDA does not consider listings of basic information about clinical investigations to be advertising for recruitment.  We consider basic information to be information such as the title of the clinical investigation, purpose of the clinical investigation, protocol summary, basic eligibility criteria, investigational site locations, and how to contact the site for further information.  An example of a basic information listing is the National Institutes of Health clinical trial registry (https://clinicaltrials.gov/), where many FDA-regulated clinical investigations are required to be registered.  Any posting about a clinical investigation where the format limits the information provided to basic information does not need to be reviewed by the IRB.  However, a posting that provides more than basic information should be submitted for IRB review.",
        "metadata": {
            "document_id": "ICD - Document 1.pdf",
            "chunk_index": 159,
            "source": "markdown",
            "embedding_version": "v1"
        }
    },
    {
        "id": "27119f2a-97c4-4562-8828-4a4bc0fe3099",
        "text": "Contains Nonbinding Recommendations\ninvestigation involves subjects who are likely to be vulnerable to coercion or undue influence, IRBs must determine that additional safeguards have been included in the clinical investigation to protect their rights and welfare (21 CFR 56.111(b)).  In the event an IRB regularly reviews clinical investigations involving vulnerable subject populations, for such clinical investigations, the IRB membership should include individuals with knowledge about and/or experience working with such subjects, in order to provide expertise and identify techniques for obtaining their informed consent. 56\nThe IRB has the authority to require that subjects receive information in addition to what 21 CFR 50.25 requires, if in the judgment of the IRB, the information would meaningfully add to the protection of the rights and welfare of the subjects (21 CFR 56.109(b)).  For example, the IRB may determine that local circumstances necessitate the inclusion of additional information relevant to the informed consent process for prospective subjects from that particular community.",
        "metadata": {
            "document_id": "ICD - Document 1.pdf",
            "chunk_index": 160,
            "source": "markdown",
            "embedding_version": "v1"
        }
    },
    {
        "id": "f05ebbeb-4214-4974-87b2-2dc1d846a256",
        "text": "Contains Nonbinding Recommendations\nHHS recommends that IRBs consider whether subjects should be informed of any financial relationships or interests that are associated with the clinical investigation, such as payments for services, equity interests or intellectual property rights. 57 As indicated in the HHS guidance, some conflicting financial interests in the clinical investigation may affect the rights and welfare of subjects, and IRBs should consider approaches to assure subjects are adequately protected, including providing subjects with information about the financial relationships and interests.  IRBs should determine whether subjects should be provided with information regarding the source of funding, funding arrangements, financial interests of parties involved in the clinical investigation, and any financial interest management techniques applied.  The IRB should consider the kind, amount, and level of detail of information to be provided to subjects.\n56 For additional information see Frequently Asked Question #6, 'What are some considerations for enrolling subjects with low literacy and numeracy?'; Frequently Asked Question #7, 'What are some considerations for enrolling physically challenged subjects?'; and Frequently Asked Question #8, 'What are some considerations for enrolling subjects with impaired consent capacity?'",
        "metadata": {
            "document_id": "ICD - Document 1.pdf",
            "chunk_index": 161,
            "source": "markdown",
            "embedding_version": "v1"
        }
    },
    {
        "id": "f47088e0-2936-4e2a-9ea8-868a294cc06e",
        "text": "Contains Nonbinding Recommendations\n57 This topic is addressed in the HHS guidance document, 'Financial Relationships and Interests in Research Involving Human Subjects:  Guidance for Human Subject Protection.'  This guidance, which applies to FDAregulated clinical investigations as well as human subjects research conducted or supported by HHS, is available at https://www.hhs.gov/ohrp/regulations-and-policy/guidance/financial-conflict-of-interest/index.html.",
        "metadata": {
            "document_id": "ICD - Document 1.pdf",
            "chunk_index": 162,
            "source": "markdown",
            "embedding_version": "v1"
        }
    },
    {
        "id": "c53cdd23-5b72-4d82-836c-abbfd64b1a30",
        "text": "a. Adequacy and Appropriateness of Wording\nThe IRB has the authority and responsibility to require that information given to subjects as part of informed consent be in accordance with 21 CFR 50.25. 58 In order to approve the research, the IRB must determine that informed consent will be obtained in accordance with the informed consent regulations (21 CFR 56.111(a)(4)).\nInvestigators must use an IRB-approved written consent form when documenting informed consent, in accordance with 21 CFR 50.27, except as provided in 21 CFR 56.109(c).  Thus, the IRB should review the adequacy and appropriateness of all wording in the consent materials, as well as the overall length and presentation of information.  Consent forms that are long, complex, legalistic, and have a high reading level may overwhelm prospective subjects and may inhibit reading of the full document and understanding of the relevant information.",
        "metadata": {
            "document_id": "ICD - Document 1.pdf",
            "chunk_index": 163,
            "source": "markdown",
            "embedding_version": "v1"
        }
    },
    {
        "id": "556af1de-34cf-4081-b945-4582967f1f97",
        "text": "a. Adequacy and Appropriateness of Wording\nThe IRB should ensure that technical and scientific concepts and terms are explained, or common terms substituted, so that the anticipated subject population can understand all provided information (see 21 CFR 50.20). 59 Pictures, diagrams, or other visual aids may be used to improve understanding of medical terms or how an investigational product functions.  IRBs may wish to evaluate, through subject discussions, how well the consent materials communicate critical information.  Additional guidance on the requirements at 21 CFR 50.20 can be found in section III.A, 'General Requirements for Informed Consent' above.",
        "metadata": {
            "document_id": "ICD - Document 1.pdf",
            "chunk_index": 164,
            "source": "markdown",
            "embedding_version": "v1"
        }
    },
    {
        "id": "50c9b499-2535-4b06-8708-9d72316176a7",
        "text": "b. Use of Standardized Language\nInstitutions may develop standard language or a standard format to use in portions of all consent forms (for example, for those elements that deal with confidentiality, compensation, answers to questions, and the voluntary nature of participation) to meet certain FDA regulatory requirements, as well as institutional and other Federal, State, or local requirements.\n58 See 21 CFR 56.109(b).\n59 Various strategies exist to improve communication with patients, for example, see Doak CC, Doak LG, Friedell GH, Meade CD. Improving comprehension for cancer patients with low literacy skills: strategies for clinicians. CA Cancer J Clin. 1998 May-Jun;48(3):151-62. doi: 10.3322/canjclin.48.3.151. PMID: 9594918.",
        "metadata": {
            "document_id": "ICD - Document 1.pdf",
            "chunk_index": 165,
            "source": "markdown",
            "embedding_version": "v1"
        }
    },
    {
        "id": "95479644-a3ec-4e51-9e44-0a390f777451",
        "text": "2. Review of the Consent Process\nThe investigator should notify the IRB of the consent process to be used.  The process may be described in the protocol, or the investigator may provide a brief document describing the process to be used.  The materials and procedures used for subject recruitment, which typically include advertisements, must be reviewed and approved by the IRB to ensure that these materials are appropriate, as described in section IV.A.1, 'Review of All Informed Consent Materials' (see 21 CFR 56.109(b) and 56.111(a)(4)). 60 The IRB must determine that investigators will seek consent from prospective subjects under circumstances that minimize the possibility of coercion and undue influence (21 CFR 50.20 and 56.111(a)(4)).  FDA considers this to include ensuring that the consent process described by the investigator allows sufficient time for prospective subjects to consider the information, provides time and opportunity for the subjects to ask questions and have those questions answered, and allows time and opportunity for the subjects to consider fully whether to participate.",
        "metadata": {
            "document_id": "ICD - Document 1.pdf",
            "chunk_index": 166,
            "source": "markdown",
            "embedding_version": "v1"
        }
    },
    {
        "id": "8a9edd0e-9ac1-406a-a205-467610dc5769",
        "text": "2. Review of the Consent Process\nTo approve a clinical investigation, the IRB must find that informed consent will be sought from each prospective subject or the subject's LAR and that informed consent will be appropriately documented, in accordance with and to the extent required by 21 CFR part 50 (21 CFR 56.111(a)(4) and (5)).  FDA recommends that the IRB inquire as to who will conduct the consent discussion and what procedures will be followed.  If procedures other than a face-to-face consent discussion are proposed, such as by telephone, the IRB should consider whether the procedures will provide effective communication and accomplish the goals of the informed consent process.  Alternative procedures may be of special concern when the clinical investigation involves complex procedures or when risks may be difficult to comprehend.\nFDA regulations authorize the IRB to observe or have a third party observe the consent process, as well as the research (21 CFR 56.109(f)).  IRBs should consider using this authority when it may be appropriate 61 or enhance the protection provided to subjects (for example, when the investigator is also",
        "metadata": {
            "document_id": "ICD - Document 1.pdf",
            "chunk_index": 167,
            "source": "markdown",
            "embedding_version": "v1"
        }
    },
    {
        "id": "03a84b49-5de8-42e4-b75f-a5788924b8f3",
        "text": "2. Review of the Consent Process\n60 For further information, see the FDA Information Sheet 'Recruiting Study Subjects,' available at https://www.fda.gov/regulatory-information/search-fda-guidance-documents/recruiting-study-subjects.\n61 In the \"Institutional Review Board; Report and Recommendations of the National Commission for the Protection of Human Subjects of Biomedical and Behavioral Research,' published in the Federal Register , November 30, 1978 (43 FR 56174), the Commission stated:  'Observation of the consent process or conduct of research is both a difficult and delicate task.  The designation of staff or members of the IRB to observe research activities can impose a substantial strain on the limited resources of the IRB.  Further, such observation may intrude on confidential relationships or the privacy of individual subjects.  IRBs should take these factors into account when determining appropriate means for continuing review of a protocol, and alternatives such as investigator reporting requirements should be considered.  However, certain research will warrant observation to assure the protection of subjects, and in such cases IRBs have an obligation to take suitable measures.'  Id. at 56179.",
        "metadata": {
            "document_id": "ICD - Document 1.pdf",
            "chunk_index": 168,
            "source": "markdown",
            "embedding_version": "v1"
        }
    },
    {
        "id": "0be65320-4996-4fbc-88e4-afdaa00d3837",
        "text": "Contains Nonbinding Recommendations\nthe treating physician for a prospective subject, when the person conducting the consent interview is relatively inexperienced, or when the clinical investigation involves vulnerable subjects).  In addition to observing a sample of consent discussions, the IRB could interview subjects to assess the consent process and evaluate the subjects' understanding of the clinical investigation.",
        "metadata": {
            "document_id": "ICD - Document 1.pdf",
            "chunk_index": 169,
            "source": "markdown",
            "embedding_version": "v1"
        }
    },
    {
        "id": "6c02b196-4a0d-4be0-a7c8-79bdd9eb5ac9",
        "text": "3. IRB Review of Updated Informed Consent Documents\nAll information given to subjects as part of the consent process is to be reviewed and approved by the IRB (21 CFR 56.109(a)-(b) and 56.111(a)(4)-(5)). 62 During the clinical investigation, new information about the research or changes to the clinical investigation may arise that affect the rights or welfare of subjects.  FDA recommends that IRBs have procedures in place for the timely, efficient, and effective review of such new information or changes.  This would include procedures for the clinical investigator and/or sponsor to notify the IRB of any significant new findings that arise during the clinical investigation relevant to a subject's decision to continue participation (see section III.C.5, 'Providing Significant New Findings to Subjects', and Frequently Asked Question #16).  When new information or changes in the clinical investigation warrant revisions of the consent form (and any accompanying changes to the protocol), such revisions must be reviewed and approved by the IRB before the revisions are initiated, except when necessary to eliminate apparent immediate hazards to subjects (21 CFR 56.108(a)(3)-(4)).",
        "metadata": {
            "document_id": "ICD - Document 1.pdf",
            "chunk_index": 170,
            "source": "markdown",
            "embedding_version": "v1"
        }
    },
    {
        "id": "943e9d94-b92a-4542-b71b-3a4250c652ef",
        "text": "3. IRB Review of Updated Informed Consent Documents\nSome changes may be reviewed and approved by expedited means, as provided for by 21 CFR 56.110. For example, an IRB may decide expedited review is appropriate for changes to the consent form that reflect minor changes in the protocol or recruitment plan (e.g., new advertising for subjects following initiation of the clinical investigation when the advertisement incorporates wording from the approved consent form).  When expedited review is used, if the IRB reviewer is unsure whether the change qualifies for expedited review under 21 CFR 56.110(b), FDA recommends that the reviewer (if other than the IRB chair) consult with the IRB chair.  If doubts persist as to whether the change qualifies for expedited review, then the change should be reviewed at a convened meeting of the IRB. 63\nAdministrative changes, such as the correction of typographical and spelling errors, and changes in telephone numbers, may be submitted to the IRB at any time, including during continuing review, and do not require formal review and approval.  Although such changes do not need IRB review, updated",
        "metadata": {
            "document_id": "ICD - Document 1.pdf",
            "chunk_index": 171,
            "source": "markdown",
            "embedding_version": "v1"
        }
    },
    {
        "id": "7feddf1c-38ee-4a9a-bd59-8210127ea583",
        "text": "3. IRB Review of Updated Informed Consent Documents\n62 This would include all addenda to the consent form and other materials used in the consent process.\n63 As indicated at section IV.B, when new information is added to the consent form that might affect the willingness of already enrolled and actively participating subjects to continue in the clinical investigation, the IRB should determine the need to inform the previously enrolled subjects of the new information and determine their willingness to continue in the research.",
        "metadata": {
            "document_id": "ICD - Document 1.pdf",
            "chunk_index": 172,
            "source": "markdown",
            "embedding_version": "v1"
        }
    },
    {
        "id": "3abb40b2-cd5e-46fc-a565-14a0ca34aeef",
        "text": "Contains Nonbinding Recommendations\nversions of the consent form should be sent to the IRB so that they have current copies of the informed consent form on file. 64",
        "metadata": {
            "document_id": "ICD - Document 1.pdf",
            "chunk_index": 173,
            "source": "markdown",
            "embedding_version": "v1"
        }
    },
    {
        "id": "f42fb4cf-b305-49a6-8a08-8955b3af8dff",
        "text": "4. Identification of Revised Consent Forms\nThe IRB should ensure that there is a way to identify a revised consent form so that continued use of a previously approved version does not occur.  While not required by FDA regulations, the use of date stamps is one possible mechanism for ensuring use of the most recently approved version of the consent form.",
        "metadata": {
            "document_id": "ICD - Document 1.pdf",
            "chunk_index": 174,
            "source": "markdown",
            "embedding_version": "v1"
        }
    },
    {
        "id": "b481e762-f268-41e4-94a8-08aeb0d74adf",
        "text": "B. The Clinical Investigator\nThe clinical investigator is responsible for protecting the rights, safety, and welfare of subjects during a clinical investigation, and for ensuring that, unless an exception applies, legally effective informed consent is obtained from each subject or the subject's LAR before that subject takes part in the clinical investigation (see 21 CFR 50.20(a), 312.60, and 812.100).  Legally effective informed consent includes meeting all applicable Federal, State, and local laws that require additional information in the informed consent form beyond what FDA regulations require.  Sponsors and investigators may wish to seek legal guidance regarding specific local consent requirements applicable to their research.",
        "metadata": {
            "document_id": "ICD - Document 1.pdf",
            "chunk_index": 175,
            "source": "markdown",
            "embedding_version": "v1"
        }
    },
    {
        "id": "f9c6aa3a-c6b0-4853-9366-d57cf97f2a54",
        "text": "B. The Clinical Investigator\nThe clinical investigator should notify the IRB regarding the consent process, including who (e.g., the investigator or another study team member) will conduct the consent discussion.  Any information that will be given to subjects to review and discuss as part of informed consent must be submitted to the IRB for review and approval (21 CFR 56.109(a)-(b) and 56.111(a)(4)-(5)).  An investigator may not begin the informed consent process with prospective subjects until the IRB reviews and approves the clinical investigation, consent form, and any other information to be given to subjects as part of the consent process (21 CFR 50.20, 50.27, and 56.109).\nThe clinical investigator's institution may have standard language or a standard format for consent forms (for example, for those elements that deal with confidentiality, compensation, answers to questions, and the voluntary nature of participation).  FDA recognizes that investigators may also need to identify and\n64 See section IV.A.4 for guidance regarding identification of the most up-to-date version of the informed consent form.",
        "metadata": {
            "document_id": "ICD - Document 1.pdf",
            "chunk_index": 176,
            "source": "markdown",
            "embedding_version": "v1"
        }
    },
    {
        "id": "1cf415a1-d630-4ad4-88d8-637317291f8c",
        "text": "Contains Nonbinding Recommendations\nmeet institutional requirements and incorporate them into the consent form for the IRB's initial review of the clinical investigation.\nDuring the clinical investigation, the investigator may need to revise the consent form to address new information that might arise during the conduct of the trial, such as a change to the protocol or new safety information.  The investigator will need to obtain IRB review and approval of the revised consent form (21 CFR 50.27 and 56.109).  In addition, because the consent form is being modified to reflect new information that might affect the willingness of already enrolled and actively participating subjects to continue in the clinical investigation, the IRB should determine the need to inform the previously enrolled subjects of the new information and determine their willingness to continue in the research (see Frequently Asked Questions #16).",
        "metadata": {
            "document_id": "ICD - Document 1.pdf",
            "chunk_index": 177,
            "source": "markdown",
            "embedding_version": "v1"
        }
    },
    {
        "id": "658faa81-f4dd-431a-a826-4884e3e401b6",
        "text": "Contains Nonbinding Recommendations\nAny new information that is part of the consent process must be reviewed and approved by the IRB as a change in approved research before it is initiated, except where necessary to eliminate apparent immediate hazards to the subject (see 21 CFR 56.108(a)(4)).  In the rare event that urgent safety information is provided to the subject prior to IRB approval, the IRB should promptly be notified of both the safety issue and the notification of subjects.\nBelow are specific areas for consideration by the clinical investigator:",
        "metadata": {
            "document_id": "ICD - Document 1.pdf",
            "chunk_index": 178,
            "source": "markdown",
            "embedding_version": "v1"
        }
    },
    {
        "id": "87e36549-0671-4778-b26a-85f1b0d7d2fd",
        "text": "1. Delegation of Consent Discussion\nFDA regulations require that the investigator obtain the legally effective informed consent of subjects (21 CFR 50.20, 312.60 and 812.100).  If the investigator delegates this responsibility, FDA expects that the individual to whom the responsibility is delegated be qualified by education, training, and experience to perform this activity.  The individual obtaining informed consent should be knowledgeable about the clinical investigation and have the appropriate training and credentials to be able to address any questions or concerns the subject may have about the study and/or alternative procedures or courses of treatment, if any, that might be advantageous to the subject.  The investigator should have a detailed plan for the supervision and training of staff, and oversight of the clinical investigation, including the informed consent process. 65 Even when a task is delegated to another individual, the investigator remains\n65 See FDA's 'Guidance for Industry Investigator Responsibilities - Protecting the Rights, Safety, and Welfare of Study Subjects' at https://www.fda.gov/regulatory-information/search-fda-guidance-documents/investigatorresponsibilities-protecting-rights-safety-and-welfare-study-subjects.",
        "metadata": {
            "document_id": "ICD - Document 1.pdf",
            "chunk_index": 179,
            "source": "markdown",
            "embedding_version": "v1"
        }
    },
    {
        "id": "5999b82e-3778-4826-9f59-59261b8ec51c",
        "text": "Contains Nonbinding Recommendations\nresponsible for ensuring that legally effective informed consent is obtained for all subjects in accordance with 21 CFR part 50.",
        "metadata": {
            "document_id": "ICD - Document 1.pdf",
            "chunk_index": 180,
            "source": "markdown",
            "embedding_version": "v1"
        }
    },
    {
        "id": "67ceec47-3f95-4577-8166-1138e7d9012e",
        "text": "2. Financial Relationships and Interests\nThe clinical investigator should consider whether information related to financial relationships or interests should be provided to subjects. 66 Clinical investigators should consider the potential effects that a financial relationship might have on the clinical investigation or on interactions with subjects.  When there are financial relationships or interests, clinical investigators should consider the following actions:\n- Including information in the informed consent form, such as:\n- -The source of funding and funding arrangements for the conduct and review of the clinical investigation, or\n- -Information about a financial arrangement or interest (e.g., stock in the study sponsor, patent on the investigational product) of an institution or an investigator and how it is being managed.\n- Using special measures to modify the informed consent process when a potential or actual financial conflict exists, such as:\n- -Having another individual who does not have a potential or actual conflict of interest involved in the consent process, especially when a potential or actual conflict of interest could influence the tone, presentation, or type of information presented during the consent process.\n- -Using independent monitoring of the consent process.",
        "metadata": {
            "document_id": "ICD - Document 1.pdf",
            "chunk_index": 181,
            "source": "markdown",
            "embedding_version": "v1"
        }
    },
    {
        "id": "90f1255b-fe03-4ba3-aea3-51e2b5a0967f",
        "text": "2. Financial Relationships and Interests\nAlthough the clinical investigator should consider these issues regarding financial relationships and interests, IRBs have the final responsibility of determining whether subjects should be provided with information regarding the source of funding, funding arrangements, or financial interests of parties involved in the clinical investigation as part of the informed consent process (see 21 CFR 56.109 and 56.111(a)(4)-(5)).\n66 See the HHS guidance document, 'Financial Relationships and Interests in Research Involving Human Subjects: Guidance for Human Subject Protection,'  available at https://www.hhs.gov/ohrp/regulations-andpolicy/guidance/financial-conflict-of-interest/index.html#.",
        "metadata": {
            "document_id": "ICD - Document 1.pdf",
            "chunk_index": 182,
            "source": "markdown",
            "embedding_version": "v1"
        }
    },
    {
        "id": "3ee6382f-76d2-4fa4-a0c6-9e9ebf7f3173",
        "text": "C. The Sponsor\nSponsors often provide clinical investigators with a model consent form that may be adapted by the clinical investigator to meet local needs.  When the consent form for studies that require an IND or IDE application is submitted to FDA for review, FDA's comments are generally directed to the sponsor (see section IV.D.1, 'Investigational New Drugs and Biologics,' and section IV.D.2, 'Investigational Medical Devices').  The sponsor should promptly provide the clinical investigator with any necessary modifications required to satisfy the regulations at 21 CFR 50.25 so that changes can be made to the consent forms.  A modified model consent form reflecting the changes may be used to convey the necessary edits.  Because the clinical investigator must receive IRB approval before starting the clinical investigation (see 21 CFR 312.66 and 21 CFR 812.110(a)), the sponsor should work closely with the clinical investigator to make certain the modified consent form is reviewed and approved by the IRB. The clinical investigator should provide the sponsor with a copy of the consent form approved by the IRB.\nBelow are specific areas for consideration by the sponsor:",
        "metadata": {
            "document_id": "ICD - Document 1.pdf",
            "chunk_index": 183,
            "source": "markdown",
            "embedding_version": "v1"
        }
    },
    {
        "id": "5c90ed91-d471-4368-9a1f-5b4b50fae197",
        "text": "1. Considerations for Multicenter Clinical Investigations\nFor multicenter clinical investigations, changes may need to be made to the consent form to address local and institutional requirements.  For multicenter clinical investigations reviewed by more than one IRB, when local IRB review results in substantive modifications to the consent form, i.e., changes that affect the rights, safety, or welfare of the subjects, FDA expects the sponsor to share the revisions with all investigators and their IRBs.  In this situation it may be more efficient to share the changes with the sites using a modified model consent form, when appropriate.  If the multicenter clinical investigation has a central IRB cooperating with local IRBs or human research protection offices, the revisions should be forwarded to the central IRB. 67 Alternatively, local issues may be addressed by the central IRB depending on the review agreement between the local IRB(s) and central IRB.  Note that for medical",
        "metadata": {
            "document_id": "ICD - Document 1.pdf",
            "chunk_index": 184,
            "source": "markdown",
            "embedding_version": "v1"
        }
    },
    {
        "id": "8175c413-b3ae-4918-a61e-d46ebd546a0b",
        "text": "1. Considerations for Multicenter Clinical Investigations\n67 See 'Guidance for Industry, Using a Centralized IRB Review Process in Multicenter Clinical Trials,' available at https://www.fda.gov/regulatory-information/search-fda-guidance-documents/using-centralized-irb-reviewprocess-multicenter-clinical-trials.",
        "metadata": {
            "document_id": "ICD - Document 1.pdf",
            "chunk_index": 185,
            "source": "markdown",
            "embedding_version": "v1"
        }
    },
    {
        "id": "08e57216-d613-466e-9c75-3a027c487877",
        "text": "Contains Nonbinding Recommendations\ndevice studies that require submission of an IDE application, such changes must be submitted to FDA. 68, 69",
        "metadata": {
            "document_id": "ICD - Document 1.pdf",
            "chunk_index": 186,
            "source": "markdown",
            "embedding_version": "v1"
        }
    },
    {
        "id": "e4841982-33fe-4916-b893-b46e0a877013",
        "text": "2. Sponsor Personnel\nSponsor personnel (usually a field engineer) may be present during the procedure and/or follow-up visits for some medical device studies.  These individuals may provide technical support and/or record studyrelated information for the test article.  If sponsor personnel will be present during the procedure or follow-up, or if the activities of the sponsor personnel directly affect the subject, those activities should also be described in the informed consent form. 70",
        "metadata": {
            "document_id": "ICD - Document 1.pdf",
            "chunk_index": 187,
            "source": "markdown",
            "embedding_version": "v1"
        }
    },
    {
        "id": "83547f81-71fb-454e-9759-6dc3f9e7905c",
        "text": "D. The FDA\nFDA's regulations for drug (including biologic) and device investigations have different requirements for the submission of informed consent materials (see sections IV.D.1, 'Investigational New Drugs and Biologics,' and IV.D.2, 'Investigational Medical Devices,' for additional information).  Sponsors are not required to submit informed consent materials to FDA for all clinical investigations (see, for example, 21 CFR 312.2(b) and 21 CFR 812.2(b) and (c)); however, FDA may require that they be submitted in some cases as discussed below.\nGenerally, when informed consent materials are submitted, FDA reviewers assess the adequacy of the consent form by considering its communication of reasonably foreseeable risks or discomforts to the\n68 See 21 CFR 812.35(a).",
        "metadata": {
            "document_id": "ICD - Document 1.pdf",
            "chunk_index": 188,
            "source": "markdown",
            "embedding_version": "v1"
        }
    },
    {
        "id": "ca3d3645-ca05-4ed2-80bf-641bd337f03f",
        "text": "D. The FDA\n69 The 2018 Common Rule requires that any institution located in the United States that is engaged in cooperative research conducted or supported by a Federal Department or Agency must rely upon approval by a single IRB for that portion of the research that is conducted in the United States, unless the research is not subject to the provision (45 CFR 46.114(b)). The compliance date for research subject to this provision was January 20, 2020.  On September 28, 2022, FDA issued a proposed rule to harmonize with this requirement to the extent practicable and consistent with statutory provisions (see https://www.federalregister.gov/documents/2022/09/28/202221089/institutional-review-boards-cooperative-research).  The January 19, 2017, final rule revising the Common Rule is available at https://www.hhs.gov/ohrp/regulations-and-policy/regulations/finalized-revisions-commonrule/index.html.",
        "metadata": {
            "document_id": "ICD - Document 1.pdf",
            "chunk_index": 189,
            "source": "markdown",
            "embedding_version": "v1"
        }
    },
    {
        "id": "307f40fa-becb-4cad-8b07-9934d6bc198f",
        "text": "D. The FDA\n70 See 'Guidance for Industry: Investigator Responsibilities - Protecting the Rights, Safety, and Welfare of Study Subjects,' available at https://www.fda.gov/regulatory-information/search-fda-guidance-documents/investigatorresponsibilities-protecting-rights-safety-and-welfare-study-subjects.",
        "metadata": {
            "document_id": "ICD - Document 1.pdf",
            "chunk_index": 190,
            "source": "markdown",
            "embedding_version": "v1"
        }
    },
    {
        "id": "a347fad3-7748-44bf-9ca8-d1f4145467d1",
        "text": "Contains Nonbinding Recommendations\nsubject and other elements required by 21 CFR 50.25.  In some situations, FDA may find a consent form to be misleading, inaccurate, or incomplete in a way that would make informed consent inadequate and noncompliant with 21 CFR part 50.  In these cases, FDA may require that specific revisions be made to address the concern(s) before the clinical investigation can proceed (21 CFR 312.42 and 812.30).\nFDA's review of the consent form as part of an IND or IDE application submission does not substitute for the responsibility or authority of the IRB to review and approve the consent form and consent process as a condition for the clinical investigation to begin (21 CFR 56.103(a)).  IRBs are responsible for ensuring the adequacy of the information in the consent form and may require modification as appropriate (21 CFR 56.109(a)-(b)).\nBelow are specific areas FDA considers in its review of the consent form:",
        "metadata": {
            "document_id": "ICD - Document 1.pdf",
            "chunk_index": 191,
            "source": "markdown",
            "embedding_version": "v1"
        }
    },
    {
        "id": "03a365aa-3fd8-47dc-829e-f0a14ff5bfb1",
        "text": "1. Investigational New Drugs and Biologics 71\nThe IND regulations (21 CFR part 312) do not specifically require submission to FDA of the consent form with the IND.  However, if FDA determines that review of the consent form is necessary to make the determination of whether the clinical investigation may safely proceed, the Agency will request that the sponsor submit the consent form for review under 21 CFR 312.23(a)(11).\nAs a general matter, FDA will review the informed consent form for treatment INDs and treatment protocols (21 CFR part 312, subpart I) and INDs for studies conducted under the Exception From Informed Consent Requirements for Emergency Research (21 CFR 50.24) for consistency with 21 CFR 50.25 (see 21 CFR 50.24(a)(6)).\nFor other clinical investigations of drugs, FDA often considers the following factors in determining whether to require submission and review of the consent form:\n- Nonclinical studies submitted in support of the first administration of a drug in humans have identified an unusual toxicity.\n- Unusual known toxicity is associated with the investigational drug, the drug class to which the drug belongs, or with a different drug with characteristics similar to those of the study drug.",
        "metadata": {
            "document_id": "ICD - Document 1.pdf",
            "chunk_index": 192,
            "source": "markdown",
            "embedding_version": "v1"
        }
    },
    {
        "id": "715f43b7-e64f-47c3-8501-dc790e4b8324",
        "text": "1. Investigational New Drugs and Biologics 71\n71 For the purposes of this document, unless otherwise specified, all references to 'drugs' or 'drug products' include human drug products and biological products that are also drugs.",
        "metadata": {
            "document_id": "ICD - Document 1.pdf",
            "chunk_index": 193,
            "source": "markdown",
            "embedding_version": "v1"
        }
    },
    {
        "id": "519a5f35-e489-464f-94c5-07b0a00cd0db",
        "text": "Contains Nonbinding Recommendations\n- The study subject population is particularly vulnerable.\n- The study design is unusual for the therapeutic class.\n- The clinical investigation is a postmarketing safety clinical trial, required under section 505(o) of the FD&C Act to assess a serious risk.\n- The clinical investigation has significant potential for serious risk to human subjects.\n- The clinical investigation involves asking subjects to forgo or delay effective treatment that is known to decrease long-term mortality or irreversible morbidity.\n- FDA has other confidential or proprietary information not available to an IRB that affects the assessment of whether the informed consent form adequately addresses risks.",
        "metadata": {
            "document_id": "ICD - Document 1.pdf",
            "chunk_index": 194,
            "source": "markdown",
            "embedding_version": "v1"
        }
    },
    {
        "id": "11b282f3-e92b-4d9e-908e-422f8d51e6e5",
        "text": "Contains Nonbinding Recommendations\nAfter reviewing the consent materials, if the FDA review divisions have specific concerns about the adequacy or compliance of the consent materials with 21 CFR part 50, details about these concerns normally will be conveyed to the sponsor in writing.  In rare circumstances, FDA may find a consent form to be misleading, inaccurate, or incomplete in a way that makes informed consent inadequate and noncompliant with 21 CFR part 50 to the extent that subjects would be exposed to an unreasonable and significant risk of illness or injury.  In these cases, FDA may require that specific revisions be made to address the concern(s) before the clinical investigation can proceed (21 CFR 312.42).",
        "metadata": {
            "document_id": "ICD - Document 1.pdf",
            "chunk_index": 195,
            "source": "markdown",
            "embedding_version": "v1"
        }
    },
    {
        "id": "40eacc1d-bcf0-41e4-9ae0-0e415cf50e43",
        "text": "2. Investigational Medical Devices\nFor clinical investigations of medical devices for which an IDE application is required to be submitted to FDA, the sponsor must include in the application copies of all forms and informational materials that will be provided to subjects to obtain informed consent (21 CFR 812.20(b)(11)).  FDA reviews the consent form to ensure that it conforms to the requirements of 21 CFR part 50.  After review, FDA may send the sponsor a letter citing deficiencies regarding the consent form (21 CFR 812.30(a) and (b)(4)).  The clinical investigation may not begin until the sponsor has corrected these deficiencies (21 CFR 812.30(a) and 812.42).  In the event an IRB requires substantive changes to the informed consent document after IDE approval, i.e., changes that affect the rights, safety, or welfare of the subjects, the sponsor must submit the revised informed consent document to FDA for its review and approval prior to implementing the changes to the document (see 21 CFR 812.35(a)).",
        "metadata": {
            "document_id": "ICD - Document 1.pdf",
            "chunk_index": 196,
            "source": "markdown",
            "embedding_version": "v1"
        }
    },
    {
        "id": "b9d47b22-e9b9-42a2-a7cd-986bae8ec840",
        "text": "V. FREQUENTLY ASKED QUESTIONS\nThis section of the guidance document is intended to provide answers to frequently asked questions about FDA's regulations for the protection of human subjects.  The numbers assigned to the questions are intended for ease of reference and do not represent the frequency with which these questions are asked.",
        "metadata": {
            "document_id": "ICD - Document 1.pdf",
            "chunk_index": 197,
            "source": "markdown",
            "embedding_version": "v1"
        }
    },
    {
        "id": "6ae41fa7-8d1d-4522-92c6-fafe33c7fccc",
        "text": "1. What are some considerations for enrolling a child 72 into a clinical investigation?\nFDA regulations provide additional safeguards for children enrolled in clinical investigations, as described in 21 CFR part 50, subpart D. 73 If a child is to be enrolled in a clinical investigation, parental or guardian permission must be obtained in accordance with the requirements for informed consent in 21 CFR part 50 (21 CFR 50.55(e)) 74 and be documented in accordance with 21 CFR 50.27 (21 CFR 50.55(f)).  When appropriate, the assent of the child also must be obtained (see 21 CFR 50.55(a)-(d)).  As with informed consent for adult subjects, the exceptions to informed consent requirements described in section III.A.1, 'Exceptions to Informed Consent', apply to research involving children.",
        "metadata": {
            "document_id": "ICD - Document 1.pdf",
            "chunk_index": 198,
            "source": "markdown",
            "embedding_version": "v1"
        }
    },
    {
        "id": "a8fd2a2d-4804-43e1-bd4f-8c007b955b6c",
        "text": "1. What are some considerations for enrolling a child 72 into a clinical investigation?\nThe IRB may determine that the permission of one parent is sufficient for clinical investigations involving no greater than minimal risk to children to be conducted under 21 CFR 50.51, or clinical investigations involving greater than minimal risk to children but presenting the prospect of direct benefit to individual subjects in accordance with 21 CFR 50.52 (21 CFR 50.55(e)(1)).\nFor clinical investigations to be conducted in accordance with either 21 CFR 50.53 or 21 CFR 50.54, 75 where permission is to be obtained from parents, the permission of both parents is required unless one\n72 For purposes of 21 CFR part 50, the term children means 'persons who have not attained the legal age for consent to treatments or procedures involved in clinical investigations, under the applicable law of the jurisdiction in which the clinical investigation will be conducted.'  See 21 CFR 50.3(o).",
        "metadata": {
            "document_id": "ICD - Document 1.pdf",
            "chunk_index": 199,
            "source": "markdown",
            "embedding_version": "v1"
        }
    },
    {
        "id": "5067aa5a-9aa5-47a4-bdf8-a857b07ca498",
        "text": "1. What are some considerations for enrolling a child 72 into a clinical investigation?\n73 FDA promulgated 21 CFR part 50, subpart D, \"Additional Safeguards for Children in Clinical Investigations,\" as an interim rule in April 2001 (see 66 FR 20589, April 24, 2001; https://www.govinfo.gov/content/pkg/FR-2001-0424/pdf/01-10008.pdf), and issued a final rule in February 2013 (see 78 FR 12937, February 26, 2013; https://www.govinfo.gov/content/pkg/FR-2013-02-26/pdf/2013-04387.pdf).\n74 Note that the waiver of parental permission found in 45 CFR 46.408(c) is not available under FDA's regulations.",
        "metadata": {
            "document_id": "ICD - Document 1.pdf",
            "chunk_index": 200,
            "source": "markdown",
            "embedding_version": "v1"
        }
    },
    {
        "id": "03c3e091-ee13-47fb-9c6c-ce096cc6fbcd",
        "text": "1. What are some considerations for enrolling a child 72 into a clinical investigation?\n75 21 CFR 50.53 applies to clinical investigations presenting greater than minimal risk and no prospect of direct benefit to the individual subjects, but that are likely to yield generalizable knowledge about the subjects' disorder or condition.  21 CFR 50.54 applies to clinical investigations that do not meet the requirements of 21 CFR 50.51, 50.52, or 50.53 but present a reasonable opportunity to understand, prevent, or alleviate a serious problem affecting the health or welfare of children.",
        "metadata": {
            "document_id": "ICD - Document 1.pdf",
            "chunk_index": 201,
            "source": "markdown",
            "embedding_version": "v1"
        }
    },
    {
        "id": "1e573718-c19a-4c62-9508-d6491ae8b74b",
        "text": "Contains Nonbinding Recommendations\nparent is deceased, unknown, incompetent, or not reasonably available, or when only one parent has legal responsibility for the care and custody of the child (21 CFR 50.55(e)(2)). 76\nThe general requirements for informed consent, found in 21 CFR 50.20, 21 CFR 50.25 and 21 CFR 50.27, apply to parental permission (21 CFR 50.55(e)-(f)).  When obtaining parental permission, in the event the parents of a child do not understand English, the parental permission must be obtained and documented in language that is understandable to the parents (21 CFR 50.20).  The child who will be participating in the research should not be used as an interpreter for the parent, even if the child is fluent in English and may be able to assent.  Similarly, if child assent is required, the information given to the child should be in language that is understandable to the child.",
        "metadata": {
            "document_id": "ICD - Document 1.pdf",
            "chunk_index": 202,
            "source": "markdown",
            "embedding_version": "v1"
        }
    },
    {
        "id": "fc7d474c-138d-4548-9050-ac5c32e0a568",
        "text": "Contains Nonbinding Recommendations\n'Assent' means a child's affirmative agreement to take part in a clinical investigation, not just the failure to object (21 CFR 50.3(n)).  Child assent, when appropriate, and parental (or guardian) permission taken together meet the ethical requirement to obtain informed consent.  Absent a waiver of the assent requirement (21 CFR 50.55(d)), the IRB must determine that there are adequate provisions for soliciting the assent of children when, in the IRB's judgment, the children are capable of providing assent (21 CFR 50.55(a)).  In deciding whether children are capable of providing assent, the IRB must consider the ages, maturity, and psychological state of the children to be involved in the clinical investigation (21 CFR 50.55(b)). 77 A child does not need to fully understand the clinical investigation in order to provide assent, provided the child is capable of understanding the interventions and the related procedures.",
        "metadata": {
            "document_id": "ICD - Document 1.pdf",
            "chunk_index": 203,
            "source": "markdown",
            "embedding_version": "v1"
        }
    },
    {
        "id": "09e989f9-dfe0-4dfc-845b-aa243a92fb64",
        "text": "Contains Nonbinding Recommendations\nFor example, a child may be able to understand and provide assent if the child understands and agrees to the interventions and/or procedures in the trial (e.g., drawing a blood sample for a test), even though the child may not be capable of understanding a randomized clinical trial.",
        "metadata": {
            "document_id": "ICD - Document 1.pdf",
            "chunk_index": 204,
            "source": "markdown",
            "embedding_version": "v1"
        }
    },
    {
        "id": "26cc1ca0-1902-49cb-b76f-4a2caacbb003",
        "text": "Contains Nonbinding Recommendations\nAn IRB may determine that assent is not necessary or may waive the assent requirement in certain situations (21 CFR 50.55(c) and (d)).  For example, the assent of children is not a necessary condition for proceeding with a clinical investigation if the IRB determines that the intervention or procedure involved in the clinical investigation holds out a prospect of direct benefit that is important to the health or wellbeing of the children and is available only in the context of the clinical investigation (21 CFR 50.55(c)(2)).  Also, the IRB may waive the assent requirement for children capable of assenting if the IRB finds and documents that the clinical investigation involves no more than minimal risk to the subjects; the waiver will not adversely affect the rights and welfare of the subjects; the clinical investigation could not practicably be carried out without the waiver; and, when appropriate, the subjects will be provided with",
        "metadata": {
            "document_id": "ICD - Document 1.pdf",
            "chunk_index": 205,
            "source": "markdown",
            "embedding_version": "v1"
        }
    },
    {
        "id": "9d906794-3487-4e2a-92de-f41f68b69f33",
        "text": "Contains Nonbinding Recommendations\n76 For additional discussion on what is meant by 'not reasonably available,' see the Secretary's Advisory Committee on Human Research Protections (SACHRP) recommendations at https://www.hhs.gov/ohrp/sachrpcommittee/recommendations/attachment-d-november-13-2018/indes.html.\n77 FDA recognizes that IRBs may adopt procedures setting an age below which children are presumed incapable of providing assent.\nadditional pertinent information after participation (21 CFR 50.55(d)).  Parental permission requirements (to the extent consent is required under 21 CFR part 50) remain in these circumstances.\nWhen the IRB determines that assent is required, it must also determine whether and how assent must be documented (21 CFR 50.55(g)).  Some of the same considerations noted above for determining capability of children to provide assent should be considered when determining whether assent should be in writing or oral.",
        "metadata": {
            "document_id": "ICD - Document 1.pdf",
            "chunk_index": 206,
            "source": "markdown",
            "embedding_version": "v1"
        }
    },
    {
        "id": "a48c26b4-b3ea-40bf-9f25-da2255d3891e",
        "text": "Contains Nonbinding Recommendations\nWhen a written assent process is appropriate or required by the IRB, FDA does not require the use of a written assent form (21 CFR 50.55(g)), but FDA strongly encourages the use of a separate assent form that is 'child-oriented' and developmentally appropriate.  A separate assent form does not need to include all of the elements of a consent document but should focus on those aspects of the clinical investigation that may impact on a child's willingness to participate.\nParental permission and child assent should be viewed as an ongoing process throughout the duration of a clinical investigation.  If and when a child who was enrolled in a clinical investigation with parental permission reaches the legal age of consent, that subject no longer meets the definition of a child under 21 CFR 50.3(o), and the investigator should obtain the subject's informed consent under 21 CFR part 50, subpart B, prior to performing any further research interventions and/or procedures involving that subject.",
        "metadata": {
            "document_id": "ICD - Document 1.pdf",
            "chunk_index": 207,
            "source": "markdown",
            "embedding_version": "v1"
        }
    },
    {
        "id": "5f529f83-645e-46bb-b00b-fb505c330869",
        "text": "Contains Nonbinding Recommendations\nIn addition,  50.3(o) defines children as 'persons who have not attained the legal age for consent to treatments or procedures involved in clinical investigations, under the applicable law of the jurisdiction in which the clinical investigation will be conducted'.  However, in some situations, a State may grant certain minors of a specific age the right to consent to treatments or procedures on their own behalf. These mature minors do not meet the definition of children for purposes of a clinical investigation that involves solely those 'treatments or procedures' for which they can give consent outside the research context and thus, the requirements of 21 CFR part 50, subpart D, do not apply to the research with respect to these minors.  Similarly, minors deemed ''emancipated'' by State law, such that they may provide consent to treatments and procedures in the clinical setting, also do not meet the definition of children under  50.3(o), and the requirements of 21 CFR part 50, subpart D do not apply to the research with respect to these emancipated minors.",
        "metadata": {
            "document_id": "ICD - Document 1.pdf",
            "chunk_index": 208,
            "source": "markdown",
            "embedding_version": "v1"
        }
    },
    {
        "id": "3186b37e-7cb9-4087-8382-11aef0cee196",
        "text": "Contains Nonbinding Recommendations\nIn these cases, the mature or emancipated minors can consent to participation in FDA-regulated research without the need for parental or guardian permission.  For example, if a clinical trial is being conducted in a jurisdiction that has laws that explicitly allow a minor of a particular age, to consent to receive specific sexual transmitted disease (STD) services in the clinical setting, these minors may be able to provide informed consent for participation in a clinical trial of a product intended to treat or diagnose an STD.",
        "metadata": {
            "document_id": "ICD - Document 1.pdf",
            "chunk_index": 209,
            "source": "markdown",
            "embedding_version": "v1"
        }
    },
    {
        "id": "10e8c912-6007-4f47-aa8c-a3334ee8f5e2",
        "text": "2. Are there any additional protections required when enrolling children who are wards of the state?\nChildren who are wards of the state or any other agency, institution, or entity can be included in a clinical investigation that is approved under 21 CFR 50.53 and 50.54 provided the clinical investigation is either: (1) related to their status as wards; or (2) conducted in schools, camps, hospitals, institutions, or similar settings in which the majority of children involved as subjects are not wards (21 CFR 50.56).  In other words, one of these criteria must be satisfied in order for children who are wards to be enrolled in clinical investigations involving greater than minimal risk and no prospect of direct benefit, but likely to yield generalizable knowledge about the subjects' disorder or condition (21 CFR 50.53) or clinical investigations not otherwise approvable that present an opportunity to understand, prevent, or alleviate a serious problem affecting the health or welfare of children (21 CFR 50.54).",
        "metadata": {
            "document_id": "ICD - Document 1.pdf",
            "chunk_index": 210,
            "source": "markdown",
            "embedding_version": "v1"
        }
    },
    {
        "id": "6b8023c5-4c5f-4098-bf36-a94e682d1b3f",
        "text": "2. Are there any additional protections required when enrolling children who are wards of the state?\nIf a clinical investigation is approved under 21 CFR 50.56(a), the IRB must require that an advocate be appointed for each child who is a ward (21 CFR 50.56(b)).  The IRB must ensure that such an advocate is in place, but the IRB itself is not required to appoint the advocate.  The advocate, who may serve as an advocate for more than one child, serves in addition to any other individual acting on behalf of the child as guardian or in loco parentis 78 (21 CFR 50.56(b)(1) and (2)).  The advocate must be an individual who has the background and experience to act in, and agrees to act in, the best interest of the child for the duration of the child's participation in the clinical investigation (21 CFR 50.56(b)(3)).  The appropriate expertise for an advocate should include, but is not limited to, education and/or experience in pediatric medicine, law, child advocacy, foster parenting, behavioral sciences, or child psychology.",
        "metadata": {
            "document_id": "ICD - Document 1.pdf",
            "chunk_index": 211,
            "source": "markdown",
            "embedding_version": "v1"
        }
    },
    {
        "id": "17d68d3e-30ae-4880-8d71-66440a3d382e",
        "text": "2. Are there any additional protections required when enrolling children who are wards of the state?\nThe advocate should be adequately informed about the potential risks and benefits of the proposed clinical investigation, and about how the intervention is likely to affect the individual child.  The advocate must not be associated in any way (except in the role as advocate or member of the IRB) with the clinical investigation, the investigator(s), or the guardian organization (21 CFR 50.56(b)(4)).",
        "metadata": {
            "document_id": "ICD - Document 1.pdf",
            "chunk_index": 212,
            "source": "markdown",
            "embedding_version": "v1"
        }
    },
    {
        "id": "524a98ab-655b-4740-9050-1e7d49464845",
        "text": "2. Are there any additional protections required when enrolling children who are wards of the state?\nWards of the state can participate in clinical investigations approved under 21 CFR 50.51 (i.e., research involving no more than minimal risk) and 21 CFR 50.52 (i.e., research involving greater than minimal risk but presenting the prospect of direct benefit), and FDA regulations do not require the appointment of an advocate for children who are wards involved in clinical investigations approved under these sections. However, IRBs should consider the appointment of an advocate in such clinical investigations in order to ensure that there is someone who will act in the best interest of the ward(s) for the duration of their participation in the clinical investigation.  Before enrolling any child who is a ward in a clinical investigation approved under 21 CFR 50.51 or 21 CFR 50.52, IRBs should ensure that each child has a\n78 FDA considers an individual acting in loco parentis to be an individual having the legal authority and responsibility to act in place of a parent.",
        "metadata": {
            "document_id": "ICD - Document 1.pdf",
            "chunk_index": 213,
            "source": "markdown",
            "embedding_version": "v1"
        }
    },
    {
        "id": "4a5068bf-71de-49bb-a217-52c20c6f25fa",
        "text": "Contains Nonbinding Recommendations\nguardian and/or advocate with the background, experience and commitment to act in the best interest of the child.",
        "metadata": {
            "document_id": "ICD - Document 1.pdf",
            "chunk_index": 214,
            "source": "markdown",
            "embedding_version": "v1"
        }
    },
    {
        "id": "3f441de4-83be-4a7f-92a8-c48691d662ff",
        "text": "3. What are some considerations for enrolling non-English speaking subjects 79 ?\nProspective subjects who do not understand English may ask or be asked to participate in a clinical trial in locations where English is the predominant language.  The investigators and the IRBs that review such research should carefully consider the ethical ramifications of enrolling or excluding prospective subjects when a language barrier may exist between the investigator(s) and some or all of the prospective subjects. Consistent with the requirement that selection of subjects be equitable (21 CFR 56.111(a)(3)), individuals should not routinely be excluded from participating in research simply because they do not understand English.\nWhen prospective subjects who do not understand English are to be enrolled in a clinical study, IRBs and investigators must ensure that the information given to such prospective subjects or their LARs is in language understandable to the subjects or their LARs (21 CFR 50.20).  FDA considers understandable to mean that the information presented to prospective subjects is in a language and at a level they can comprehend, including an explanation of scientific and medical terms.",
        "metadata": {
            "document_id": "ICD - Document 1.pdf",
            "chunk_index": 215,
            "source": "markdown",
            "embedding_version": "v1"
        }
    },
    {
        "id": "446b27ef-be4a-46ed-8241-a54e9b0fd013",
        "text": "3. What are some considerations for enrolling non-English speaking subjects 79 ?\nThe IRB must review and approve consent documents (long form or short form with written summary) that are to be used by investigators to document the informed consent of subjects (21 CFR 50.27(a) and 21 CFR 56.111(a)(4) and (5)).  When translation and interpretation are needed for written and oral information that is to be presented to subjects, FDA recommends that the IRB review, and if appropriate, approve reasonable procedures for ensuring that the translations will be prepared by a qualified individual or entity, and that interpretation assistance is available.",
        "metadata": {
            "document_id": "ICD - Document 1.pdf",
            "chunk_index": 216,
            "source": "markdown",
            "embedding_version": "v1"
        }
    },
    {
        "id": "d223c8ca-1eb3-4546-bc11-85d0ec3bd2eb",
        "text": "3. What are some considerations for enrolling non-English speaking subjects 79 ?\n79 FDA strongly encourages stakeholders to ensure that informed consent documents are accessible to individuals with limited English proficiency. To the extent an organization receives Federal financial assistance from HHS, Title VI of the Civil Rights Act of 1964 and its implementing regulations require the organization to take reasonable steps to provide meaningful access by individuals with limited English proficiency. See 42 U.S.C. 2000d, et seq ; 45 CFR part 80; see also Section 1557 of the Affordable Care Act, 42 U.S.C. 18116, which provides similar protections as those under Title VI in health programs and activities receiving Federal financial assistance. This guidance provides information to assist institutional review boards (IRBs), clinical investigators, and sponsors in complying with FDA's informed consent regulations for clinical investigations. It does not provide guidance on how to comply with any regulatory obligations stemming from a source outside of the statutes FDA administers and FDA's regulations.",
        "metadata": {
            "document_id": "ICD - Document 1.pdf",
            "chunk_index": 217,
            "source": "markdown",
            "embedding_version": "v1"
        }
    },
    {
        "id": "3889f83e-bd88-4b2b-81af-c5f64efb527b",
        "text": "Contains Nonbinding Recommendations\nA protocol amendment in which the investigator proposes to include use of translated informed consent documents for a study already approved by the IRB with English language consent documents may be considered no more than a minor change to the research and may qualify for an expedited review procedure under FDA regulations at 21 CFR 56.110(b).\nFDA notes that informed consent should be viewed as an ongoing process throughout the course of a subject's involvement in the research.  Therefore, FDA recommends that whenever subjects who do not understand English are involved in research, appropriate interpreter services be made available throughout the course of the research.",
        "metadata": {
            "document_id": "ICD - Document 1.pdf",
            "chunk_index": 218,
            "source": "markdown",
            "embedding_version": "v1"
        }
    },
    {
        "id": "11dd3ccb-7071-40c8-9643-14c89b71c15e",
        "text": "4. What process should be followed when it is expected that subjects who do not understand English will be enrolled?\nWhen investigators reasonably expect that the subject population for a proposed study will include individuals who do not understand English and can anticipate the specific language(s) that these individuals will understand, the investigator should submit to the IRB, prior to its initial review, appropriately translated consent documents (i.e., either a long form or a short form with written summary).  The investigators should also provide the IRB with a description of how interpreters for oral communication will be made available to subjects during the research.  For example, if the investigators reasonably expect that the subject population for a proposed research protocol will include individuals who only understand Spanish and others who only understand Russian, the investigators should submit to the IRB, prior to its initial review, consent documents (i.e., either a long form or a short form with written summary) translated into Spanish and Russian along with a description of how interpreters for oral communication in Spanish and Russian will be made available during the research.  The next Frequently Asked Question describes the process that may be followed when the enrollment of a subject who does not understand English is unexpected and no prior arrangements for this possibility have been made.",
        "metadata": {
            "document_id": "ICD - Document 1.pdf",
            "chunk_index": 219,
            "source": "markdown",
            "embedding_version": "v1"
        }
    },
    {
        "id": "eb89aaca-9464-49e6-b744-669a8f0cb4f3",
        "text": "5. What process should be followed when the enrollment of subjects who do not understand English is not expected?\nFDA recognizes that investigators on occasion face circumstances where: (1) a prospective subject who does not understand English is eligible for an IRB-approved research protocol; and (2) the investigator has an IRB-approved English language long form but does not have an appropriate IRB-approved written translation of the long form or written summary for the study.  This may occur because neither the investigator nor the IRB reasonably expected enrollment of a subject for whom a translation would be needed.",
        "metadata": {
            "document_id": "ICD - Document 1.pdf",
            "chunk_index": 220,
            "source": "markdown",
            "embedding_version": "v1"
        }
    },
    {
        "id": "d96fb938-c747-48bd-8717-151bd78742fc",
        "text": "Contains Nonbinding Recommendations\nFor some research, the timeframe for subject enrollment may provide sufficient time for the preparation of an appropriately translated long form or an appropriately translated written summary to be used with a short form.  When translation or interpretation is needed for written and oral information that is to be presented to subjects, FDA recommends that the IRB review, and if appropriate, approve reasonable procedures for ensuring that the translations will be prepared by a qualified individual or entity, and that interpretation assistance is available.\nFor other research, the timeframe for enrollment of a subject who does not understand English may not provide sufficient time for preparation of appropriately translated consent documents.  As a contingency for this situation, many IRBs have arranged for translation of a generic short form in multiple languages that satisfies the requirements of FDA regulations at 21 CFR 50.27(b)(2) and have prospectively approved the use of such short forms for enrollment of subjects who do not understand English as needed for any research protocol.  In such circumstances, FDA considers procedures that include the following sequential steps to be one acceptable way of obtaining and documenting the informed consent of the subject:",
        "metadata": {
            "document_id": "ICD - Document 1.pdf",
            "chunk_index": 221,
            "source": "markdown",
            "embedding_version": "v1"
        }
    },
    {
        "id": "d2e4445e-4a6b-400f-bb57-9bc44c8a8191",
        "text": "Step 1 - Determine That There is Sufficient Justification to Enroll the Subject Without Using a Translated Long Form to Document the Subject's Informed Consent\nThe investigator, in consultation with the IRB chairperson (or another IRB member designated by the chairperson, hereafter referred to as designee) whenever feasible, determines that there is sufficient justification (e.g., due to a limited therapeutic window) for obtaining the subject's consent without waiting for a translated long form to be reviewed and approved by the IRB prior to enrollment of the subject.  In making a decision to allow enrollment of a subject who does not understand English into a research protocol without waiting for a written translation of the long form, the investigator (and whenever feasible the IRB chairperson or designee) should consider whether the consent process, under this circumstance, will provide the subject with sufficient opportunity to understand the information being presented.  If consent is sought and the investigator believes that the prospective subject has not understood the information presented, then the individual should not be enrolled in the research.",
        "metadata": {
            "document_id": "ICD - Document 1.pdf",
            "chunk_index": 222,
            "source": "markdown",
            "embedding_version": "v1"
        }
    },
    {
        "id": "b9a6cee6-d245-42ed-b3ac-3e42847e2dfe",
        "text": "Step 2 - Obtain and Document the Subject's Informed Consent in Accordance with FDA Regulations at 21 CFR 50.20, 21 CFR 50.25 and 21 CFR 50.27 Using a Translated Short Form and the English Language Version of the Long Form as the Written Summary\nIn accordance with the requirements of 21 CFR 50.27(b)(2), informed consent is documented using a short form that has been translated into a language understandable to the prospective subject and approved by the IRB.  As a prerequisite to using this procedure, the investigator must have available a short form written in a language understandable to the prospective subject or LAR and previously approved by the IRB (21 CFR 50.20 and 21 CFR 50.27(a)).  To meet this prerequisite, the IRB must",
        "metadata": {
            "document_id": "ICD - Document 1.pdf",
            "chunk_index": 223,
            "source": "markdown",
            "embedding_version": "v1"
        }
    },
    {
        "id": "291f7635-9cda-4bcf-a084-565d4fbb1a0d",
        "text": "Contains Nonbinding Recommendations\nrequire that the sponsor or investigator arrange for translation of a generic short form into a language understandable by the prospective subject or LAR, and the IRB must have approved the prospective use of such short forms for enrollment of subjects who do not understand English, as needed.  Additionally, the IRB must approve a written summary of what is to be said to the subject or the LAR (21 CFR 50.27(b)(2)).  The IRB-approved English long form often serves as this written summary.  The translator should be fluent in both English and in the subject's language.  It may be appropriate to have a translator available for all subsequent study visits to relay information between the subject and study personnel.\nThe procedure for obtaining and documenting the subject's informed consent with a translated short form and an English version of the long form includes the following:",
        "metadata": {
            "document_id": "ICD - Document 1.pdf",
            "chunk_index": 224,
            "source": "markdown",
            "embedding_version": "v1"
        }
    },
    {
        "id": "941fc618-06ee-4278-9535-422272fba7c6",
        "text": "Contains Nonbinding Recommendations\n- (1) The investigator (or their designee) obtaining informed consent, with the assistance of an interpreter if needed (e.g., if the investigator is not bilingual), provides orally to the subject the elements of informed consent required by FDA regulations at 21 CFR 50.25 and any additional pertinent information included in the IRB-approved English version of the long form.  This presentation may be an oral translation of the IRB-approved English version of the long form. The oral presentation must be in language understandable to the subject (21 CFR 50.20).  The investigator, with the assistance of an interpreter if needed, answers any questions from the prospective subject.  There must be a witness to the oral presentation who must not be the person obtaining informed consent (21 CFR 50.27(b)(2)).  Furthermore, FDA strongly recommends the witness be fluent in the language of the oral presentation.",
        "metadata": {
            "document_id": "ICD - Document 1.pdf",
            "chunk_index": 225,
            "source": "markdown",
            "embedding_version": "v1"
        }
    },
    {
        "id": "7047a3dc-5e0d-46d3-965b-b10507d7307d",
        "text": "Contains Nonbinding Recommendations\nThe witness must, at a minimum, have sufficient proficiency in the language of the oral presentation to be able to attest to the information that was to the presented orally to the prospective participant (21 CFR 50.27(b)(2).) In addition, if possible, the witness should not be related to the subject.\n- (2) At the time informed consent is sought, the subject is given the IRB-approved translated short form and a copy of the IRB-approved English version of the long form, which serves as the written summary.\n- (3) The short form is signed and dated by the subject or LAR.\n- (4) The witness signs both the short form and the copy of the IRB-approved English version of the long form. (Note that when an interpreter assists the person obtaining consent, the interpreter may serve as the witness, but is not required to do so.)\n- (5) The person actually obtaining consent signs the copy of the IRB-approved English version of the long form.",
        "metadata": {
            "document_id": "ICD - Document 1.pdf",
            "chunk_index": 226,
            "source": "markdown",
            "embedding_version": "v1"
        }
    },
    {
        "id": "2d76ba2f-f458-4692-80af-33c90ea8e4ae",
        "text": "Step 3 - Take Additional Actions Following Subject Enrollment\nAfter the subject has been enrolled in the research, the investigator takes the following additional actions:",
        "metadata": {
            "document_id": "ICD - Document 1.pdf",
            "chunk_index": 227,
            "source": "markdown",
            "embedding_version": "v1"
        }
    },
    {
        "id": "d22e84e5-a255-4ab8-8972-102f8abbb247",
        "text": "Contains Nonbinding Recommendations\n- (1) If a subject was enrolled in the research using an untranslated long form to serve as the written summary, and if the investigator did not consult with the IRB chairperson (or designee) prior to enrollment of the subject who does not understand English, the investigator should promptly notify the IRB chairperson (or designee) that such a subject was enrolled.",
        "metadata": {
            "document_id": "ICD - Document 1.pdf",
            "chunk_index": 228,
            "source": "markdown",
            "embedding_version": "v1"
        }
    },
    {
        "id": "ec63c2cc-2e81-477b-8b59-62a446ab50d4",
        "text": "Contains Nonbinding Recommendations\n- (2) The investigator must obtain a translated copy of the IRB-approved English version of the long form that served as the written summary, which should be done promptly.  The investigator promptly submits it to the IRB for review and approval.  Once the translated long form/written summary is approved by the IRB, the investigator must provide it to the subject or LAR and should do so as soon as possible.  FDA considers this step essential to the requirement that informed consent be documented by the use of a written consent document and that the subject be provided a copy (21 CFR 50.27).  Many of the clinical investigations regulated by FDA involve ongoing interventions and may involve long-term follow-up.  For this reason, translation of the long form is critically important as a means of providing subjects or their LAR an ongoing source of information understandable to them.\nAdditionally, as noted above in Frequently Asked Question #3, FDA recommends that whenever subjects who do not understand English are involved in research, appropriate interpreter services be made available throughout the course of the research.",
        "metadata": {
            "document_id": "ICD - Document 1.pdf",
            "chunk_index": 229,
            "source": "markdown",
            "embedding_version": "v1"
        }
    },
    {
        "id": "a908e80b-32e7-4fbe-b61c-6c19df0a393c",
        "text": "6. What should be considered when enrolling subjects with low literacy and numeracy?\nAlthough a competent person who does not read and write well can give informed consent and enroll in a clinical investigation, the sponsor, clinical investigator, and IRB should consider whether any modifications to the informed consent process are necessary to ensure that the informed consent process is understandable.\nFor subjects with apparent low literacy and/or low numeracy, oral presentation of the information contained in the consent document is especially important.  When the elements of informed consent are presented orally to the subject or the subject's LAR, the IRB may want to consider approving the use of a short form and written summary (21 CFR 50.27(b)(2)), which includes a witness to the oral presentation of the informed consent elements who also signs the consent document (see section III.E.4.b, 'Short Form').  It should be noted that, even if the information is presented orally, the subject or the subject's LAR is required to sign the consent form (whether the long form or short form is used) unless the IRB has waived documentation of informed consent under 21 CFR 56.109(c).",
        "metadata": {
            "document_id": "ICD - Document 1.pdf",
            "chunk_index": 230,
            "source": "markdown",
            "embedding_version": "v1"
        }
    },
    {
        "id": "e83d8f38-76b8-439c-b89e-0586f2e95a00",
        "text": "6. What should be considered when enrolling subjects with low literacy and numeracy?\nSubjects who cannot write can indicate their consent by \"making their mark\" on the consent document, in lieu of signing and dating the consent form when consistent with applicable law.  In these situations, a note should be included in subject case histories required to be maintained under 21 CFR 312.62(b) or 21",
        "metadata": {
            "document_id": "ICD - Document 1.pdf",
            "chunk_index": 231,
            "source": "markdown",
            "embedding_version": "v1"
        }
    },
    {
        "id": "4acea85b-a78e-4898-a779-cd82562f4c71",
        "text": "Contains Nonbinding Recommendations\nCFR 812.140(a)(3) indicating the reason for the lack of a signature and date as required by 21 CFR 50.27(a).  The date consent was obtained should be recorded in this note.",
        "metadata": {
            "document_id": "ICD - Document 1.pdf",
            "chunk_index": 232,
            "source": "markdown",
            "embedding_version": "v1"
        }
    },
    {
        "id": "284b44da-8ed2-44c8-bd04-e00fe557dfb2",
        "text": "7. What should be considered when enrolling subjects with physical or sensory disabilities?\nA person with physical or sensory disabilities (for example, physically unable to talk or write or has hearing or visual loss) can enroll in a clinical investigation if competent and able to signal consent consistent with applicable law.  Enrolling such subjects into a clinical investigation does not require a LAR to be involved with the informed consent process or to sign the consent document unless required by State or local law.  The records relating to the clinical investigation must include documentation of the informed consent process (21 CFR 50.27) unless excepted under 21 CFR 56.109(c).  FDA recommends including in subject case histories required under 21 CFR 312.62(b) or 21 CFR 812.140(a)(3) a description of the specific means by which the prospective subject communicated agreement to take part in the clinical investigation and how questions were answered.  FDA recommends that investigators provide reasonable modifications and auxiliary aids and services when necessary to meet the specific needs of the study population. 80 For example, for subjects with vision disabilities, the investigator could use an audio recording of the contents of the consent form or a consent form with enlarged font, depending on the degree of impairment.",
        "metadata": {
            "document_id": "ICD - Document 1.pdf",
            "chunk_index": 233,
            "source": "markdown",
            "embedding_version": "v1"
        }
    },
    {
        "id": "66a87e90-a10c-4f0c-b1c5-ee23004af5d7",
        "text": "8. What should be considered when enrolling adult subjects with impaired consent capacity? 81\nConsent capacity is a person's ability to understand information relevant to the decision to enroll in a study, that is, to weigh the risks and benefits of participation, to appreciate the available alternatives (including nonparticipation), to reach an informed and voluntary decision regarding participation, and to communicate that decision.  Consent capacity also depends, in part, on the complexity of the decision that\n80 FDA strongly encourages stakeholders to ensure that informed consent documents are accessible to individuals with disabilities. To the extent an organization receives Federal financial assistance from HHS, the organization must comply with the Rehabilitation Act of 1973. This guidance provides information to assist IRBs, clinical investigators, and sponsors in complying with FDA's informed consent regulations for clinical investigations. It does not provide guidance on how to comply with any regulatory obligations stemming from a source outside of the statutes FDA administers and FDA's regulations.",
        "metadata": {
            "document_id": "ICD - Document 1.pdf",
            "chunk_index": 234,
            "source": "markdown",
            "embedding_version": "v1"
        }
    },
    {
        "id": "e3dfcfb6-4359-47a1-ab0d-3a886c67af8d",
        "text": "8. What should be considered when enrolling adult subjects with impaired consent capacity? 81\n81 For further information on consent capacity, see 'Research Involving Individuals with Questionable Capacity to Consent:  Points to Consider,' National Institutes of Health (NIH), Office of Extramural Research, available at https://grants.nih.gov/grants/policy/questionablecapacity.htm and SACHRP's 'Recommendations Regarding Research Involving Individuals with Impaired Decision-making,' available at https://www.hhs.gov/ohrp/sachrpcommittee/recommendations/2009-july-15-letter-attachment/index.html.",
        "metadata": {
            "document_id": "ICD - Document 1.pdf",
            "chunk_index": 235,
            "source": "markdown",
            "embedding_version": "v1"
        }
    },
    {
        "id": "94ac4d91-c44c-4cbc-8489-87114d88bdbe",
        "text": "Contains Nonbinding Recommendations\nconfronts the prospective subject, which may take into account such factors as study design, risks, and anticipated benefits.\nImpaired consent capacity may involve partial impairment, impairment that fluctuates over time, or complete impairment.  For example, consent capacity can be affected by a wide range of disorders and conditions, such as dementia, stroke, traumatic brain injury, intellectual and developmental disabilities, serious mental illness, intoxication, and delirium.\nEnrollment of subjects with partial impairment may require modifications to the consent form and process to enable those subjects to consent on their own behalf.  When a subject's consent capacity is sufficiently impaired that the subject is unable to provide legally effective informed consent, the subject may not be enrolled unless the subject's LAR consents on the subject's behalf (21 CFR 50.3(l) and 50.20).\nIRBs and investigators should carefully consider whether the inclusion in research of individuals who lack consent capacity is ethically appropriate and scientifically necessary.  Whenever individuals with impaired consent capacity (partial, fluctuating, or complete) are or may be enrolled in clinical studies, ethical and procedural challenges arise.  Considerations that may help address these challenges and provide additional safeguards include:",
        "metadata": {
            "document_id": "ICD - Document 1.pdf",
            "chunk_index": 236,
            "source": "markdown",
            "embedding_version": "v1"
        }
    },
    {
        "id": "ac23b25e-6dec-434b-917f-88656c641c5f",
        "text": "Contains Nonbinding Recommendations\n- Assessing consent capacity of prospective subjects, for example, through use of an independent, qualified professional and a process that includes:  (1) documentation of elements of capacity (such as understanding information, showing evidence of choice, showing rational reasoning, understanding the nature of the situation, and showing reasonable understanding of outcome of choice); and (2) assessments at the time of consent, at periodic intervals, and when a subject's family member expresses concern about the subject's study participation.\n- Establishing a waiting period in the decision-making process to allow additional time for decision-making.\n- Using methods to enhance consent capacity, for example through (1) simplification and/or repetition of information, (2) involvement of a subject advocate or trusted family member/friend to assist when sharing information about the clinical investigation, and (3) refraining from discussions during periods of heightened impairment, when possible.\n- Assessing a subject's understanding after information about the clinical investigation has been imparted, for example, through use of a questionnaire.\n- Re-assessing consent capacity after initiation of the clinical investigation for subjects with progressive disorders whose cognition may decline.",
        "metadata": {
            "document_id": "ICD - Document 1.pdf",
            "chunk_index": 237,
            "source": "markdown",
            "embedding_version": "v1"
        }
    },
    {
        "id": "49bfdea9-7c72-4a36-9191-7164df9fecb9",
        "text": "Contains Nonbinding Recommendations\n- Involving an LAR either initially or later in the clinical investigation if consent capacity diminishes.\n- Assessing whether prospective subjects who cannot provide legally effective consent on their own behalf may nonetheless be able to provide some form of oral agreement at the outset of the study and, as appropriate, throughout the course of the research (e.g., for subjects with progressive disorders), and how such oral agreement would be documented.  In such a circumstance, an LAR would need to provide documented written consent.\n- Emphasizing the voluntary nature of the decision to participate and the right to withdraw at any time.\n- Determining whether the IRB or a third party should observe the consent process.",
        "metadata": {
            "document_id": "ICD - Document 1.pdf",
            "chunk_index": 238,
            "source": "markdown",
            "embedding_version": "v1"
        }
    },
    {
        "id": "2f83ff60-f465-4e9e-ac4f-52b0c6f52e4e",
        "text": "9. Who can serve as a legally authorized representative (LAR) and what is their role?\nFDA regulations define an LAR as 'an individual or judicial or other body authorized under applicable law to consent on behalf of a prospective subject to the subject's participation in the procedure(s) involved in the research' (21 CFR 50.3(l)).  The key point to consider when determining who may serve as an LAR is that the LAR must be authorized under applicable law to consent on behalf of the prospective subject to the procedure(s) involved in the clinical investigation.\nIn the United States, the legal authority for who may serve as an LAR is determined by State and local law.  Where applicable law exists to determine who is authorized to serve as an LAR to consent to an individual's participation in research, consent must be obtained from an LAR in accordance with this law. Institutions, IRBs, and investigators should have the ability to access information regarding applicable laws for the clinical investigations they conduct or oversee, when necessary.  If the IRB, investigator, or sponsor is uncertain about State and local laws governing who can serve as an LAR, they should consult with their institution and/or legal counsel.",
        "metadata": {
            "document_id": "ICD - Document 1.pdf",
            "chunk_index": 239,
            "source": "markdown",
            "embedding_version": "v1"
        }
    },
    {
        "id": "96e40c04-9965-424f-bb57-fc644696a237",
        "text": "9. Who can serve as a legally authorized representative (LAR) and what is their role?\nOnce identified, an LAR may sign the informed consent form for the prospective subject, should that individual be incapable of providing their own informed consent.  Additionally, the LAR should be consulted to make decisions on behalf of the subject and to assure that any such decisions are in the subject's best interest throughout the duration of the subject's participation in the clinical investigation.\nThe inclusion of individuals who lack the ability to consent for themselves presents unique ethical and procedural challenges for IRBs and investigators.  In such situations, consent to research by an LAR is an acceptable alternative under FDA's regulations.  While some prospective subjects, such as those with profound cognitive impairment, will not be able to contribute to the consent decision, others may be able to appoint an LAR, define the limits of their own research participation, or remain actively involved in the decision to enroll and remain enrolled in the research.  As such, individuals with impaired consent capacity should be included in the process of consent to the extent possible and consistent with their",
        "metadata": {
            "document_id": "ICD - Document 1.pdf",
            "chunk_index": 240,
            "source": "markdown",
            "embedding_version": "v1"
        }
    },
    {
        "id": "65e668d3-3606-46a0-bdc6-4f3c0b12b8b3",
        "text": "Contains Nonbinding Recommendations\ndesires and abilities.  In a situation in which a prospective subject is capable of providing informed consent at the onset of a clinical investigation but is expected to become less capable of providing continued consent as the research progresses (e.g., a long-term clinical trial for Alzheimer's), consideration should be given at the start of the trial to having subjects designate an individual to serve as their LAR once the subjects' conditions warrant it.",
        "metadata": {
            "document_id": "ICD - Document 1.pdf",
            "chunk_index": 241,
            "source": "markdown",
            "embedding_version": "v1"
        }
    },
    {
        "id": "4e0d32fa-a2e5-453c-a810-c2d1f93c36a4",
        "text": "10. How can informed consent be obtained through electronic methods?\nFDA supports the use of electronic processes to obtain informed consent. 82 Electronic media are being used to provide information usually contained within a paper informed consent form, to evaluate the subject's comprehension of the information presented, and to document the consent of the subject or the subject's LAR.  Electronic processes to obtain informed consent may use an interactive interface for the informed consent process, which may facilitate the subject's ability to retain and comprehend the information.  Furthermore, these electronic processes may also promote timely entry of any electronic informed consent into a study database and facilitate collection of the subject's informed consent from remote locations.  Additional guidance on the use of electronic informed consent in clinical investigations can be found in the FDA guidance entitled, ' Guidance for Institutional Review Boards, Investigators, and Sponsors, Use of Electronic Informed Consent in Clinical Investigations - Questions and Answers '. 83",
        "metadata": {
            "document_id": "ICD - Document 1.pdf",
            "chunk_index": 242,
            "source": "markdown",
            "embedding_version": "v1"
        }
    },
    {
        "id": "ca651792-1568-448d-8e16-c7d5c8d5e2c4",
        "text": "11. Can a subject participate in more than one clinical investigation simultaneously?\nSome subjects may wish to participate simultaneously in more than one clinical trial.  Enrollment in more than one clinical investigation could increase risks to subjects, particularly because they may be exposed to more than one investigational product for which the safety profile may not be well understood, and there may be potential drug or device interactions.  Also, subjects may find it difficult to understand the risks and potential benefits or meet the demands of multiple protocols.  FDA generally discourages enrollment in multiple investigations, although there are some circumstances in which co-enrollment may be appropriate (e.g., rare disease studies that are evaluating different aspects of the condition and involvement in one study does not affect the other study).  In addition, this recommendation does not apply to certain appropriately designed studies, such as a clinical investigation of a novel drug and a companion in vitro diagnostic device that is essential for the safe and effective use of the drug.\n82 Please see footnote 80.",
        "metadata": {
            "document_id": "ICD - Document 1.pdf",
            "chunk_index": 243,
            "source": "markdown",
            "embedding_version": "v1"
        }
    },
    {
        "id": "456aeaf9-8038-43b7-aa59-7c20c5266316",
        "text": "11. Can a subject participate in more than one clinical investigation simultaneously?\n83 See FDA 'Guidance for Institutional Review Boards, Investigators, and Sponsors, Use of Electronic Informed Consent in Clinical Investigations - Questions and Answers,' available at https://www.fda.gov/regulatoryinformation/search-fda-guidance-documents/use-electronic-informed-consent-clinical-investigations-questionsand-answers.",
        "metadata": {
            "document_id": "ICD - Document 1.pdf",
            "chunk_index": 244,
            "source": "markdown",
            "embedding_version": "v1"
        }
    },
    {
        "id": "9fd770c7-fb7d-40d3-9b7d-2039c5291a33",
        "text": "Contains Nonbinding Recommendations\nSponsors generally include prohibitions related to the use of concomitant medications in the protocol or restrict (via exclusion criteria) inclusion of subjects who have participated in another clinical investigation within a specified period of time (for example, the washout period before a subject can enroll in a new clinical investigation).  Implied in the prohibitions on concomitant medications is the idea that subjects should generally not participate in more than one clinical investigation at a time.  Investigators should inquire about multiple enrollments and, when appropriate, discourage this practice in the consent document and during informed consent discussions.  Further, when appropriate, the risks of participating simultaneously in more than one clinical investigation should be discussed with subjects during the consent process but do not necessarily need to be included in the informed consent form.",
        "metadata": {
            "document_id": "ICD - Document 1.pdf",
            "chunk_index": 245,
            "source": "markdown",
            "embedding_version": "v1"
        }
    },
    {
        "id": "3c65acde-e69a-4dc3-855c-801af820f94c",
        "text": "12. How should data be handled when an enrolled subject decides to withdraw from a trial?\nUnder FDA regulations, data collected on subjects up to the time of withdrawal from clinical investigations of drugs and devices conducted under an IND or IDE must remain in the study database (see, e.g., 21 CFR 312.62(b) and 812.140(a)(3)). 84 If a subject withdraws from a study, removal of data that were already collected would undermine the scientific validity, and therefore the ethical integrity, of the research.  Such removal of data could also put enrolled subjects, future subjects, and eventual users of marketed products at an unreasonable risk and could compromise FDA's ability to perform its mission to protect public health and safety by assuring the safety and effectiveness of regulated medical products.",
        "metadata": {
            "document_id": "ICD - Document 1.pdf",
            "chunk_index": 246,
            "source": "markdown",
            "embedding_version": "v1"
        }
    },
    {
        "id": "51739cdb-ff7f-4b83-92f8-0d44b523e903",
        "text": "12. How should data be handled when an enrolled subject decides to withdraw from a trial?\nFDA recommends that subjects be advised in the consent document that the data collected on them up until the point of their withdrawal will remain part of the study database and may not be removed.  An investigator should ask a subject who is withdrawing whether they wish to withdraw from the investigational interventions only and are willing to continue in the clinical investigation for follow-up of associated clinical outcome information.  If a subject withdraws from the interventional portion of the clinical investigation but agrees to continued follow-up not addressed in the original consent document, the investigator must obtain the subject's informed consent for this limited participation using an IRBapproved consent document (21 CFR 50.20 and 50.27(a)).  If a subject withdraws from the interventional portion of a clinical investigation and does not consent to continued follow-up of associated clinical outcome information, the investigator must not access the subject's medical record or other confidential records that would require additional consent from the subject (21 CFR 50.20).  However, such records",
        "metadata": {
            "document_id": "ICD - Document 1.pdf",
            "chunk_index": 247,
            "source": "markdown",
            "embedding_version": "v1"
        }
    },
    {
        "id": "0cbc0c3b-e5b0-4778-8598-d69e4ac5ae0e",
        "text": "12. How should data be handled when an enrolled subject decides to withdraw from a trial?\n84 FDA regulations (see 21 CFR 312.62 and 812.140(a)(3)) require investigators to prepare and maintain adequate case histories recording all observations and other data pertinent to the investigation on each subject.  For further discussion, see FDA 'Guidance for Sponsors, Clinical Investigators, and IRBs: Data Retention When Subjects Withdraw from FDA-Regulated Clinical Trials,' available at https://www.fda.gov/regulatory-information/searchfda-guidance-documents/data-retention-when-subjects-withdraw-fda-regulated-clinical-trials; and OHRP guidance, 'Withdrawal of Subjects from Research Guidance,' available at https://www.hhs.gov/ohrp/regulationsand-policy/guidance/guidance-on-withdrawal-of-subject/index.html.",
        "metadata": {
            "document_id": "ICD - Document 1.pdf",
            "chunk_index": 248,
            "source": "markdown",
            "embedding_version": "v1"
        }
    },
    {
        "id": "e65b4c80-c343-43d3-9b53-aaad4e032d3a",
        "text": "Contains Nonbinding Recommendations\nmay be accessed consistent with the original consent process, without additional consent under FDA's regulations, to obtain information collected prior to the subject's withdrawal from the study.\nAn investigator may consult publicly available sources of information to determine a subject's vital status (and if deceased, cause of death) after a subject withdraws from a clinical investigation.  This activity does not require subject consent because the information is publicly available.",
        "metadata": {
            "document_id": "ICD - Document 1.pdf",
            "chunk_index": 249,
            "source": "markdown",
            "embedding_version": "v1"
        }
    },
    {
        "id": "d03c5d59-3ffb-4217-8127-9a63163b60f6",
        "text": "13. What steps should be taken to inform subjects when a study is suspended or terminated? 85\nA clinical trial may be suspended and possibly terminated for a variety of reasons.  When a study is suspended, IRBs, sponsors, and investigators should consider whether subjects should be notified, and if so, when, especially given that during a study suspension, complete information may not be available. Although the IRB has the authority to require that information be provided to subjects when in the IRB's judgment the information would meaningfully add to the protection of the rights and welfare of subjects (21 CFR 50.109(b)), all parties should consider what information should be shared with subjects in order to ensure that their rights and welfare are protected, that they are not put at risk, and that they receive appropriate care, if indicated.",
        "metadata": {
            "document_id": "ICD - Document 1.pdf",
            "chunk_index": 250,
            "source": "markdown",
            "embedding_version": "v1"
        }
    },
    {
        "id": "ce86c8a1-cb41-4fd2-9b78-e8e6e2824993",
        "text": "13. What steps should be taken to inform subjects when a study is suspended or terminated? 85\nThe parties involved, including the subjects' treating physicians (if different from the investigator), as appropriate, may need to help determine whether it is in the best interests of currently enrolled subjects to (a) continue receiving the interventions that were being administered to subjects under the study at the present site, (b) be transferred to another study site (if the study is only suspended at certain sites) so that participation of the subjects in the study may continue, or (c) be transitioned to medical management outside of the research context.  Continuation of subjects on the test article may be appropriate, for example, when the test article holds out the prospect of direct benefit to the study subjects or when withholding the test article poses increased risk to study subjects.  In general, information about these considerations should be shared with subjects so that they may understand the changes affecting their participation in the study and to allow them to make informed decisions about their continued participation.",
        "metadata": {
            "document_id": "ICD - Document 1.pdf",
            "chunk_index": 251,
            "source": "markdown",
            "embedding_version": "v1"
        }
    },
    {
        "id": "621e608e-9302-4432-9f15-3d5e3abef639",
        "text": "13. What steps should be taken to inform subjects when a study is suspended or terminated? 85\nIf a study is terminated, study subjects should be provided with as much information as possible regarding the reason for the termination.  Such a discussion not only recognizes their valuable participation in the study but also helps explain the scientific value of the information obtained due to their willingness to participate in clinical research.  Such a discussion provides an opportunity to address questions subjects may have about an investigational product that was administered to them (e.g., immediate safety\n85 For further discussion, see 'Guidance for IRBs, Clinical Investigators, and Sponsors:  IRB Continuing Review after Clinical Investigation Approval,' available at https://www.fda.gov/regulatory-information/search-fda-guidancedocuments/irb-continuing-review-after-clinical-investigation-approval.  See section III.H.2, 'Suspension or Termination of IRB Approval.'",
        "metadata": {
            "document_id": "ICD - Document 1.pdf",
            "chunk_index": 252,
            "source": "markdown",
            "embedding_version": "v1"
        }
    },
    {
        "id": "878bf1dc-c7bc-4c68-afdd-be7ad068f3f0",
        "text": "Contains Nonbinding Recommendations\nconcerns, ability to participate in another clinical trial, and appropriate waiting period to do so) and what long-term follow-up may be available or necessary.  If the reason for the study termination involves a safety concern that may impact the future medical care of the study subjects, it would be important to discuss appropriate follow-up procedures with the subjects and possibly the subjects' primary care provider(s).",
        "metadata": {
            "document_id": "ICD - Document 1.pdf",
            "chunk_index": 253,
            "source": "markdown",
            "embedding_version": "v1"
        }
    },
    {
        "id": "c353a0b6-a173-4cce-9638-c322911420ce",
        "text": "14. Should subjects be informed of aggregate study results at the completion of a trial?\nFDA recognizes that subjects are frequently interested in the aggregate results of the clinical investigation in which they were enrolled.  FDA supports the return of aggregate research results and recommends that they be returned to subjects in a clear and comprehensible manner.",
        "metadata": {
            "document_id": "ICD - Document 1.pdf",
            "chunk_index": 254,
            "source": "markdown",
            "embedding_version": "v1"
        }
    },
    {
        "id": "38fdd927-f012-428a-90fa-84948340eb16",
        "text": "14. Should subjects be informed of aggregate study results at the completion of a trial?\nTitle VIII of the Food and Drug Administration Amendments Act of 2007 (FDAAA), including its implementing regulations in 42 CFR part 11, requires the 'responsible party' (usually the sponsor or principal investigator) of certain clinical trials of drug products (including biological products) and device products (referred to in FDAAA as \"applicable clinical trials\") to register the trials and submit summary results information to the government-operated clinical trials data bank, www.ClinicalTrials.gov, within a certain time period. 86 Summary results information submitted to ClinicalTrials.gov is made publicly available in the databank. 87 As discussed in section III.D, 'Elements of Informed Consent for Applicable Clinical Trials' above, FDA issued a final rule 88 that amends the informed consent regulations (21 CFR 50.25) to require that the informed consent documents for applicable clinical trials include the specific statement that is provided in the regulation to inform subjects that clinical trial information for such clinical trials will be available at www.ClinicalTrials.gov but it will not include information that can identify subjects individually.",
        "metadata": {
            "document_id": "ICD - Document 1.pdf",
            "chunk_index": 255,
            "source": "markdown",
            "embedding_version": "v1"
        }
    },
    {
        "id": "d3bd797f-4061-450d-83e5-bf2f8b7871e2",
        "text": "14. Should subjects be informed of aggregate study results at the completion of a trial?\nFor clinical trials that are not 'applicable clinical trials,' the sponsor or principal investigator may voluntarily register the clinical trial and submit summary results information to the databank. 89 If a sponsor or principal investigator plans to submit summary results information from the trial voluntarily, nothing would prevent an investigator, sponsor, or IRB from informing prospective subjects of the plan to\n86\nSee section 801(a) of FDAAA, Pub. L. 110-85, adding 42 U.S.C. 282(j);\nhttps://uscode.house.gov/view.xhtml?req=(title:42%20section:282%20edition:prelim)%20OR%20(granuleid:USCprelim-title42-section282)&f=treesort&edition=prelim&num=0&jumpTo=true . See also 81 FR 64982 (September 21, 2016), available at https://www.govinfo.gov/app/details/FR-2016-09-21/2016-22129.",
        "metadata": {
            "document_id": "ICD - Document 1.pdf",
            "chunk_index": 256,
            "source": "markdown",
            "embedding_version": "v1"
        }
    },
    {
        "id": "20a6bfe4-6f5e-41cd-9baa-b7beebcf4873",
        "text": "14. Should subjects be informed of aggregate study results at the completion of a trial?\n87 See 42 U.S.C.  282(j)(3)(B)(ii). https://www.govinfo.gov/content/pkg/PLAW-110publ85/pdf/PLAW110publ85.pdf#page=87\n88 76 FR 256 (January 4, 2011), available at  https://www.govinfo.gov/content/pkg/FR-2011-01-04/pdf/201033193.pdf.\n89 We note that if a sponsor or principal investigator does choose to voluntarily register a clinical trial or submit summary results information for it, they may be subject to additional requirements. See 42 CFR 11.60.",
        "metadata": {
            "document_id": "ICD - Document 1.pdf",
            "chunk_index": 257,
            "source": "markdown",
            "embedding_version": "v1"
        }
    },
    {
        "id": "fab21b4f-a800-4d80-b01e-6f4c7a67c972",
        "text": "Contains Nonbinding Recommendations\nsubmit such information in an appropriate manner.  Informed consent forms can direct subjects to www.ClinicalTrials.gov, where subjects can obtain certain overall aggregated summary study results information.  Investigators and sponsors can describe other plans in the consent form for informing subjects of the outcomes of the clinical investigation.\nFDA regulations do not directly address the issue of IRB review of return of aggregated results to subjects; however, when return of aggregated results is planned at the time of initial IRB review of the study, or the decision to share results is made after initial IRB approval but while the study is still open with the IRB, then the plan for communicating this information to subjects should be reviewed by the IRB.  However, if the plan to share aggregated study results is developed after the study is closed with the IRB, the IRB does not need to review the sponsor's plan to share the aggregate results. 90",
        "metadata": {
            "document_id": "ICD - Document 1.pdf",
            "chunk_index": 258,
            "source": "markdown",
            "embedding_version": "v1"
        }
    },
    {
        "id": "ac9803ea-602b-4226-a46a-e7227d74044d",
        "text": "15. Is informed consent required to review patient records?\nSponsors and investigators may seek to review patient medical records for a variety of reasons related to a clinical investigation.  Whether the record review is considered part of the clinical investigation, as defined under FDA's regulations at 21 CFR 50.3(c) and 21 CFR 56.102(c), is determined by the IRB on a case-by-case basis.  If the record review is part of the clinical investigation, then informed consent from the subject for the record review is required under 21 CFR part 50.\nA survey of patient records at a site may be performed to determine whether the site has a sufficient number of patients with the condition of interest for the clinical investigation to be feasible.  Such a survey is in preparation for a clinical investigation and does not fall within the definition of a clinical investigation and, therefore, does not require informed consent under FDA's regulations.  However, sponsors and investigators will need to comply with all applicable requirements under HIPAA and other applicable laws in these circumstances.",
        "metadata": {
            "document_id": "ICD - Document 1.pdf",
            "chunk_index": 259,
            "source": "markdown",
            "embedding_version": "v1"
        }
    },
    {
        "id": "56bfed77-f5e7-40dc-98ca-3c28996854e7",
        "text": "15. Is informed consent required to review patient records?\nA patient's records may be reviewed to determine whether the patient is eligible for a clinical investigation.  In order to facilitate this process, limited information about the prospective subject may be recorded.  It should be noted, however, that only information to establish the patient's eligibility for the study and contact information should be recorded.  This preliminary review of the patient's record and recording of limited information is considered preparation for a clinical investigation, does not fall within the definition of a clinical investigation, and, therefore, does not require informed consent.  Even though\n90 For additional discussion of the return of aggregate study results and IRB review, see SACHRP's recommendations on this topic at https://www.hhs.gov/ohrp/sachrp-committee/recommendations/2015-april-24attachment-d/index.html.",
        "metadata": {
            "document_id": "ICD - Document 1.pdf",
            "chunk_index": 260,
            "source": "markdown",
            "embedding_version": "v1"
        }
    },
    {
        "id": "8e0322d3-75c8-4c7e-b826-20455f28b9be",
        "text": "Contains Nonbinding Recommendations\ninformed consent is not required by FDA regulations in these instances, other steps necessary to safeguard the privacy and confidentiality of the patient's information in these records may be required (e.g., under the HIPAA Privacy and Security Rules and/or institutional policies).  Many institutions have privacy boards to help fulfill this function or they may give the IRB this responsibility.  Review by these entities may be required by the institution prior to these record review activities.\nIf a patient's record does not include the basic information necessary to determine whether the patient is eligible for the clinical investigation, additional information may be needed about the prospective subject. Obtaining informed consent may be required prior to obtaining the additional information.  Please see the FDA Information Sheet 'Screening Tests Prior to Study Enrollment,' 91 for a discussion of when informed consent would be required under FDA regulations.",
        "metadata": {
            "document_id": "ICD - Document 1.pdf",
            "chunk_index": 261,
            "source": "markdown",
            "embedding_version": "v1"
        }
    },
    {
        "id": "3d7a67d3-85d9-4238-8400-b1b6abc1c84f",
        "text": "Contains Nonbinding Recommendations\nThe records of a subject who was previously enrolled in a clinical investigation may be reviewed retrospectively to collect information under certain limited circumstances, consistent with the original consent process.  If this retrospective review is to gather information that was intended to be collected but was missed (that is, the protocol required collection of the information, but it was not reported in the case report form and the purpose of the review is merely to fill in gaps in the record), then this review is considered to be covered by the previous informed consent obtained for the clinical investigation and further consent from the subject is not required. 92\nIn cases where the additional information to be collected goes beyond what was identified in the original protocol and disclosed in the original consent document, obtaining informed consent for the collection of additional information for use in a clinical investigation would be required (21 CFR 50.20).  FDA recommends that the clinical investigator anticipate the need for obtaining further information and obtain consent for medical records review and data collection as part of the initial consent process.",
        "metadata": {
            "document_id": "ICD - Document 1.pdf",
            "chunk_index": 262,
            "source": "markdown",
            "embedding_version": "v1"
        }
    },
    {
        "id": "b23d9519-7c3f-4849-9ead-cd94d51c3449",
        "text": "Contains Nonbinding Recommendations\nIn all of the above situations, privacy and patient confidentiality issues should be considered.  The clinical investigator, sponsor, and institution should consider whether institutional policies or other statutory or regulatory requirements are applicable to the review of patient records (such as under the HIPAA Privacy\n91 FDA Information Sheet 'Screening Tests Prior to Study Enrollment' is available at https://www.fda.gov/regulatory-information/search-fda-guidance-documents/screening-tests-prior-studyenrollment.\n92 For further guidance regarding the consequences of a subject's decision to withdraw from a clinical investigation see section III.C.4.\nRule (45 CFR parts 160 and 164, subparts A and E) or the HHS human subject protection regulations at 45 CFR part 46). 93",
        "metadata": {
            "document_id": "ICD - Document 1.pdf",
            "chunk_index": 263,
            "source": "markdown",
            "embedding_version": "v1"
        }
    },
    {
        "id": "1f1e1d8d-5aa4-4e31-9a96-f7880abac2ca",
        "text": "16. How should subjects be informed of new information that may affect their willingness to continue participation in the research?\nDuring the conduct of a clinical investigation, significant new information (e.g., protocol changes, new findings related to safety) may arise that could affect a subject's willingness to continue their participation in the clinical trial.  When this occurs, the IRB should determine whether currently enrolled subjects should be provided with the new information and given an opportunity to affirm their willingness to continue in the research.  In the research community this process is frequently referred to as 'reconsent.' FDA regulations do not use or define the term reconsent, nor do FDA regulations specify the process an IRB should use to determine the need or method to inform subjects who are already enrolled in the study of the new information.  As such, IRBs have flexibility to establish procedures they think are appropriate to provide for subjects to have an opportunity to affirm their willingness to continue in the research.",
        "metadata": {
            "document_id": "ICD - Document 1.pdf",
            "chunk_index": 264,
            "source": "markdown",
            "embedding_version": "v1"
        }
    },
    {
        "id": "2b4f2ede-1cc2-443a-9057-a6ceebd3d03c",
        "text": "16. How should subjects be informed of new information that may affect their willingness to continue participation in the research?\nAs a consequence of new information, the investigator may need to revise the consent form to include the new information for new enrollees and obtain IRB review and approval before it is used (see 21 CFR 50.27(a) and 56.109).  Because the consent form is being modified to reflect the new information, the IRB should determine whether the investigator should provide currently enrolled subjects with the new information either with the revised informed consent document or an alternative method such as a consent addendum or information sheet describing the new information.",
        "metadata": {
            "document_id": "ICD - Document 1.pdf",
            "chunk_index": 265,
            "source": "markdown",
            "embedding_version": "v1"
        }
    },
    {
        "id": "a3c23bad-69ba-469e-92b1-386df587838a",
        "text": "16. How should subjects be informed of new information that may affect their willingness to continue participation in the research?\nWhen a revised consent form is used to inform enrolled subjects of new information and to document their willingness to continue in the trial, the investigator may use a prepared summary of the change(s) to reduce confusion about the change(s) and aid in presenting the new information.  After the discussion of the new information and an acknowledgement of understanding by the enrolled subject, the enrolled subject should be asked to sign and date the revised consent document if they are willing to continue participating in the research.  When an alternative method is used, such as a consent addendum or information sheet, the enrolled subject should be asked to sign and date the consent addendum or\n93 Please contact the Office for Civil Rights (https://www.hhs.gov/programs/hipaa/index.html) for additional information on HIPAA, including the Privacy Rule, or the Office for Human Research Protections (https://www.hhs.gov/ohrp/) for additional information on 45 CFR part 46.",
        "metadata": {
            "document_id": "ICD - Document 1.pdf",
            "chunk_index": 266,
            "source": "markdown",
            "embedding_version": "v1"
        }
    },
    {
        "id": "db448cc9-2d51-472b-aaa2-5eb1fb5e4406",
        "text": "Contains Nonbinding Recommendations\ninformation sheet. 94 FDA recommends that a copy of the signed and dated consent addendum or information sheet be provided to the subject.\nIn general, FDA does not believe it is necessary for subjects who have completed their active participation in the study to be informed of new information unless the new information relates to risks that may manifest after such participation.  In this situation, it may be appropriate to provide previously enrolled subjects with counseling regarding any risk that may be warranted.  Similarly, FDA does not believe it is necessary to inform subjects who are still actively participating of new information when the change will not likely affect their decision to continue in the study (e.g., an increase in the number of study subjects).  However, IRBs may recommend that the investigator provide the above-discussed summary to all subjects (previously and currently enrolled subjects) for their awareness.\n94 For additional discussion on providing new information to previously enrolled subjects, see SACHRP's recommendations on the topic at https://www.hhs.gov/ohrp/sachrp-committee/recommendations/april-7-2020attachment-a/index.html.",
        "metadata": {
            "document_id": "ICD - Document 1.pdf",
            "chunk_index": 267,
            "source": "markdown",
            "embedding_version": "v1"
        }
    }
]